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Abstract 
The application of ICP-MS to the fields of proteomics and genomics has arisen in part due 
to its ability to detect and quantify trace levels of S and P, which are major constituents in 
proteins and nucleic acids respectively. The development of collision/reaction cell 
technology and high resolution instruments has enabled these biologically important 
elements to be measured and quantified at the pg - ng ml-1 level. Despite these advances, 
the detection limits of P and S are still inferior compared to other elements. 
 
Oligonucleotides containing biotin functionality were labelled with Au nano-particles 
attached to a streptavidin protein to achieve site specific labelling, with 100% labelling 
efficiency. Each nano-particle contained ~86 Au atoms, resulting in an 882 fold signal 
enhancement for 24 base length oligonucleotides. However, this enhancement factor was 
only observed when one oligonucleotide bound to one nano-particle in a 1:1 ratio. Much 
lower Au labelling efficiencies and signal enhancements were observed when thiolated 
oligonucleotides were labelled with maleimide functionalised gold nano-particles. This was 
attributed to the extensive and difficult sample preparation steps that were required prior to 
labelling.   
 
The detection and quantification of adducts formed between DNA and the Pt anti-cancer 
drugs cisplatin and oxaliplatin were also investigated with ICP-MS. Acid digestion of the 
carbon based DNA matrix enabled Pt adducts to be quantified at low dose rates of 1 Pt 
atom per 1 500 000 nucleotides in ~12 µg DNA. Such sensitive mass spectrometric 
determinations could be employed in clinical tests to detect and quantify low level adducts 
formed in patients in-vivo. To complement ICP-MS analysis, electrospray ionisation linear 
ion trap mass spectrometry was employed to study the interaction of oxaliplatin with the 
four DNA nucleobases. Multiple stage mass spectrometry enabled detailed Pt-nucleobase 
adduct fragmentation pathways to be established. 
 
The method of DNA detection using P in conjunction with the collision cell, or cool plasma 
to form PO+ was also demonstrated and the limitations of the method, namely, polyatomic 
interferences and severe matrix effects were highlighted. 
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Keywords; Oligonucleotides, DNA, Phosphorus, Gold, Nano-particles, Labelling, ICP-
MS, Collision/reaction cell, HPLC-ICP-MS, ESI-MS, Platinum, Metallodrugs, Cisplatin, 
Oxaliplatin. 
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Glossary of Terms 
AC  Alternating current 
APCI  Atmospheric pressure chemical ionisation 
APPI  Atmospheric pressure photoionisation 
AU  Absorbance units 
BSA  Bovine serum albumin 
CCT  Collision cell technology 
CD  Circular dichromism 
CID  Collision induced dissociation 
CPS  Counts per second 
CRM  Consecutive reaction monitoring 
ctDNA  Calf thymus deoxyribonucleic acid  
Da  Daltons 
Dach  Diaminocyclohexane 
DEAE  Diethylaminoethane 
DNA  Deoxyribonucleic acid 
DNase 1 DNA nuclease 1 
dNMP  Deoxyribonucleotide monophosphate 
dNTP  Deoxyribonucleotide triphosphate 
DTNB  5,5’-dithiolbis(2-nitrobenzoic acid) 
DTT  Dithiothreitol 
DVB  Divinylbenzene 
EDC  N-ethyl-N’-(3-dimethylaminopropyl)carbodiimide 
EDT  Ethanedithiol 
EDTA  Ethylenediaminetetraacetic acid 
ESA  Electrostatic analyser 
ESI  Electrospray ionisation 
ESI-MS Electrospray ionisation-mass spectrometry 
GMP  Guanine monophosphate 
hnRNA Heterogeneous nuclear ribonucleic acid 
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HPLC  High performance liquid chromatography 
HR-ICP-MS High resolution inductively coupled plasma mass spectrometry 
ICP-MS Inductively coupled plasma mass spectrometry 
IKEE  Ion kinetic energy effect 
IMAC  Immobilised metal affinity chromatography 
KED  Kinetic energy discrimination 
LA  Laser ablation 
LOD  Limits of detection 
MALDI Matrix-assisted laser desorption ionisation 
MMN  Monomaleimido nanogold 
mRNA  Messenger ribonucleic acid 
MS  Mass spectrometry 
MSn  Mass spectrometry to the nth 
MS/MS Tandem mass spectrometry 
NDP  Nucleotide diphosphate 
NMP  Nucleotide monophosphate 
NMR  Nuclear magnetic resonance 
NP1  Nuclease P1 
NPR  Non porous resin 
NSI  Nanospray ionisation 
NTA  Nitrolotriacetic acid 
NTP  Nucleotide triphosphate 
PAGE  Polyacrylamide electrophoresis 
PBS  Phosphorus buffered saline 
PCR  Polymerase chain reaction 
PEEK  Polyetheretherketone 
PFA  Perfluoroalkoxy 
pI  Isoelectric point 
PLA  Post labelling assay 
PS-DVB Polystyrene divinylbenzene 
RF  Radio frequency 
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RNA  Ribonucleic acid 
RP-HPLC Reversed phase high performance liquid chromatography 
rNMP  Ribonucleotide monophosphate 
rNTP  Ribonucleotide triphosphate 
rRNA  Ribosomal ribonucleic acid 
SAP  Shrimp alkaline phosphatise 
SE  Standard error 
SEM  Secondary electron multiplier 
SERRS Surfaced enhanced resonance raman scattering 
SFNG  Alexa fluor-488 Streptavidin fluoronanogold 
SIM  Selected ion monitoring 
SNP  Single nucleotide polymorphism 
SRM  Selected reaction monitoring 
snRNA Small nuclear ribonucleic acids 
snRNP  Small nuclear ribonucloproteins 
SPE  Solid phase extraction 
SVPD  Snake venom phosphodiesterase 
T4PNK T4 Polynucleotide kinase 
TCEP  Tris(carboxyethyl)phosphine 
TMACl Tetramethyl ammonium chloride 
TMAH Tetramethyl ammonium hydroxide 
TNB  Thio-bis-(2-nitrobenzoic acid) 
TOF  Time of flight 
TRA  Time resolved analysis  
Tris  Tris(hydroxymethyl)aminomethane 
tRNA  Transfer ribonucleic acid 
UV  Ultra violet 
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1. Introduction 
1.1 Objectives 
Inductively coupled plasma mass spectrometry (ICP-MS) is the most sensitive and versatile 
analytical technique in elemental and isotopic analysis. Most elements in the periodic table 
can be ionised in the ICP source including biologically important elements such as P and S. 
As a result, biomolecules such as nucleic acids and proteins can be detected by their P and 
S content respectively.1-3 Further, proteins containing metallic components such as Zn and 
Mn can be analysed by ICP-MS due to the detectable ions. Such developments have 
resulted in the increased use of ICP-MS in the analysis of biomolecules.  
 
The traditional organic mass spectrometry methods based on electrospray ionisation (ESI) 
and matrix assisted laser desorption ionisation (MALDI) mass spectrometry, provide 
structural information and good powers of detection, but quantification can be problematic. 
ICP-MS provides complementary information to conventional organic mass spectrometry 
and has many additional advantages.4-6 Firstly, ICP-MS offers very low limits of detection, 
which generally range from pg l-1-µg l-1 depending on the analyte. Calibration and 
quantification are much easier and only require inorganic elemental standard solutions. In 
addition, because ICP-MS measures the total concentration of an element regardless of 
chemical form, it facilitates mass balance calculations, which are vital for establishing 
analyte recovery and method validation. Although the ICP is a hard ionisation source and 
molecular information is destroyed, it can be employed as a selective detector when 
coupled to various separation techniques, providing a means of separating molecular 
species prior to elemental detection.6, 7 These factors have helped increase the popularity of 
ICP-MS in biological analysis. Figure 1:1 summarises the main analytical techniques 
available for obtaining both molecular and elemental information from biomolecules. 
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Figure 1:1: Analytical methods available for biomolecule analysis. 
 
Despite the advantages of ICP-MS, P and S are problematic elements because they have 
high first ionisation potentials (10.5 and 10.4 eV respectively), which results in incomplete 
ionisation (~35% and 15% for P and S respectively)8 and they suffer from polyatomic 
interferences at m/z 31 and 32, which are derived from atmospheric gases and the sample 
solvent.9 The advancements in collision/reaction cell1,9-11 and high resolution      
instruments 3, 11, 12 has made it possible to remove or resolve the analyte ions from their 
interferences, but whilst metallic elements can readily be detected at pg l-1 levels, the 
detection limits for these elements are much higher. These problems can be avoided and the 
biomolecule signal enhanced if the biomolecule is labelled with a metallic element or a 
metal nano-particle, which is measured instead of P or S.13-16 Since the sensitivity of     
ICP-MS increases with increasing number of similar isotopes in the sample, the 
incorporation of metal nano-particles, which contain multiple copies of the same isotope, 
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would allow for quantification at very low levels and avoids the problems encountered with 
P and S measurement, providing the metal label does not suffer any interferences.  
 
Apart from avoiding the problems associated with P and S detection, metal or nano-particle 
labelling of biological molecules has additional advantages: 
• Biomolecule structure and configuration does not necessarily have to be maintained, 
since only the elemental label will be detected and not the biomolecule directly. 
Thus, the sample does not have to be analysed immediately after sample preparation 
or stored in specialised conditions to prevent degradation.10, 16  
• Reduced interferences, since a more favourable region of the mass spectrum is 
measured. 
• More than one elemental label can be used simultaneously if there is more than one 
target molecule to study.10, 13  
• Easy calibration and therefore quantitative analysis. 
• Mass balance determinations.17 
 
The primary aim of this thesis is to develop improved methods of biomolecule detection by 
using metal/nano-particle labelling coupled with analysis by ICP-MS. 
 
This introduction will discuss the structure and function of DNA, whilst highlighting its 
importance in living systems. The analytical methods currently used for DNA detection 
will be briefly reviewed. The first aspect of the investigation will then be discussed, which 
involves improving DNA detection using elemental mass spectrometry by means of metal 
nano-particle labelling, where each nano-particle contained approximately 86 Au atoms. 
Gold has lower first ionisation potential than P and does not suffer the same interferences, 
resulting in improved sensitivity when bound to nucleic acids. More importantly, because 
each nano-particle contained ~86 Au atoms, a greater enhancement in sensitivity can be 
obtained to achieve ultra sensitive detection of nucleic acids. Two nanogold labelling routes 
were developed; both methods resulted in site specific labelling on the nucleic acid 
allowing for easy quantification. The methods of modifying DNA, the labelling procedure 
and the methods of purifying and detecting the conjugates will be discussed in detail. 
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The second aspect of this thesis concentrates on the ICP-MS analysis of DNA that had been 
treated with cisplatin or oxaliplatin anti-cancer drugs. These Pt containing complexes are 
known to interact with DNA in-vivo and in-vitro. Pt does not suffer from the same 
problems as P, hence the incorporation of Pt into the DNA molecule provides an additional 
label that can be employed for the ICP-MS analysis of DNA.18 The total platinum 
concentration associated with DNA treated with varying doses of these drugs was 
determined. The ultimate aim was to develop a clinical test to detect and quantify the low 
level adducts formed in patients in-vivo, and to identify patients who are not responding 
well to the selected treatment. In addition to elemental mass spectrometry, the interaction of 
oxaliplatin with DNA nucleobases was investigated with ESI linear ion trap mass 
spectrometry. Detailed fragmentation pathways were established, whilst proposed product 
ion structures were presented, highlighting the complementary nature of elemental and 
molecular mass spectrometry techniques.  
 
Finally, DNA detection by measuring the P signal associated with the sugar phosphate 
backbone will be discussed. The practical problems and limitations of P detection by ICP-
MS will be highlighted. Figure 1:2 summarises the various routes by which nucleic acids 
have been detected and quantified in this thesis using ICP-MS. 
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Figure 1:2: Schematic showing the various methods of detecting DNA by elemental mass spectrometry. 
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1.2 Genomics 
1.2.1 Structure of DNA 
Deoxyribonucleic acid (DNA) contains the chemical instructions required to create and 
sustain a living organism. All physical and biochemical characteristics of an organism are 
determined by the set of chemical instructions contained within DNA. The vast quantity 
and complexity of information stored in this genetic material provides the basis of genomic 
research. But remarkably only three main ingredients constitute DNA: 
• Pentose sugar 
• Nitrogen containing base 
• Phosphate group 
 
All three of the above ingredients are combined to form the basic sub-units required to 
create a DNA strand. The carbon atoms comprising the pentose sugar are numbered 1’ to 5’ 
as illustrated in Figure 1:3. The 2’ carbon of the pentose sugar in DNA is not oxygenated, 
hence the term ‘deoxyribonucleic acid’. A nucleoside is formed upon addition of a 
nitrogen-containing base to the 1’ carbon atom of the pentose sugar. Further, the nucleoside 
becomes a nucleotide upon addition of a phosphate group on the 5’ pentose carbon.19, 20 The 
structures of deoxyribose sugar, nucleoside and nucleotide are illustrated in Figure 1:3. 
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Figure 1:3: Structures of deoxyribose sugar, nucleoside and nucleotide. 
 
The hydroxyl group on the 3’ pentose carbon can form a phosphodiester bond with the 5’ 
phosphate group of another nucleotide. The formation of such phosphodiester bonds 
between nucleotides results in a polynucleotide chain.20 DNA is essentially a polymer of 
nucleotides, which are bonded together through these ester bonds. The first nucleotide in 
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the nucleic acid chain has a triphosphate group located on the 5’ carbon of the pentose 
sugar. The reason for the presence of a triphosphate group on the first nucleotide in the 
chain will be explained in subsequent sections. The position of the phosphate group on the 
sugar is called the C5 position, which is also called the 5’ end. The last nucleotide in the 
nucleic acid chain always has a hydroxyl group (-OH) at the C3 position on the pentose 
sugar. Hence, the hydroxyl group position is called the 3’ end. Thus, nucleotides are joined 
together by the 5’ end of one nucleotide forming a phosphodiester bond with the 3’ end of 
another nucleotide.19, 20 Figure 1:4 illustrates the phosphodiester bond along with the 3’ and 
5’ positions on the nucleotide. 
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Figure 1:4: Phosphodiester bond formation between nucleotides. 
 
One of four nitrogen bases can be incorporated onto the 1’ carbon of a nucleoside, namely; 
adenine (A), cytosine (C), guanine (G) or thymine (T). The structures of the bases can be 
seen in Figure 1:5 and can be separated into two groups; purines and pyrimidines. 
Pyrimidine bases consist of one aromatic ring, whereas, purines are composed of two fused 
rings. Like in the case of the ribose sugar, the carbon and nitrogen atoms within the 
nucleobases are numbered as shown below. This ring numbering system has important 
implications in subsequent chapters when the interactions of nucleobases with metallodrugs 
are discussed. 
 
 
26 
Purine bases: 
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Pyrimidine bases: 
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Figure 1:5: Structures of the purine and pyrimidine DNA bases. 
 
Genomic DNA is arranged into two polynucleotide strands to form a helix, which is 
commonly known as the double helix. For the double helix to form, the bases on one strand 
form hydrogen bonds with bases on the neighbouring strand. This is known as 
complementary base pairing. However, the base pairing process is not random, but specific 
with only adenine and thymine pairing and also guanine and cytosine pairing. Two 
hydrogen bonds are formed between adenine and thymine, whilst three hydrogen bonds 
form between guanine and cytosine. This coupling of bases is known as complementary 
base pairing, thus, a complementary base pair consists of a purine and a pyrimidine.20  
 
Adenine can only bind to thymine, and cytosine can only bond to guanine. The reasons for 
this can be explained by two factors. Firstly, the size of the bases has to be considered. The 
internal diameter of the double helix (1.1 nm wide) is not sufficient to allow adenine and 
guanine to pair.20 Conversely, cytosine and thymine are not wide enough to fit within the 
sugar phosphate backbone and form a stable hydrogen bond, since the strength of hydrogen 
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bonds diminishes rapidly with distance. For these reasons a base pair has to be composed of 
a purine and a pyrimidine.  
 
However, adenine and cytosine are not complementary base pairs, neither are guanine and 
thymine, yet both these pairs contain a purine and pyrimidine. This brings about the second 
factor that has to be considered, which is hydrogen bonding. Hydrogen bonds hold the two 
complementary base pairs together and ultimately help form the double helix. For a stable 
hydrogen bond to form the base pairs must have the appropriate hydrogen bond donor and 
acceptor atoms, along with a short distance between the base pairs. Although adenine-
cytosine and guanine-thymine have a distance between them that could sustain a stable 
hydrogen bond, the hydrogen bond donors and acceptors are not properly matched, thus the 
DNA helix would have to disort to allow for this base pair combination.21 For these reasons 
the complementary DNA base pairs are: adenine-thymine and guanine-cytosine. This strict 
pairing of bases helps minimise errors in the replication of DNA. Figure 1:6 shows how the 
bases are arranged in double stranded DNA. Note, that one DNA strand runs in the 5’→3’ 
direction and the complementary strand is parallel but in the 3’→5’ direction.  
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Figure 1:6: Base pairing of DNA. 
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The pentose sugars and phosphate groups alternate along the outside of the DNA helix to 
form the sugar phosphate backbone, whilst the base pairs are inside the helix holding the 
two polynucleotide strands together by hydrogen bonding. The width of the DNA molecule 
is 2 nm (outer diameter) and the length is approximately 1.8 m.19 Each base pair is 3.4 Å 
apart and one complete turn contains 10 base pairs, therefore one turn is 34 Å in length.20  
 
The external sugar phosphate backbone results in DNA carrying a net negative charge, 
which allows water molecules to pack around the outside of the DNA molecule to create 
hydration spheres around the sugar phosphate backbone.22 Cations are also attracted to the 
exterior of the DNA molecule; thus, DNA can act as a cation exchange medium. Many 
other molecules within biological systems can also interact with DNA, as will be discussed 
later. 
 
1.2.2 DNA Function 
DNA has two main functions which include; the replication of itself so genetic material can 
be passed onto new cells and ultimately offspring. The second function of DNA is protein 
synthesis. The DNA molecule contains regions of base pairs that code for specific proteins, 
these areas are called genes. Genes are decoded and proteins are synthesised by two 
processes known as transcription and translation. Both these processes will be discussed in 
detail in following sections. The discussion of DNA replication and protein synthesis are 
relevant to eukaryotic organisms. 
 
1.2.3 DNA Replication 
DNA has the function of storing all the genetic information of an organism and to pass this 
genetic code onto new cells and ultimately offspring. As mentioned in the previous section, 
the complementary base pairing of DNA bases minimises the chances of errors occurring 
during DNA replication, hence the correct genetic code is passed on to new cells and 
offspring. DNA is stored in the cell nucleus where replication takes place. The nucleus 
helps protect DNA, as certain chemicals and radiation can easily damage it. If DNA were 
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stored in the cytoplasm, it would almost certainly be damaged leading to mutations.19 The 
replication process is referred to as semi-conservative and is exhibited by all organisms.20 
The term ‘semi-conservative’ will become apparent during discussion. 
 
The first stage of replication requires the DNA double helix to unwind, which is aided with 
the enzyme helicase. The origin of replication is where the two DNA strands unwind; this 
forms two exposed DNA strands known as the replication forks. The replication bubble is 
the name given to the regions of newly synthesised DNA.20 The relative positions of the 
replication fork and bubble are shown in Figure 1:7. The replication bubble increases in 
size as the replication fork works its way along the DNA molecule and the new DNA chain 
grows.20, 23 
 
Figure 1:7: DNA Replication. 
 
Short chain ribonucleic acids (RNA), known as primers mark the point where DNA 
replication is to begin. As a result, the base sequence of primers is complementary to the 
DNA base sequence where replication begins. The RNA primers anneal to the DNA with 
the help of an enzyme called RNA primase.19 A covalent bond is then formed between the 
3’ (hydroxyl) end of the RNA primer and the 5’ end of the newly synthesised DNA 
strand.20 As the DNA helix unwinds, the base pairs become exposed and free surrounding 
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deoxynucleotide triphosphates (dNTP) bond to their complementary bases on the partially 
unwound DNA.  
 
Both DNA strands act as templates for the formation of the new DNA (see Figure 1:7). 
Since one template strand will be exposed in the 3’→5’ direction and the other strand 
exposed in the 5’→3’ direction, the DNA replication forks of the two DNA template 
strands work in opposite directions.20 The template strand, which is exposed in the 3’→5’ 
direction, is copied continuously and the new DNA is formed in the 5’→3’ direction; this is 
known as the leading strand. However, the other strand, which was exposed in the 5’→3’ 
direction is copied discontinuously, but the new DNA is also formed in the 5’→3’ direction 
and is known as the lagging strand. The discontinuous nature of replication on the lagging 
strand forms segments of new DNA called Okazaki fragments.20, 23 The replication of the 
two anti-parallel strands occurs simultaneously.  
 
As the free dNTP bond to their complementary bases on the unwound template DNA 
strands, they are hydrolysed to form deoxynucleotide monophosphates (dNMP) as they are 
added onto the growing DNA strand. Figure 1:8 illustrates the addition and hydrolysis of 
free dNTP’s. Since the dNTP’s are converted to dNMP’s, two phosphate groups are 
removed, which is known as pyrophosphate and is subsequently converted to phosphate as 
shown in Figure 1:9. 
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Figure 1:8: Addition of free dNTP onto a growing DNA chain. 
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Figure 1:9: Conversion of pyrophosphate. 
 
The pyrophosphate side product is converted to phosphate in a reaction that ensures dNTP 
is hydrolysed to dNMP and DNA polymerisation is irreversible.24 DNA polymerase α 
catalyses the formation of hydrogen bonds between the free nucleotides and the exposed 
DNA bases. This enzyme is also responsible for the formation of the phosphodiester bonds 
between neighbouring nucleotides. There are three types of DNA polymerase, the roles of 
these enzymes are summarised in Table 1:1. 
Table 1:1: Functions of DNA Polymerase Enzymes.
20
 
Polymerase Function 
DNA Polymerase α Polymerisation enzyme 
DNA Polymerase β Repair enzyme 
DNA Polymerase γ DNA replication in mitochondria 
 
The newly formed DNA strands are complementary to their corresponding template strand, 
but it is important to note that the template DNA and new DNA strands are not identical, 
due to the complementary nature of base pairing. The two strands are said to be anti-
parallel.19 The Okazaki fragments that are formed as a result of discontinuous replication on 
the lagging strand (Figure 1:7) are joined together with DNA ligase to create a continuous 
complementary strand. This enzyme inserts the missing phosphodiester bonds between the 
Okazaki fragments to complete the sugar phosphate backbone.19  
 
The final stage of replication involves the enzyme DNA polymerase, which removes the 
RNA primers that marked the starting points for DNA replication, and replaces the primers 
with new deoxynucleotides.19 Methylating agents such as methionine, methylates the new 
DNA at various points along the strand. This acts as a protection mechanism for the DNA 
by preventing endonucleases destroying the organism’s own genetic information.24 
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The whole process of replication is known as semi-conservative, since both DNA strands 
act as templates for the formation of new DNA. When replication is complete, two helices 
are present, each helix contains a DNA template strand (old DNA) and a new DNA strand. 
 
1.2.4 Protein Synthesis 
Protein synthesis is another vital role of DNA and is imperative for the sustainability of all 
living organisms. DNA contains sections of sequential nucleotides called genes that code 
for specific proteins. Each gene along the genome contains the genetic instructions for 
protein synthesis. There are two main stages in the production of proteins; transcription and 
translation. 
 
DNA is not the only important component in protein synthesis; there is a group of nucleic 
acids called ribonucleic acids (RNA) that are vital for the production of proteins. RNA like 
DNA is composed of a pentose sugar, nitrogen containing bases and phosphate groups. 
However there are differences between the two nucleic acids, namely, the RNA ribose 
sugar is oxygenated at the 2’ carbon, whereas in DNA this carbon position is deoxygenated. 
In addition, thymine is absent in RNA, but uracil is present instead. These subtle 
differences between the two nucleic acids are summarised in Table 1:2 and Figure 1:10.19  
Table 1:2: Differences between DNA and RNA. 
 DNA RNA 
Pentose Sugar Deoxyribose sugar Ribose sugar 
   
Bases A, C, G and T A, C, G and U 
   
Size 1.8 m in length Various lengths, but 
significantly smaller than DNA. 
   
Number of Strands Double stranded Usually single stranded however 
there are some double stranded 
forms of RNA. 
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The process of protein synthesis requires the genetic information contained in DNA to be 
decoded. Transcription is responsible for transferring the genetic code from DNA into an 
RNA molecule, whilst translation uses the transcribed genetic code to build amino acid 
chains.19 There are many types of RNA all of which have a specialised role in protein 
synthesis. Each type of RNA will be defined as the transcription and translation processes 
are discussed. 
 
1.2.4.1 Transcription 
The genetic information contained in genes is transcribed into an RNA molecule called 
messenger RNA (mRNA), which is the product of transcription. The transcribed mRNA 
can be transported out of the nucleus to the cytoplasm, where proteins are produced.19 
Messenger RNA is therefore the carrier or messenger containing the genetic code required 
for protein synthesis. 
 
The first step in transcription requires part of the DNA double helix to unwind, which is 
again aided by the helicase enzyme. Once the DNA has unwound the DNA bases are 
exposed and can be used as a template for mRNA production, analogous to DNA 
replication.19 The enzyme RNA polymerase helps in the initiation of transcription by 
binding to the part of the DNA molecule where transcription is to begin. This specific site 
on the DNA molecule is known as the promoter, which determines which DNA strand is to 
be transcribed. Specific proteins known as transcription factors help RNA polymerase 
recognise the promoter site. The combination of all these components is known as the 
initiation complex.24  
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The anti-sense DNA strand is used as a template during transcription; the resulting mRNA 
molecule therefore has a base sequence, which is identical to the sense strand and 
complementary to the anti-sense strand. However, it must be noted that uracil is present in 
mRNA instead of thymine and the ribose sugar is oxygenated at the 2’ carbon.19  
 
RNA primers mark the section of DNA to be transcribed and just like DNA replication; the 
primers have a base sequence complementary to the start and end points of the gene to be 
transcribed. Once the DNA bases are exposed, free ribonucleotide bases can bind to the 
exposed DNA bases by complementary base pairing. RNA polymerase catalyses the 
formation of hydrogen bonds between the complementary DNA-RNA bases, as well as 
catalysing the growth of the RNA strand. The free ribonucleotide triphosphates (rNTP) are 
converted to ribonucleotide monophospates (rNMP) as they are added to the growing RNA 
molecule. The pyrophosphate side product is again formed during mRNA formation and 
the polymerisation reaction is made irreversible by the conversion of pyrophosphate to 
phosphate (Figure 1:9).24 Transcription along the DNA molecule occurs in the 3’→5’ 
direction, so the resulting mRNA molecule grows in the 5’→3’ direction.  
       
RNA polymerase moves along the DNA strand catalysing the growth of the mRNA 
molecule. The energy released during the hydrolysis of rNTP is sufficient to allow the RNA 
polymerase to move along the DNA molecule. Many genes along the genome may be 
transcribed simultaneously, which in turn requires many RNA polymerase enzymes.24 The 
portion of DNA that is transcribed is called the transcription unit. Once the transcription 
unit has been transcribed, the DNA double helix reforms and the newly formed mRNA 
molecule is removed form the DNA template.  
 
There are three main types of RNA polymerase; each is responsible for the formation of 
different RNA molecules. RNA polymerase II is responsible for the formation of mRNA 
during transcription. Table 1:3 summarises the types of RNA and the corresponding RNA 
polymerase required for synthesis. 
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Table 1:3: The types of RNA and their corresponding RNA polymerase required for formation.
24
 
RNA Polyermase RNA Production 
RNA Polymerase I rRNA 
RNA Polymerase II mRNA and snRNA 
RNA Polymerase III Low molecular weight RNA molecules and tRNA 
 
Once transcription is complete the resulting mRNA molecule undergoes some 
modifications before it is ready to leave the nucleus for protein synthesis. The unmodified 
mRNA is called pre-mRNA or the primary transcript and is much longer than the modified 
or mature mRNA that is employed during translation.24 There are regions of bases within 
genes that do not code for proteins. These regions are known as intervening sequences or 
introns and are transcribed into the pre-mRNA, but need to be removed prior to translation. 
Exon is the name given to the useful parts of the transcribed gene that are required for 
translation.24 There are numerous mechanisms which enable these transcribed introns to be 
removed from the pre-mRNA for mature mRNA production. Heterogeneous nuclear RNA 
(hnRNA) is another name given to the mRNA precursor. Pre-mRNA or hnRNA molecules 
are contained in the nucleus and have a half-life as short as a few minutes.24  
 
Introns are removed from the hnRNA by a method called RNA splicing. Splicing has to be 
highly accurate, since additional bases or missing bases in the mature mRNA molecule 
would effect the transcription process, hence the translated protein may not contain the 
correct amino acid sequence.24 Breaks or splice sites have to be introduced into the pre-
mRNA molecule. These splice sites contain specific base sequences. Specific sequences 
also occur in exons, which promote the recognition of introns; these sites are known as 
exonic enhancers.24 Splicing requires another type of RNA called small nuclear RNA 
(snRNA), which is found in the nucleus. SnRNA combines with specific proteins to create 
complexes called splicosomes. The pre-mRNA and splicosomes associate to form a 
macromolecular complex that removes introns from the pre-mRNA.24 
 
In addition to splicing, the 5’ end of the pre-mRNA molecule has a methylguanosine cap 
incorporated. It was discussed in the DNA replication section that the first nucleotide in a 
nucleic acid sequence is a triphosphate, since the first nucleotide is not hydrolysed to 
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rNMP. In the case of mRNA, this triphosphate is converted to a diphsosphate by enzymatic 
action, then guanine monophosphate (GMP) is added to the diphosphate nucleotide via its 
5’ phosphate group. Thus, a triphosphate bridge links the first two nucleosides in the 
mRNA molecule. Both the terminal guanine and the neighbouring nucleotide in the mRNA 
chain are methylated. Methylation prevents endonucleases recognising and destroying the 
polynucleotide chain.24 The modified mRNA molecule also has an adenosine polymer 
attached to its 3’ end.24 The adenosine polymer is added to the mRNA with the help of the 
enzyme, poly (A) polymerase and does not require a DNA template for the addition of the 
adenosine tail. The poly A tail also prevents the mRNA being degraded by nucleases.24 The 
release of the mRNA from the nucleus is also aided by the capped 5’ end.24 
 
1.2.4.2 Translation 
The second stage of protein synthesis translates the genetic code contained in mRNA into a 
string of amino acids, which are subsequently used in the formation of proteins. Translation 
employs a range of RNA molecules, each having there own specialised functions.  
 
The modified or mature mRNA complete with the 3’ and 5’ modifications has to be 
transported out of the nucleus, through the cytoplasm to structures called ribosomes, where 
translation takes place. Ribosomes consist of proteins and another type of RNA called 
ribosomal RNA (rRNA). There are vast numbers of rRNA in cells for protein synthesis, for 
this reason the gene coding for rRNA is repeated throughout the genome many times.24 
Ribosomes can be found in the cytoplasm or situated on the surface of organelles known as 
the endoplasmic reticulum, which are also located in the cytoplasm of the cell. The 
ribosomes consist of two units; the large sub-unit and the small sub-unit, which are 
composed of four types of rRNA; 5S, 5.8S, 18S and 28S along with ribosomal proteins. 
The larger the rRNA molecule the higher the S value associated with it (the S value is 
called the Sedimentation Coefficient).24 The large sub-unit contains three of the four types 
of rRNA; 5S, 5.8S and 28S. Hence, the small sub-unit contains the 18S rRNA.24  
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Translation consists of three distinct stages; initiation, elongation and termination. Each of 
these three stages has a different sequence of events that are involved in the decoding of 
genetic information. 
 
Initiation 
Three adjacent bases along the mRNA chain are called codons and code for a particular 
amino acid. However, some codons also code for the initiation or termination of the 
transcription process. The triplet code is another name given to three adjacent bases that are 
involved in the decoding of genetic information on mRNA. Once the mRNA is transported 
to the ribosomes, the small ribosome sub-unit binds to the mRNA chain via the first codon, 
which is the initiator codon AUG. The large sub-unit then binds to the mRNA in 
preparation for amino acid assembly.24  
 
There are three regions in the ribosome complex; Exit site (E site), Peptidyl site (P site) and 
the Aminoacyl site (A site). Each of the three-ribosome sites has important functions during 
the elongation process.24 The first codon (AUG) in the mRNA molecule is held in the P 
site, and the next codon along is held at the A site, as shown in Figure 1:11. Many protein 
initiation factors are involved in the initiation of translation. The decoding of genetic 
information is thought to take place in the small ribosome sub-unit and the catalysis of 
peptide bonds between neighbouring amino acids takes place in the large ribosome sub-
unit.24 
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Figure 1:11: Ribosome Complex. 
 
Elongation 
Another form of RNA known as transfer RNA (tRNA) is involved in translation and is 
responsible for transporting the correct amino acid to the mRNA molecule, and hence 
stringing the correct amino acid sequence together. There are approximately 50 types of 
tRNA; each is coded for by genes within the genome. RNA polymerase III is responsible 
for tRNA formation.24 
 
The translation of the genetic code contained in mRNA into a protein is achieved by 
decoding the triplet codes or codons, which are contained within mRNA. As already stated; 
three sequential nucleotide bases along the mRNA code for an amino acid. Since there are 
four bases (A, U, G and C) and three bases code for an amino acid, there are 64 (43 = 64) 
possible codons, allowing for 64 amino acids to be coded for. Since there are only 20 
amino acids; each amino acid is normally coded by more than one codon. In addition, there 
are three triplets that do not code for any amino acids, but act as initiation or stop functions 
along the mRNA chain.24 
 
Transfer RNA molecules are relatively large, containing between ~70-90 nucleotides. 
These molecules adopt distinctive configurations containing double stranded or folded 
regions known as stems. Stems are formed where the tRNA nucleotide sequence contains 
regions, which are complementary to other portions of the molecule, thus the 
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complementary regions of the tRNA molecule bind through hydrogen bonding. Loops are 
also found in the molecule due to lack of hydrogen bonding between other tRNA regions.24 
Figure 1:12 illustrates the distinctive ‘clover leaf’ configurations adopted by tRNA, due to 
the stems and loops. 
 
Figure 1:12: Structure of tRNA.
  
 
The 3’ end of the tRNA molecule always contains the base adenine, which reacts with an 
amino acid and thus acts as the attachment site. The middle loop in the tRNA has a 
sequence of three bases called an anticodon. The anticodon is directly opposite the amino 
acid binding site on the tRNA molecule and must be complementary to an mRNA codon 
for an amino acid to be added to the new peptide chain.24  
 
A tRNA molecule with an anticodon complementary to the first codon on the mRNA chain 
will bind to the ribosome at the P site (Figure 1:13). A second tRNA molecule with an 
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anticodon complementary to the second codon along the mRNA strand, will bind at the A 
site on the ribosome. Peptidyl transferase then catalyses the formation of peptide bonds 
between the amino acid at the A site and the amino acid at the P site.19, 23, 24 The tRNA at 
the P site is then transferred to the E site as the ribosome moves along the mRNA, exposing 
the next codon on the mRNA molecule.24 The amino acid at the A site is now located at the 
P site and contains two amino acids bound by a peptide bond. Another tRNA molecule with 
the correct anticodon sequence binds to the exposed A site. A peptide bond then forms 
between the amino acid at the A site and the amino acid dimer at the P site. Once the 
peptide bond is formed, the tRNA molecule at the P site moves to the E site on the 
ribosome and the neighbouring tRNA molecule which now contains three amino acids 
bonded together by peptide bonds, moves to the P site.24 This process repeats itself until all 
the appropriate amino acids are added to the growing peptide chain. The exit site is the 
actual site where the tRNA molecules are released from the ribosome complex.24 The 
process of elongation is summarised in Figure 1:13. 
 
Figure 1:13: Schematic showing the process of elongation. 
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Translocation is the name given to the process where the ribosome moves along the mRNA 
chain, releasing the tRNA held at the E site and exposing the next available codon on the 
mRNA molecule. The translation of mRNA occurs in the 5’→3’ direction.19, 24   
 
Termination 
The elongation process is stopped once the ribosome reaches one of the stop codons (UAA, 
UGA and UAG) on the mRNA molecule.19 These codons do not code for an amino acid, 
but ensures translation stops and the newly synthesised protein chain can be released from 
the tRNA by releasing factors.24 The fate of the mRNA molecule depends on how much 
protein is required. Re-translation of mRNA can occur if the protein is in high demand.19 
 
1.3 Inductively Coupled Plasma Mass Spectrometry 
Inductively coupled plasma mass spectrometry (ICP-MS) provides elemental and isotopic 
information and is capable of detecting most elements in the periodic table owing to its 
efficient ionisation source. This method is highly sensitive, selective, quantitative and 
exhibits a large linear range.10, 25 This technique also boasts the capability of multi-
elemental analysis, high sample throughput and isotope ratio measurements.12, 26-28 In 
addition, numerous methods of sampling are available including; solution sample 
introduction, laser ablation15, 29, 30 and the coupling of chromatographic techniques.28, 31-33 
For these reasons ICP-MS is an attractive alternative to traditional organic mass 
spectrometry techniques for detecting biomolecules.34-36 ICP-MS instrumentation will be 
briefly discussed in the following section and then the applications in bioanalysis will be 
reviewed.  
 
1.3.1 Instrumentation 
The instrumentation will be briefly discussed, although further sources of information will 
be referenced where appropriate. For simplicity, ICP-MS instrumentation will be broken 
down into five main sub-units, which are listed below, whilst the relative position of these 
sub-units in a conventional instrument are shown in Figure 1:14. 
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• Sample introduction system 
• The plasma – ionisation 
• The interface 
• The mass analyser 
• The detector 
 
Figure 1:14: Schematic diagram of a typical ICP-MS instrument. 
 
1.3.1.1 The Sample Introduction System 
The standard way of introducing samples into the ICP ionisation source is through solution 
nebulisation. There are many types of commercially available nebuliser,27 the most 
common being the concentric nebuliser, which is shown in Figure 1:15. The liquid sample 
is introduced through the central capillary, whilst a stream of argon gas is introduced at a 
right angle to the sample. As the sample and argon meet at the tip of the nebuliser, the 
sample is broken up into droplets due to the pneumatic action of the gas. A typical 
nebuliser uptake rate is approximately 1 ml min-1, although microflow nebulisers with 
uptake rates of between 20-600 µl min-1 have gained popularity. The main advantage of 
low flow nebulisers is that only small sample volumes are required for analysis, this is 
particularly important in the biological field, where only limited sample may be available. 
Microflow nebulisers are available from a wide range of manufacturers’ and are available 
in a wide range of materials to suit the application. Traditionally, nebulisers were 
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constructed of glass, however; other materials such as PFA, quartz and polyimide are also 
available to suit the application. For example, PFA nebulisers have the advantage of being 
inert and resistant to acids, bases and solvents.  
 
The liquid droplets formed in the nebuliser aerosol vary in size. Only the small droplets, 
typically those <6 µm in size are efficiently ionised in the plasma. Therefore, large droplets 
are removed with the aid of spray chambers. Like nebulisers, there are many types of spray 
chamber, but they all carry out the same function of excluding large aerosol droplets and 
allowing the smaller droplets to go through to the plasma. 
 
Figure 1:15: Concentric nebuliser, reprinted with permission of Meinhard Glass Products (Colorado, 
USA). 
 
1.3.1.2 The Plasma 
A mass spectrometric method requires the analyte to be ionised, which is achieved here 
using the plasma. A plasma is a partially or fully ionised gas, which in the case of the ICP 
is formed at atmospheric pressure. Argon gas, a torch, radio frequency (RF) coil and a RF 
generator are required for plasma generation.37 The torch is usually made from quartz and 
consists of three concentric tubes; sample injector, outer and middle tube, as illustrated in 
Figure 1:16. The RF generator is generally operated between 1100-1500 W and provides 
RF power to the coil, this results in an oscillating current within the coil, which in turn 
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produces an electromagnetic field. A high voltage spark is then applied to the argon 
flowing through the torch to ionise the gas. This releases electrons which are then 
accelerated in the magnetic field and cause further ionisation of the gas by colliding with 
argon atoms. This results in a chain reaction, which effectively sustains the plasma and is 
known as the plasma discharge.27, 37 The argon plasma is maintained at atmospheric 
pressure, but temperatures within the plasma range from 6000-10 000 K. At these 
temperatures almost everything is ionised, making ICP-MS a versatile analytical tool 
capable of detecting most elements in the periodic table.  
 
 
Figure 1:16: RF coil and torch arrangement. 
 
1.3.1.3 The Interface Region 
It was mentioned in the above section that the plasma is formed and maintained at 
atmospheric pressure. But, the mass analyser and detector are operated in a vacuum at 
approximate pressures of 10-6 mbar. For this reason, the pressure has to be reduced so the 
analyte ions can be analysed in vacuum. The role of the interface is to sample ions from the 
atmospheric pressure plasma and step down the pressure, so ions can be extracted through 
to the analyser region.  
 
Two water cooled metal cones (usually made from nickel or platinum) make up the 
interface region. The first larger cone is called the sampler cone and has an orifice of 
approximately 0.8-1.2 mm is the centre and is positioned at the end of the plasma. Behind 
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the sampler cone sits the skimmer cone, which has a slightly smaller orifice diameter of 
~0.6 mm.38 The region between the two cones is called the expansion region and is 
evacuated to pressures of approximately 2-3 mbar, which is effectively an intermediate 
pressure between the atmospheric plasma and the vacuum of the analyser region. As the 
atmospheric pressure plasma ions are transported through the sampler cone, the plasma 
expands and the ions exceed the speed of sound. This results in a shock wave forming 
behind the sampler cone, within which is the zone of silence. Figure 1:17 illustrates the 
interface region along with the positions of the shock wave and zone of silence. The 
skimmer cone effectively sits within the zone of silence and samples ions from this 
region.27 
 
Figure 1:17: The interface region. 
 
1.3.1.4 Mass Analyser and Detectors 
The role of the mass analyser is to separate the ions that were generated in the plasma, 
according to their mass-to-charge ratio (m/z). Once extracted through the interface region, 
the ion beam is directed towards the mass analyser by a series of lenses. These lenses are 
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essentially metal components that have voltages applied to them, and enable the ion beam 
to be electro-statically directed to the analyser. 
 
There are many types of mass analyser available. These include; quadrupole, 
collision/reaction cell, time-of-flight (TOF), electrostatic and magnetic analysers. The 
quadrupole analysers are the most common, mainly due to their stability and relatively low 
cost. The theory and principles behind the operation of the collision/reaction cells and 
electrostatic and magnetic analysers will be discussed in sections 1.3.2.2 and 1.3.2.3 
respectively. The theory of the remaining mass analysers is beyond the scope of this 
introduction, but such literature is available elsewhere.27  
 
Once the plasma ions have been separated according to their m/z they are directed to a 
detection system. The most common detectors are those based on the electron multiplier 
and Faraday cup. The latter of these is normally employed for extending the dynamic range 
of the instrument and will be mentioned in more detail in section 1.3.2.3.27  
 
1.3.2 Application of ICP-MS to Genomics Research 
There has been increasing interest over the past two decades concerning the analysis and 
detection of DNA. The inspiration for this interest has come from the ability to identify 
individual gene sequences and effectively decode the genome. There are many methods 
available for the detection and quantitative determination of DNA, each has their merits and 
drawbacks. The traditional method of detecting DNA is to covalently attach fluorescent 
labels to the molecule.39, 40 The DNA-fluorophore conjugates are stable and can withstand 
the conditions used during polymerase chain reaction (PCR) procedures, but the fluorescent 
labels and instrumentation are costly.39 Radioisotope labelling is another popular method of 
detecting and quantifying DNA,41 as in the Post Labelling Assay (PLA), which employs 
32P.42 Even though this technique is sensitive, there are concerns about safety, cost and time 
taken to carry out the analysis.  
 
Surface Enhanced Resonance Raman Scattering (SERRS) has been recently employed for 
detecting and quantifying nucleotides. Raman signals of Raman active molecules are 
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enhanced by employing roughened metal surfaces and metal particles. Raman scattering 
can be dramatically enhanced by Ag and Au. Hence, nucleic acids and other biomolecules 
labelled with these metals can be detected at low levels.39, 43, 44 Further Raman signal 
enhancement can be obtained by depositing Ag metal onto Au particles.39 It has been 
reported that SERRS can exhibit limits of detection three orders of magnitudes lower than 
those obtained with fluorescent analysis methods.40  
 
There have been numerous other methods of quantifying DNA, some of these methods 
based on optical,39 electrical45 and colorimetric methods.46 
 
It has already been discussed that ICP-MS can be employed for the detection of 
biologically important molecules if these molecules contain ICP detectable elements. Table 
1:4 summarises the metals associated with some commonly known metalloproteins. 
Conversely, if the biomolecule does not contain an element which is easily detected by 
ICP-MS, or lower limits of detection are required, the analyte can be labelled with an 
elemental tag.6, 13, 15-17, 47-49  
Table 1:4: Elements contained in typical metalloproteins.
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Element Metalloenzyme/ Metalloprotein 
Fe Transferrin, Ferritin, Catarase, Nitrogenase, Chitochrome. 
Mo Nitrogenase 
Zn Carbonic anhydrase, Carboxypeptidase, Alcohol dehydrogenase, Alkaline phosphatase, DNA 
polymerase and RNA polymerase. 
Cu Plastocyaneine 
Se Gluthathion peroxidase 
Ni Urease 
 
Phosphorus is contained in DNA and phosphorylated proteins, likewise S is contained in 
the amino acids methionine and cysteine, thus nucleic acids and proteins can be detected by 
ICP-MS.2 However, the analysis of these two biologically important elements is fairly 
problematic due to the high ionisation potential of P and S and the abundance of 
polyatomic interferences at the low m/z ratios. These interferences originate from the 
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sample solvent and atmospheric gases. Table 1:5 summarises the ionisation potentials and 
common interferences associated with these two elements.  
Table 1:5: Ionisation potential and common interferences for P and S. 
Element 
First Ionisation 
Potential (eV) 
Common Interferences Limit of Detection 
P 10.5 
14N16O1H+, 15N15N1H+, 15N16O+   
14N17O+, 13C18O+, 12C18O1H+ 
1 ng ml-1 (quadrupole) 
<50 pg ml-1 (high res) 
    
S 10.4 
16O2
+, 14N18O+, 14N18O1H+, 15N17O+, 
15N16O1H+ 
20 ng ml-1 (quadrupole) 
<50 pg ml-1 (high res) 
 
The introduction of collision/reaction cell technology and high resolution instruments has 
overcome the problems associated with P and S analysis. Both methods minimise 
interferences associated with these elements.2, 10 However, the sensitivity of these two 
elements is still inferior compared to metal ions. The principles of collision cells and high 
resolution instruments will be discussed in subsequent sections, along with the recent 
applications of ICP-MS to biological analysis. 
 
1.3.2.1 Cool Plasma 
ICP-MS instruments are generally operated with a forward power of between               
1100-1500 W, however, by decreasing the forward power to approximately 800 W, plasma 
temperature is lowered and a cool plasma is produced. Operating a cool plasma has the 
advantages of reducing many argon based polyatomic interferences that occur during 
normal operation. This is one method of minimising the formation of problematic 
interferences. However, the cool plasma approach is susceptible to matrix effects. For 
example, HPLC eluents containing organic solvents or buffers may cause severe matrix 
effects such as signal suppression.51  
 
1.3.2.2 Collision/Reaction Cells 
An alternative method of removing interferences is to move the analyte away from the 
problematic mass-to-charge ratio. This can be achieved by reacting the analyte ion with a 
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reactive gas to form an ion of higher m/z, which can then be measured. Alternatively, the 
interfering species can be converted to a different mass or to a neutral species, so the 
analyte ion can be measured free from interferences. Either method results in the removal 
of the interfering species. However, such reactions may also create increased interferences 
in other parts of the spectrum.51 The removal of interferences takes place in a 
collision/reaction cell, which is a multipole consisting of either; a quadrupole, hexapole or 
octapole. The cell rods have RF (and DC in the case of quadrupole cells) applied to them. 
Collision/reaction cells therefore act as an ion focussing guide and not a mass separation 
device due to the RF only field.51 Quadrupole cells however can be employed in the RF 
only or RF/DC mode, allowing mass separation in the latter case.52 Once inside the cell, 
ions collide with a collision gas, which is present at low pressure and typically bled into the 
multipole at a rate of 0.5-10 ml min-1. The collision cell is generally operated in 
conjunction with a RF/DC quadrupole mass filter and is positioned between the interface 
and the mass analyser. Hence, the incoming ion beam enters the collision/reaction cell and 
undergoes the appropriate reactions before entering the quadrupole mass filter.  
 
There are six main reactions which can take place within collision/reaction cells, these are 
summarised below along with examples of each reaction: 
 
i. Hydrogen atom transfer53 
Ar+ + H2 → ArH
+ + H 
ii. Charge transfer54 
O2
+ + Xe → Xe+ + O2 
iii. Proton transfer53 
ArH+  + H2 → H3
+ + Ar 
iv. Condensation55 
CeO+ + O2 → CeO2
+
 + O 
v. Association55 
Zr+ + nO2 → ZrOn
+ 
vi. Collisional dissociation 
Ar2
+ + He → Ar + Ar+ + He 
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The charge transfer reaction between O2
+ and Xe was successfully used to reduce the 32O2  
interference enabling 32S determination.54  
 
Collision/reaction cells were originally developed for organic MS to generate daughter 
fragments/product ions from parent species. The chances of identifying the structure of the 
parent molecule increased with increasing collision induced fragmentation steps. However, 
in elemental MS polyatomic interferences had to be minimised, so secondary reactions 
were a disadvantage.51 There are several types of collision/reaction cell for ICP-MS which 
are commercially available. Table 1:6 summarises a few of the commercially available 
collision/reaction cell ICP-MS instruments, along with the type of multipole employed. 
Table 1:6: Commercially available collision/reaction cells.
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Instrument Manufacturer Multipole RF or DC potentials 
PQ ExCell Thermo Elemental Hexapole RF only 
7500c Agilent Octapole RF only 
Sciex Elan DRC Perkin Elmer-Sciex Quadrupole RF only or RF and DC 
 
The extent of cell reactions can be controlled by manipulating ion energy input. By making 
the collision/reaction cell potential more positive with respect to the plasma potential, or by 
using high reaction gas pressures, the ion kinetic energy can be retarded upon entering the 
cell. Slower ions tend to have larger reaction cross sections, therefore increasing cell 
reactions, this effect is known as the ion kinetic energy effect (IKEE).56, 57 Dexter et al., 
demonstrated that cell reactivity is significantly effected by IKEE for both exothermic and 
endothermic reactions, where exothermic reaction rates are increased by implementing 
IKEE and endothermic reaction rates are decreased.56 
 
Unwanted secondary reactions can take place in the cell, resulting in unwanted product ions 
that need to be removed. These unwanted products from the collision cell are prevented 
from entering the quadrupole by discrimination by kinetic energy or mass.51 By adjusting 
the collision cell bias in relation to the quadrupole, the unwanted products of the reaction 
can be prevented from entering the mass analyser. For example, by making the collision 
cell slightly less positive than the quadrupole, analyte ions which have more energy than 
the collision cell bias are transmitted to the quadrupole and the unwanted species which 
52 
have the same energy as the cell bias are rejected.51 This is commonly known as kinetic 
energy discrimination (KED).51, 58 An energy barrier is effectively created between the 
collision cell and quadrupole. Only the analyte ions which have the required energy are 
able to cross this barrier and enter the quadrupole. Hence, collision/reaction cell rates can 
be increased and unwanted product ions from the cell removed by implementing IKEE and 
KED respectively.56 KED can only be employed if there is a significant energy difference 
between the analyte and unwanted product ions.52, 57 All three of the instruments detailed in 
Table 1:6 can employ KED.  
 
Mass discrimination is another way of rejecting the unwanted collision cell products. The 
diffuse stability boundaries of higher order multipoles, makes them unable to discriminate 
by mass.51 However, quadrupoles are mass discriminatory, since they operate in DC and 
RF modes and the stability boundaries are well defined. Since these cells can discriminate 
against mass, unwanted product ions are easily removed. Reactive gases such as ammonia 
and methane are commonly used, which are more effective at reducing interferences than 
the inert gases such as helium.51 It should also be noted that the quadrupole cell can also 
discriminate using KED.52 
 
The presence of a collision/reaction gas in the multipole results in decreased transmission 
of lighter ions due to scattering. This effect is more pronounced for heavier collision gases 
(e.g. O2) compared to lighter gases (e.g. He). Transmission of heavier ions can be enhanced 
by the presence of a collision gas,32 since the lighter gas molecules prevent the heavier 
analyte ions diffusing out of the cell. This is referred to as collisional focussing and is 
relevant to both elemental and molecular mass spectrometry.27, 54  
 
Collision/reaction cells have been used extensively for the detection of 31P and              
32S.9-11, 32, 54, 59-61 The common interferences for these elements are summarised in Table 
1:5. One method of minimising interferences at m/z 31 and 32 is to employ oxygen 
collision gas to form the oxide of P or S. The corresponding oxide ion is then measured at 
m/z 47 and 48 for 31P16O and 32S16O respectively.9, 11, 59 Thus, the m/z of P and S is 
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increased by 16, which moves the analytes away from the polyatomic interferences at m/z 
31 and 32.  
31P+ + O2 → 
31P16O+ + 16O  Reaction constant k = 5.3 x 10-10 molecules-1 cm3 s-1 
          Reaction enthalpy ∆Hr = -71.4 kcal mol
-1 
32S+ + O2 → 
32S16O+ + 16O Reaction constant k = 1.8 x 10-11 molecules-1 cm3 s-1 
          Reaction enthalpy ∆Hr = -6.2 kcal mol
-1 
 
The above data (obtained from reference 9) shows that the reactions of S and P with 
oxygen are kinetically and thermodynamically favourable. However, the reaction of oxygen 
with the major interferences; O2
+, NO+ and NOH+ do not occur due to the reactions being 
kinetically and thermodynamically unfavourable in the cell conditions.9 Bandura et al., also 
noted that 47,48Ti could interfere with 31P16O and 32S16O, however, Ti readily reacts with 
oxygen at a rate comparable to P and S reaction rates (k = 5.0 x 10-10).9 Thus, any 47,48Ti in 
a sample would be oxidised to TiO+ and thus be removed from m/z 47 and 48.  
 
An alternative collision cell reaction for the direct determination of 31P employs He 
collision gas in conjunction with a collision/reaction cell.1, 60-62 The interfering polyatomic 
ions (predominantly 14N16O1H and 15N16O) collide with the He gas to a greater extent than 
the elemental 31P analyte, due to their greater cross sectional area. As a result, the 
polyatomic ions decelerate and lose energy rapidly due to the collisions. Then by applying 
KED, an energy barrier is essentially created that allows the higher energy 31P ions through 
to the mass analyser, but prevents the lower energy polyatomic ions being transmitted.60 In 
addition to employing He for reducing polyatomic interferences, Mason et al., reduced 
interfering polyatomic ions at m/z 32 by employing a hexapole collision cell with mixtures 
of He, Xe and H2 gases.
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1.3.2.3 High Resolution ICP-MS 
Resolution is defined from the following equation; R = m/∆m, where m is the analyte mass 
and ∆m is the peak width at 5% peak height. Quadrupole based instruments have typical 
mass resolution capabilities of 300, yet resolutions of 10 000 are possible with high 
resolution instruments.27, 63 The improved resolving power of high resolution instruments 
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enables P/S to be separated from their corresponding polyatomic interferences, and thus 
enables P and S to be determined directly and avoids using collision/reaction cells. Table 
1:7 shows the resolution required to separate P and S from some common interferences, 
such resolutions cannot be achieved with a standard quadrupole based instrument.  
Table 1:7: Resolution required to separate P and S from their common interferences.
27, 64
  
Isotope Interference Resolution 
31P 14N16O1H 970 
32S 
 
16O2 
14N18O 
15N16O1H 
14N16O1H1H 
1800 
1061 
1040 
770 
 
High resolution instruments employ two types of analyser; electrostatic and magnetic mass 
analysers. The magnetic analyser can be placed before the electrostatic analyser (ESA), in 
what is known as the reversed Nier-Johnson geometry, whereas the alternative arrangement 
is referred to as the forward Nier-Johnson geometry.27 The reversed Nier-Johnson geometry 
is employed in the Element 2 sector field instrument; the reasons for this will be explained 
later in this section; whilst the forward geometry is employed in the Thermo-Finnigan 
Neptune and Nu Plasma multi-collector instruments. Figure 1:18 shows a schematic of a 
typical reversed Nier-Johnson magnetic sector instrument.  
55 
 
Figure 1:18: Schematic of a reverse Nier-Johnson magnetic sector instrument. 
 
Ions formed in the plasma are accelerated along a curved flight path at approximately 8 kV 
where they pass through an ion lens system before reaching the magnetic analyser, which is 
water cooled to provide good mass stability.65 The magnetic field is perpendicular to the 
flight path and is both mass and energy discriminatory. Ions are separated according to 
mass due to the fact that ions are deflected in the magnetic field according to their mass-to-
charge ratio.27, 66  
  
A limitation on resolution in ICP-MS is the wide ion energy spread. The ESA is therefore 
energy focussing and helps improve resolution.12 By having an ESA after the magnet, the 
energies of the ions are focussed before reaching the detector,66 which in turn lowers the 
overall energy spread of the ions. A 2 eV kinetic energy spread has been reported for ions 
entering the Element 2 (Thermo Finnigan, Bremen, Germany) mass spectrometer.67 This 
has the effect of improving abundance sensitivity and hence resolution; which is an obvious 
advantage in ICP-MS.27 An ESA typically consist of two curved plates with DC voltage 
applied to them, the inner plate is usually negatively charged and the outer plate positively 
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charged. Hence, the inner plate attracts ions and the outer plate repels them, thus ions are 
focussed and deflected as they pass through the two plates.27, 65 
 
Ions are separated according to m/z only when these two mass analysers are used in 
conjunction, since the magnetic analyser is mass and energy discriminatory and the ESA is 
energy only.27 Both analysers provide angular focussing, that is the ion beam is focussed as 
it exits the analyser. For this reason, such instruments are referred to as double  
focussing.12, 27 
 
Electron multiplier detectors are commonly employed in ICP-MS instruments. The 
detection system used in the Element 2 (Thermo Finnigan, Bremen, Germany) is a dual 
mode secondary electron multiplier (SEM). After passing through the magnetic and 
electrostatic analyser, the ion beam hits a conversion dynode where electrons are produced. 
These electrons are then directed to the SEM where secondary electrons are formed upon 
impact with the multiplier surface. The secondary electrons impact again on the electron 
multiplier surface forming more and more electrons, which results in a cascade effect. The 
current from the released electrons can then be converted to a signal. Counting and 
analogue SEM detection modes are available in the Element 2. Analogue detection mode 
allows elements of approximately 1 mg l-1 concentration to be measured. A Faraday 
detector can be employed for extending the linear range further, with concentrations of 
approximately 1000 mg l-1 potentially measured. A Faraday cup is essentially a hollow 
device which the ion beam enters. The charge (positively charged ion beam) is collected on 
a capacitor which is then discharged, the ion detection system then processes the number of 
discharges.65 The approximate intensity (counts per second) that each detector operates 
along with the approximate concentrations measurable with each detector is shown in 
Figure 1:19 (data taken from reference 68). 
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Figure 1:19: Approximate signal intensity and concentration range of each detector for the Element 
2XR.
 68
 
 
The resolution of most commercial instruments can be adjusted. For example, the Element 
2 is a second generation high resolution instrument and has three fixed resolution settings; 
low (resolution ~300), medium (resolution ~4000) and high (resolution ~10 000). The 
resolution is set by adjusting the widths of slits which are positioned at the entrance and 
exit of the mass spectrometer, these slits are known as the entrance and exit slits.12 Low 
resolution is achieved by using wide slits, as the slit width decreases the resolution 
increases. Thus, high resolution has the disadvantage of degrading sensitivity due to the 
narrow slit widths. At a resolution setting of 1460 which is needed to resolve 31P from 
15N16O, ion transmission is only 53%.63 Only 1-2% ion transmission is obtained in high 
resolution setting compared to low resolution. This can be a problem if low limits of 
detection are needed.  
 
Flat topped peaks are obtained when operating in low resolution mode, which are useful for 
obtaining precise measurements, since the signal intensity should be the same wherever the 
peak is sampled due to the flat top.12 The peak shape becomes progressively more 
triangular as the resolution is increased. This causes measurements to become less precise, 
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since signal intensity will vary considerably depending on where the peak is sampled.27 In 
high resolution mass spectrometry, peak widths become progressively narrower at the low 
mass end of the spectrum and as resolution increases. This is because peak width is a 
function of both mass and resolution, as defined by the equation R = m/∆m.67 Despite the 
reduction in sensitivity upon increasing resolving power, these instruments by character 
have good sensitivity and low background levels in low resolution mode. As a result, 
heavier mass elements such as Au and Pt which only require low resolution can exhibit 
extremely low limits of detection.12, 27, 63  
 
Two modes of scanning are available for high resolution instruments; magnetic scanning 
and voltage scanning. A Hall probe controls the magnetic field in the magnetic analyser, 
and is located within the magnet gap.27 Magnetic scanning has the disadvantage of being 
very slow due to the time required for the magnet to move between masses and        
settle.27, 63, 67 An additional disadvantage of magnetic analysers is a phenomenon known as 
magnet hysteresis.69 If a magnetic field is applied to a material, the material will experience 
a change due to the applied magnetic field, but it will not return back to its original state 
when the applied magnetic field is removed. Another field of opposite direction is required 
to return the material back to its original state, which ultimately increases the time of a 
magnet scan in mass spectrometry. Voltage scanning has the advantage of being much 
faster.64 In this mode of measurement, the magnetic field is held constant whilst the voltage 
is varied to transmit the analyte ions. Voltage scanning can measure a peak up to 30% 
above the mass where the magnet is settled, hence the magnet does not necessarily have to 
be moved when voltage scanning is employed.67  
 
Along with a choice of voltage or magnet scanning, the Element 2 has two scanning modes; 
mass accuracy and speed. The choice of scan is dependent upon the application. For 
standard quantitative analysis of solutions, mass accuracy should be implemented. This 
scanning mode is set by default in the instrument software and is used when mass accuracy 
is important and not scanning speed. Conversely, for applications requiring faster magnet 
scanning, such as chromatographic and laser ablation applications, speed scanning should 
be selected.70  
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There are three fixed magnet positions on the Element 2; zero mass (m/z 0), rest mass    
(m/z ~100) and high mass (m/z~ 254). The two different scanning modes refer to the way 
the magnet jumps between these masses during the scanning cycle. Each method will be 
discussed in turn.70 
 
Mass Accuracy 
The magnet jump cycle during a mass accuracy scan is summarised in Figure 1:20. Before 
the measurement of the analytes begins, the magnet goes through an initial scanning cycle, 
where the magnet jumps from the rest mass to the high mass and then to the zero mass 
point.70 The final step in the initial magnet cycle is for the magnet to jump from the zero 
mass point to the first analyte isotope.70 Only after the initial scan are the isotopes of 
interest scanned and measured. However, before returning to the first analyte isotope for a 
repeat scan, the magnet again jumps to the high mass then the zero mass point. After the 
required number of scans has been carried out, the magnet returns to the rest mass. The 
continual jumping of the magnet between the fixed reference points during a scan 
inevitably increases analysis time, especially when multiple isotopes are to be determined.70  
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Figure 1:20: Magnet cycle during mass accuracy scan. 
 
Speed Scanning 
This scanning mode has a much shorter scanning cycle, thus less time is spent moving and 
settling between masses, which has the effect of decreasing analysis times. This is 
particularly important where fast transient peaks are to be measured and as many data 
points as possible are required. The schematic in Figure 1:21 summarises the magnet 
movement during a speed scan. It is important to note that an initial magnet cycle is not 
conducted during a speed scan. Also, the magnet does not jump to the high mass, followed 
by the zero mass point during the scan cycle as observed with mass accuracy scanning. 
Ultimately, speed scanning involves the magnet repeatedly jumping to and from the 
selected isotopes only.70 Again once scanning is complete, the magnet returns to the rest 
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mass. Settling time refers to the time taken for the magnet to move and settle between the 
selected isotopes during a scan. The default settling times given in a method can be 
amended to decrease analysis time further, but caution should be taken when reducing 
settling times too much, since this will have the effect of decreased signal intensity for the 
selected analyte. 
 
Figure 1:21: Magnet cycle during speed scanning. 
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1.4 Linear Ion Trap Mass Spectrometry 
Since all structural information is lost during ICP analysis, complementary analytical 
techniques are advantageous for providing such information. Organic mass spectrometry 
allows for structural analysis and can be used as a complementary technique to ICP-MS as 
opposed to a competing technique.1, 2, 4, 5, 49 Both elemental and structural information can 
be obtained when using the two mass spectrometry methods in parallel, which may be 
useful in the fields of genomics and proteomics.49 
 
Linear ion trap instruments have found a niche within genomic and proteomic research, 
predominantly for the determination of nucleic acid and peptide sequences.71-74 Figure 1:22 
shows a schematic of a typical ion trap instrument. There are parallels between the 
instrumentation found in organic and inorganic mass spectrometers. The ion trap employs 
an atmospheric pressure ionisation source, ion optics/ion guides, mass analyser to isolate 
ions of interest and finally a detection system. This is similar to elemental mass 
spectrometry; however, the principles of operation of some aspects do vary between the 
two mass spectrometry techniques as will be discussed. 
 
 
Figure 1:22: Schematic showing the linear ion trap instrumentation of a Thermo Finnigan LTQ. 
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1.4.1 Instrumentation 
1.4.1.1 Ionisation 
There are many techniques available for analyte ionisation, these include; electrospray 
ionisation (ESI), atmospheric pressure chemical ionisation (APCI) and atmospheric 
pressure photoionisation (APPI) amongst others. The choice of ionisation technique 
depends on the nature of the sample and the application. Only electrospray ionisation (ESI) 
will be discussed here due to its relevance in this project. Information regarding the other 
ionisation techniques is available elsewhere.75-77 
 
ESI can be applied to any compound that forms an ion in solution, making it especially 
good for biological molecules that often are highly charged and polar. For example, nucleic 
acids contain nitrogen containing nucleobases, which can become protonated and thus carry 
a positive charge in solution. Therefore, high molecular weight molecules such as nucleic 
acids and proteins can be analysed when using ESI due to multiple charging of the analyte 
ions, which creates a range of mass-to-charge ratios that most mass spectrometers can 
comfortably analyse.78 The process of ESI is illustrated in Figure 1:23. A solution 
containing the analyte flows through a fused silica capillary towards the ESI needle, which 
has a high voltage applied to it, typically in the region of 3-6 kV.76, 79 The liquid surface is 
disrupted by the applied electric field, which results in a fine mist containing small charged 
droplets being formed. This is known as an electrospray, although nebulisation can also be 
assisted with a nebuliser gas.79, 80 There are two accepted mechanisms of ion formation; 
charge residue model (CRM) and ion evaporation model (IEM).81 In both cases the sample 
solvent evaporates from the droplets, which results in increased charge density on the 
droplets, due to their decreasing size. According to the charge residue model, the 
electrostatic repulsion within the droplet will eventually exceed the surface tension of the 
sample solvent. At this point, which is known as the Rayleigh stability limit or coulomb 
explosion,76, 82 the droplets divide into even smaller droplets. The process of dividing 
droplets is repeated until all the solvent is removed, at which point the analyte/parent ions 
are converted to a free ion in the gas phase.78 In the case of the ion evaporation model, ions 
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are evaporated from the droplet at a certain droplet size due to coulombic repulsion.81 The 
entire electrospray process occurs at atmospheric pressure.  
 
 
Figure 1:23: ESI process in positive ion mode. 
 
The efficiency of ESI depends on the applied voltage, droplet size, volatility and surface 
tension of the sample solvent. A compound with high charge will have improved ionisation 
compared to a lower charged compound.78 Likewise, a higher voltage is required for 
producing a stable electrospray for high surface tension solvents.79 
 
Positive or negative ions can be generated at the source depending on the application. If 
positive ions are to be analysed the ESI needle is positively charged, so positive ions are 
repelled from the needle and ejected into the transfer capillary. Likewise, the needle is 
negatively charged for the analysis of negative ions. When sample quantity is restricted and 
only small sample volumes are available, nanospray ionisation (NSI) is possible. The 
ionisation process is identical to ESI, but ionisation and mass spectrometry analysis is 
possible with sample volumes as low as 1 µl. 
 
Matrix-assisted laser desorption ionisation (MALDI) is also widely used for the analysis of 
large biomolecules such as DNA and proteins.75, 83, 84 As its name suggests, the ionisation 
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process involves the use of a laser (ultraviolet or infrared) to ionise the analyte with the aid 
of a matrix. The matrix contains small organic molecules that strongly absorb the laser 
incident light.75 Singly charged ions are predominantly formed by MALDI as opposed to 
multiply charged species observed with ESI, and Time-of-flight (TOF) mass analysers are 
typically employed. In addition, MALDI is more tolerant to salts, buffers and solvents, 
although the removal of such contaminants improves the quality of the mass spectra. 
Conversely, the presence of buffers in ESI can contaminate the source and create very 
complicated spectra due to the formation of adducts. Therefore, volatile buffers at low 
concentration are preferred for ESI.75  
 
1.4.1.2 Interface 
The ions formed in the ionisation source are transferred to the mass analyser via the transfer 
capillary, which is heated to approximately 270 oC for ESI. Upon exiting the transfer 
capillary, the ions travel through the tube lens where the ions are focussed for transmission 
through the skimmer. As in ICP, the skimmer acts to step down the pressure between the 
interface (~1.3 mbar) and the mass analyser region (~0.067 mbar).78 
 
1.4.1.3 Ion Guides and Optics 
Once the ions are transmitted through the skimmer, they travel through a series of ion 
guides and lens. Two quadrupoles and an octapole help guide the ions to the mass analyser. 
Quadrupole 1 and 2 consists of four square profile rods, which have RF and DC voltages 
applied to them. The ions initially enter quadrupole 1; those ions with a stable path through 
the quadrupole are transmitted. Subsequently, the ions are guided by a lens to quadrupole 2. 
Finally, the ions are guided through the gate lens followed by the octapole and then the 
mass analyser. The injection of ions into the mass analyser is controlled by the gate lens 
(see Figure 1:22).78 
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1.4.1.4 Quadrupole Linear Ion Trap Mass Analyser 
Like a conventional quadrupole, the quadrupole linear ion trap consists of the four parallel 
rods, but the rods of a linear ion trap are cut into three separate sections; two end sections 
and a centre section. The centre rod is 37 mm in length and the two end sections are 12 mm 
in length. Two of the central rods have a 30 x 0.25 mm slit cut into them to allow ions to be 
ejected from the analyser, these rods are therefore known as the exit rods.78, 85  
 
A DC voltage is applied to each of the quadrupole rod sections, the central section having a 
lower potential than the two end sections, which has the effect of trapping the incoming 
ions in the axial direction.78, 85 Table 1:8 shows the potentials applied to each rod section 
during positive ion storage and analysis. A large potential well is created in the centre 
quadrupole section during mass analysis, due to the increased potential of +20 V on the two 
end sections.  The potentials are reversed for negative ion storage and analysis.78 
Table 1:8: DC potentials of the linear ion trap during positive ion storage and transmission.
78
 
Rod Section Ion Storage Potential (V) Mass Analysis Potential (V) 
Front -9 +20 
Centre -14 -14 
Back -12 +20 
 
Storage in the radial direction is achieved by applying AC voltages to the quadrupole rods. 
The frequency of the AC voltage is constant and in the radio frequency range, but the 
amplitude varies, this voltage is referred to as the main RF voltage.78 During ion storage the 
main RF voltage is low; so ions are stable within the quadrupole; this is called the RF 
storage voltage. During analysis, the RF potential is ramped at a constant rate which has the 
effect of causing ions of increasing mass-to-charge ratio to become unstable and oscillate in 
the radial direction. Eventually, the ions become so unstable that they are ejected through 
the exit rods. The resonance voltage is the voltage at which the ion of defined m/z is ejected 
from the quadrupole ion trap. The ejected ions impinge on the conversion dynodes to 
produce ions which are consequently directed to electron multiplier detectors.78  
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The ion storage, isolation, fragmentation and scan out events that take place in the trap are 
summarised below and are illustrated in Figure 1:24-Figure 1:27, which only show the 
central quadrupole sections for diagram simplicity. 
 
i. Ion Storage 
• DC voltages applied to the three quadrupole rod sections, the central 
sections having a lower voltage to create a potential well and trap ions in the 
axial (z) direction. 
• Main RF voltage amplitude is low, so ions are stable in the radial (x,y) 
direction and therefore confined in the mass analyser. This is known as the 
storage voltage.78 
 
Figure 1:24: Ion Storage. 
 
ii. Ion Isolation 
• Applicable to single ion monitoring (SIM), selected reaction monitoring 
(SRM), consecutive reaction monitoring (CRM) and general tandem MS 
(MSn). 
• AC voltage is applied to the exit rods in what is called the ion isolation 
waveform voltage.78  
• An ion of specified m/z is trapped by the main RF and ion isolation 
waveform, whilst all other ions are ejected from the ion trap. 
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Figure 1:25: Ion isolation.  
 
iii. Collision/Fragmentation 
• Applicable to SRM, CRM and MSn. 
• Ion movement in the radial direction is stimulated by voltages, which are 
applied to the exit rods and is known as the resonance excitation voltage.78 
• This voltage is not sufficient to eject the ions, but causes the ions to collide 
with He.78 
• Eventually the parent ion will fragment due to successive collisions with He, 
to form product ions. 
 
 
Figure 1:26 Parent ion fragmentation. 
 
iv. Ion Scan Out 
• Ion ejection is facilitated by the resonance ejection RF voltage that is 
applied to the exit rods.78 
• The amplitude of the resonance ejection RF voltage is ramped to resonate 
the ions.78 
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• During resonance the ion moves further away from the centre of the trap. 
Space charge effects are smaller and the main RF voltage is stronger the 
further away from the trap centre, which has the effect of ejecting the ion.78 
 
 
Figure 1:27: Product ion scan out from the linear ion trap. 
 
Linear ion traps have numerous advantages over the traditional three dimensional ion traps. 
Firstly, linear ion traps exhibit enhanced trapping efficiencies due to the reduced axial 
motion induced by collisions with the He dampening gas.86 Space charge effects are 
defined as the repulsion of ions of like charge which inevitably occurs in mass 
spectrometry.87 This effect is detrimental to mass spectrometer performance, since it results 
in broad peaks, loss of resolution and reduced sensitivity.86, 88 Since linear ion traps are 
larger than their three dimensional counterparts, they are capable of storing more ions 
before space charge effects become apparent.85, 86 In addition, ions are focussed along the 
axial direction, in a line along the centre of the linear ion trap, compared to point focussing 
with three dimensional traps. It has been reported that line focussing may be beneficial in 
minimising space charge effects.86  
 
The ion trap allows the analyte ion with defined m/z to be stored, fragmented and then 
transmitted to the detector. Unlike ICP-MS where fragmentation and secondary reactions 
are to be avoided within collision/reaction cells, molecular mass spectrometry utilises such 
reactions for structure elucidation.75 As discussed above, the mass analyser is filled with He 
gas which can be used to induce fragmentation of the parent ions through collisions. The 
resulting fragment ions are called product ions, which can be analysed. This type of mass 
analysis can be repeated many times depending on how much structural information is 
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required for a compound, since each fragmentation step reveals more information on 
structure. An MS/MS experiment employs two stages of ion selection and fragmentation, 
followed by analysis of the product ions. However, MSn can be used, where n is the number 
of stages in the mass analysis.  
 
As well as inducing fragmentation, He gas also acts as a buffering gas and induces 
collisional focusing. The kinetic energy of the injected ions is reduced in the ion trap by 
collisions with He which ultimately prevents ions diffusing out of the quadrupole, but 
keeps them near the centre of the analyser. This has the effect of increasing       
sensitivity.75, 78, 85 
1.4.1.5 Detector 
Noise is minimised in the linear ion trap by orientating the two electron multiplier detectors 
off-axis (Figure 1:22). As ions are ejected from the linear ion trap via the exit rod slits, they 
impinge on a conversion dynode where secondary particles are produced upon impact. If 
the instrument is operated in negative ion mode, the conversion dynode will release 
positively charged particles, conversely, negative particles are released from the conversion 
dynode when in positive ion mode.78 The secondary charged particles are then directed 
towards the off-axis secondary electron multiplier which works in a similar manner to those 
described in section 1.3.2.3. 
 
1.4.2 Scanning Modes 
It has been discussed that the linear ion trap is capable of trapping a parent ion and either 
analysing this ion directly in a single MS experiment, or fragmenting the ion once or 
multiple times with He to produce parent ions. In addition, there are several types of scan 
available for obtaining information on a particular ion, namely; full scan, selected ion 
monitoring (SIM), selected reaction monitoring (SRM), consecutive reaction monitoring 
(CRM) and zoom scan. Figure 1:28 shows the scanning modes available. 
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1.4.2.1 Full Scan 
The full scan mode allows all the ions associated with the sample to be detected, since all 
the parent ions are sequentially scanned out of the ion trap. Full scanning lacks sensitivity, 
but it does provide a lot of information. Full scanning is also very slow, since all the ions in 
a given mass range specified by the operator are scanned out of the ion trap and detected.78  
 
1.4.2.2 Selected Ion Monitoring (SIM) 
In SIM target ions of specified m/z are only monitored, thus this scan mode is more 
sensitive and faster than the full scan, since more time is spent monitoring the ions of 
interest and ejecting the unwanted ions. The parent ions are stored in the ion trap and all the 
ions apart from those of interest are scanned out of the mass analyser. Then a selected ion 
mass spectrum is created by scanning out of the parent ions of interest. However, if another 
compound other than the analyte forms parent ions at the same m/z as the ions of interest, 
they will also be detected as the target ion, therefore, SIM gives low specificity.78 
 
1.4.2.3 Selected Reaction Monitoring (SRM) 
SRM is similar to SIM, but it is a two stage MS scan that is more specific. The parent ions 
are stored in the ion trap and all the ions except those of interest (which have been 
specified) are scanned out of the trap. The parent ions of interest are then fragmented with 
He to form product ions. The product ions of interest which have also been specified are 
selected whilst all the other ions are ejected from the mass analyser. A SRM mass spectrum 
is then obtained by scanning out the product ions of interest.78 SRM is more specific than 
SIM, since both the parent and corresponding product ions are monitored. Hence, it is 
unlikely that an interfering compound will form a parent ion and product ion of the same 
m/z as the analayte.75, 78  
 
1.4.2.4 Consecutive Reaction Monitoring (CRM) 
CRM is similar to SIM and SRM, but involves more MS steps, where MSn can be achieved. 
As with SIM and SRM, the parent ions are stored in the ion trap and all ions except those of 
specified m/z are ejected. Fragmentation of the selected parent ion is then achieved with the 
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He collision gas and the product ion of interest is selected, whilst all the other product ions 
are ejected. The selected product ion effectively becomes the new parent ion, which is 
fragmented further to yield new product ions. The process is repeated where the entire 
product ions except the one specified is ejected out of the mass analyser, whilst the selected 
product ion then becomes the new parent ion for further fragmentation. This process is 
repeated up to MS10 and has the advantage of increasing specificity. A CRM mass spectrum 
is achieved after the final mass analysis step, where the selected product ions are then 
scanned out of the mass analyser.78 
 
1.4.2.5 Zoom Scan 
This high resolution scan allows the molecular weight and charge state of an ion to be 
determined, by evaluating 12C/13C isotopic separation. Hence, this function is useful if the 
molecular weight of an unknown compound is to be calculated. Further details of this 
function can be found elsewhere.78 
 
Figure 1:28: Scanning modes available for the linear ion trap. 
 
1.4.3 Experiment Modes 
There are several types of experiment available with this type of instrumentation. The type 
of experiment selected depends on the information required, the sample type (e.g. analyte is 
only present at trace levels or present amongst a complex mixture) and how much is known 
about the parent ions and their corresponding product ions. The types of experiment that 
will be discussed in this section are as follows; general MS and MSn , data dependent, ion 
mapping and ion tree.  
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1.4.3.1 MS and MS
n
 
For general MS experiments, the masses of the parent ions need to be known and in the 
case of MSn experiment; the masses of both the parent and product ions need to be known. 
The more steps involved in the MSn experiment, the more detailed information regarding 
the compound obtained.78  
 
1.4.3.2 Data Dependent Experiments 
Very little user input is required for data dependent experiments, yet detailed structural 
information can be obtained.  If very little information is known about the sample, a data 
dependent experiment can be created where the ion trap can select the most predominant 
parent ions, trap them whilst ejecting minor parent ions. The selected parent ions can then 
be fragmented and the most predominant product ions within a given mass range can then 
be isolated and fragmented further. This type of experiment gives detailed information on 
the parent ions in the sample.78 Figure 1:29 summarises the steps involved during a MS/MS 
data dependent experiment, although MSn is possible. 
 
Alternatively, if information about the parent ions is known, their masses can be specified 
and the ions selected and fragmented to give product ion spectra. A list of parent ions that 
should be ignored can also be created to prevent MSn of unwanted parent ions. This type of 
experiment collects detailed MS information on each stage of the mass analysis.78 
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Figure 1:29: A summary of the processes occurring within the linear ion trap during a data dependant 
experiment. 
 
1.4.3.3 Other Experiment Types 
Ion tree and ion mapping are further types of experiment which are possible with the linear 
ion trap. Ion tree experiments can be data dependent where the instrument decides the next 
stage of the experiment by collecting and evaluating the data, or the parent ion can be 
specified for MSn. There are two ways of prioritising LTQ data collection: depth focus or 
breadth focus, in either case, the instrument will select the most intense parent ion (unless 
specified by the user).78 In the case of depth focus, the instrument will perform the 
specified number of MS experiments (e.g. MS4) before moving to the next most intense 
parent ion and performing the specified number of MSn experiments on that ion. Breadth 
focus will perform MS on all the parent ions (whether chosen by the instrument or specified 
by the user) and then move onto the next MSn level and analyse the product ions. The 
number of MS experiments is specified by the user.78 
 
Ion mapping experiments allow unknown compounds in a mixture to be analysed and 
characterised in detail. There are three main types of ion mapping experiment, namely; total 
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ion map, parent ion map and neutral loss.78 Product ions scans from parent ions are 
obtained in a total ion map experiment. Thus, the user can establish which parent ions 
fragmented to yield specific product ions. Likewise a parent ion mapping experiment 
identifies the parent ions that formed specific product ions. Evidence of neutral fragment 
loss can be obtained with a neutral loss ion map. The details of ion tree and ion map 
experiments are beyond the scope of this introduction, but further information is available 
elsewhere.75, 78   
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2 Elemental Labelling 
2.1 Introduction 
The previous chapter outlined the various problems associated with P and S measurement 
by ICP-MS and briefly highlighted the potential of metal nano-particle labelling. This 
chapter will concentrate on the notion of nano-particle labelling of nucleic acids by 
detailing two methods of incorporating Au nano-particles into oligonucleotides. The 
advantages and limitations associated with each method will be highlighted. Although the 
emphasis is on nucleic acids, the methods can potentially be applied to proteins and related 
molecules. 
 
The signal intensity given by ICP-MS is proportional to the number of similar metal atoms 
present in the sample. Hence, if nano-particle labelling of biomolecules is to be used 
quantitatively, it is vital to know how many nano-particles and therefore metal atoms have 
been incorporated into the biomolecule. This can be achieved if the labelling reaction is site 
specific, which is viable if the biomolecule and nano-particle both contain reactive groups.7 
Site specific labelling has been achieved by employing Au labelled antibodies to bind and 
therefore label specific antigens.13, 48, 89 The interaction between biotin and avidin proteins 
is the strongest non-covalent interaction known with association constants in the region of 
1015 M-1,90 thus nano-particle labelling using these two molecules has also been         
used.39, 45, 46, 91 In addition, DNA sequences can be modified to contain thiol groups which 
then have strong affinity for Au surfaces.39, 41, 91-94 This approach has been used in DNA 
micro-arrays.39, 41, 93 Biomolecules can even be labelled using electrostatic interactions, due 
to the array of charges present on many biopolymers.95 The alternative method of achieving 
site specific labelling is to modify the biomolecule so it contains a reactive group such as a 
primary amine or sulfhydryl group. The derivatised biomolecule can then be reacted with a 
nano-particle also containing a reactive organic ligand such as maleimide or sulfo-N-
hydroxy-succinimide to achieve stoichiometric labelling.95  
 
Biomolecule conjugation to metal surfaces also has the advantage that the biological 
activity of the biomolecule can be maintained.94 This advantage is exploited in the case of 
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Au labelled antibodies and proteins, which maintain their native structure and recognise 
their corresponding antigens to enable Au labelling. The conjugation of biomolecules to 
metal surfaces has been employed extensively in micro-arrays and electron microscopy. 
The majority of biomolecule-nano-particle conjugation reactions have employed Au nano-
particles. Gold has been favoured because it is electron dense and therefore highly visible 
in electron microscopy.96 However, research has been carried out with respect to bonding 
DNA to other metals such as; Ag, Cu, Pd and Pt.22, 39, 97-100 Lanthanide labels have also 
been successfully used to label antibodies for immunoassay reactions.16, 25, 89 
 
Silver and Au enhancement are employed in electron microscopy and involve applying Ag 
or Au solutions to the Au labelled molecules. The Au nano-particles have autocatalytic 
properties that cause the reduction of Ag/Au ions on the Au surface. The deposited metal 
has its own catalytic properties, causing more Ag/Au to be deposited onto the label’s 
surface. The accumulation of metal creates larger metal clusters with diameters much larger 
than the original label. These grains allow easier observation on immunoblots, 
polyacrylamide and other gels.95 Enhancement may also be beneficial in ICP-MS as the 
number of metal atoms increases, resulting in increased sensitivity.46, 95,16 Although further 
signal enhancement will be achieved, quantitative analysis would be very difficult since the 
number of metal atoms per biomolecule would be unknown.  
 
Colloidal Au particles are easy to synthesis and commercially available, making them 
popular in many applications employing biomolecule-metal conjugation. However, there 
are numerous disadvantages of colloidal Au that could cause problems in atomic 
spectrometric applications. Firstly colloidal Au particles carry a negative charge, which 
could result in non-specific binding on the biomolecule, adversely effecting 
quantification.101 In addition, colloidal Au particles are known to become unstable and 
dissociate in solution.101 The size of the particles should also be considered, since research 
in the field of laser ablation (LA) has shown that particles below 90 nm in diameter are 
completely atomised and vaporised in the plasma,102 thus the particle size must be 
controlled. Although there are no commercially available nano-particles which display all 
the desired characteristics for atomic spectrometry, there are probes which can be 
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successfully employed for quantitative analysis. These commercially available Au nano-
particles contain approximately 80 Au atoms and have many advantages over their 
colloidal Au counterparts.91, 98, 101 Firstly, these nanogold particles are neutral and are 
stabilised by phosphine groups,96, 103, 104 minimising any non-specific binding.101 Nanogold 
particles are also stable in solution96, 103 and over a wide range of ionic concentrations.101 
The vaporisation and atomisation of the Au nano-particles should not be problematic, since 
the nano-particles have a uniform Au core diameter of 1.4 nm,95, 96, 103 although the 
presence of the stabilising organic ligands increases the total diameter to 2.7 nm.101 Most 
importantly, these probes are functionalised with a range of ligands and biological 
recognition sites to provide near stoichiometric, site specific labelling.95 Well characterised, 
commercially available probes of this type were chosen for use in this study. Two Au 
probes were investigated: Monomaleimido Nanogold (MMN) and Streptavidin 
FluoroNanogold (SFNG), both probes were obtained from Nanoprobes (Stonybrook, New 
York, USA) and contained an Au core consisting of ~80 Au atoms. 
 
This chapter concentrates on the Au nano-particle labelling of short chain, single stranded 
DNA fragments known as oligonucleotides. The ICP-MS analysis of Au labelled DNA has 
been reported elsewhere,48 however, the method employed DNA hybridised with a peptide 
sequence. Gold labelled secondary antibodies were used to label a monoclonal antibody, 
which was located at the peptide site on the hybrid biomolecule.48 Such labelling is 
therefore dependent upon incorporating peptide sequences into the nucleic acid. In addition 
to Au labelling of DNA, DNA can be detected and potentially quantified using a metallo-
intercalator as described by Tanner et al.105 This method is applicable to double stranded 
DNA where the metal complex intercalates between nucleotide pairs. Cellular DNA was 
identified using a Rh metallo-intercalator.105 The two methods detailed in this chapter differ 
to the reported procedures in that they are site specific (see below) but are not base 
sequence specific or dependent upon peptide sequences. These methods are therefore 
generic and can be applied to any nucleic acid that contains sulfyhydryl or biotin 
functionality.  
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Gold does have some disadvantages when used as a biomolecule label in ICP-MS analysis. 
Firstly, the element is mono-isotopic and has high affinity for the surfaces of sample 
introduction systems.25 This results in inefficient wash-out from the sample introduction 
system, leading to carry over between samples. Bovine serum albumin (BSA) and 
hydrochloric acid solutions have been used to minimise this effect.25 BSA complexes to the 
Au, facilitating its removal from the sample introduction system. Other sulfur containing 
molecules such as the amino acid cysteine have been used as a wash solution to minimise 
Au memory effects.106 Aqua regia and hydrochloric acid solutions are also useful for 
removing residual Au, since Au is very soluble in these acids. These issues will be 
discussed in subsequent sections. 
 
2.2 Instruments and Reagents 
A PQ ExCell ICP-MS instrument with collision cell technology (CCT) was provided by 
Thermo Electron (Winsford, Cheshire, UK). The Element 2XR high resolution ICP-MS 
instrument was obtained from Thermo-Finnigan (Bremen, Germany). The basic operating 
parameters for the PQ ExCell and Element 2XR are shown in Table 2:1 and Table 2:2 
respectively. Both instruments were tuned daily with 1 ng ml-1 115In to obtain maximum 
signal intensity and stability. Tuning of the high resolution lenses on the Element 2XR was 
achieved with a tune solution containing 1 ng ml-1 56Fe. The lenses were tuned to obtain 
maximum resolution between the 56Fe and 40Ar16O peaks. In addition, the 140Ce16O/140Ce 
ratio was monitored daily on both instruments to ensure the oxide level was below 5%. 
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Table 2:1: PQ ExCell operating parameters.  
Parameter Setting 
Gas flows Cool = 12.8 l min-1 
Auxiliary = 0.80 l min-1 
Nebuliser = 1.0-1.2 l min-1 
Quadrupole bias + 1V 
Hexapole bias * ~+ 6 V for 48SO 
~+ 7.5-8 V for 47PO 
Forward power 1350 W 
CCT O2  flow * 0.4 ml min
-1 
Nebuliser 100 µl min-1 or 1 ml min-1 glass Conikal (Glass Expansions, Melbourne, 
Australia) 
Spray chamber Impact bead 
 
* These parameters were only relevant when the collision cell was in operation for the 
determinations of P and S.  
Table 2:2: Element 2XR operating parameters. 
Parameter Setting 
Gas flows Cool = 15.5 l min-1 
Auxiliary = 0.82 l min-1 
Nebuliser = 1.0-1.2 l min-1 
Scan type E-Scan 
Scanning mode Mass accuracy (solution analysis) or speed (chromatography mode) 
Detection mode Triple 
Resolution Low (Au and Pt)  or medium (P) 
Forward power 1300 W 
Spray chamber Cyclonic or double pass (Glass Expansions, Melbourne, Australia) 
Nebuliser PFA-ST type (Elemental Scientific, Omaha, USA) or 
1ml min-1 Conikal (Glass Expansions, Melbourne, Australia) 
 
Mass accuracy scanning mode was employed when the Element 2XR was operated in 
standard solution mode. Conversely, the speed scanning mode was implemented when the 
instrument was being employed as a selective detector when coupled to HPLC. Triple 
detection mode, which is noted in Table 2:2, refers to the automatic selection of either the 
counting secondary electron multiplier (SEM), analogue SEM or faraday cup by the 
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Element 2XR. Further details on the Element scanning and detection modes are given in 
Chapter 1.  
  
A HP 1090 Series 2 HPLC system, complete with a diode array detector from Agilent 
Technologies (Waldronn, Germany) was used for HPLC-ICP-MS experiments. A LDC 
Spectromonitor 3200 variable wavelength UV detector (VG data systems, Manchester, UK) 
and HP3396A integrator (Hewlett Packard) and was used for obtaining UV data during gel 
filtration. In addition, a Shimadzu UV-1650 UV/vis spectrometer (Milton Keynes, UK) was 
employed for UV/vis analysis of collected fractions obtained during gel filtration 
chromatography.  
 
A TSKgel-DNA-NPR analytical and guard column was obtained from Tosoh Bioscience 
(Stuttgart, Germany). Both columns were 4.6 mm in diameter and had a particle size of   
2.5 µm. The analytical column was 7.5 cm in length and the guard column was 0.5 cm in 
length. The properties of the column are detailed in Appendix 1 (Chapter 8). Ni-NTA-
Agarose beads were from Qiagen (Crawley, West Sussex, UK). These agaorose beads were 
functionalised with nitrolotriacetic acid (NTA), which consequently enabled 
immobilisation of metal ions for immobilised metal affinity chromatography (IMAC). 
Synthetic oligonculeotides labelled at the 5’ end with a disulfide group and 25 base length 
(25 mer) oligonucleotides modified with a sulfhydryl group were obtained from Alpha 
DNA (Montreal, Quebec, Canada), as were other synthetic oligonucleotide 10 mers 
containing a 5’ phosphate group. Unmodified oligonucleotide 25 mers were obtained from 
Invitrogen (Paisley, Renfrewshire, UK). Oligonucleotides biotinylated at the 5’ end were 
obtained from Biotez (Berlin, Germany). The sequences of all synthetic nucleic acids used 
in this report are shown in Table 2:3. Note that the term ‘mer’ refers to the number of 
nucleobases in the oligonucleotide chain. 
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Table 2:3: Oligonucleotide sequences. 
Oligonucleotide Sequence (5’→3’) 
Backbone 
Molecular Weight 
5’ thiolated di-nucleotide  GG 597 
5’ thiolated 25 mer TGA AGA AAT TCA GTT CAT AGC TTG G 7721 
5’ phosphorylated 10 mer TGC ATT TCG A 3019 
Unmodified 25 mer  TGA AGA AAT TCA GTT CAT AGC TTG G 7721 
5’ biotinylated 18 mer TAT CTG TTC ACC CGA AAG 6145 
5’ biotinylated 24 mer TAT CTG TTC ACC GCA AAT CTG TGG 8000 
 
Deionised water (18 ΩM) was obtained from either an Elga purified water system (High 
Wycombe, Buckinghamshire, UK) or an Elix high purity water system from Millipore 
(Watford, Hertfordshire, UK). Tetramethylammonium hydroxide (TMAH) was from 
Apollo Scientific (Stockport, Cheshire, UK). Tetramethylammonium chloride (TMACl) 
was prepared by adding hydrochloric acid to TMAH until the required pH was obtained. 
Super pure hydrochloric and nitric acid were obtained from Romil (Cambridge, 
Cambridgeshire, UK). Trisodium citrate, sodium chloride, acetic acid, HPLC grade 
methanol, acetonitrile, dithiothreitol (DTT) and ammonium sulfate were obtained from 
Fisher Scientific (Loughborough, Leicestershire, UK). TWEEN-20, citric acid (free acid), 
tris base, N-ethyl-N’-(3-dimethylaminopropyl)carbodiimide (EDC), 5,5’-dithio-bis-(2-
nitrobenzoic acid) and phosphorus buffered saline pouches were obtained from Sigma 
Aldrich (Steinheim, Germany). Ammonium chloride, sodium phosphate monobasic 
(Biochimika), cysteine hydrochloride and EDTA (free acid) was obtained from Fluka 
(Buchs, Switerland). Imidazole was supplied by Alfa Aesar (Karlsruhe, Germany). 
Superdex-75 preparative grade was purchased from Amersham Pharmacia (Uppsala, 
Sweden).   
 
Numerous solid phase extraction (SPE) products were used throughout the investigation. 
C18 SPE and divinylbenzene (DVB) columns were supplied by Alltech (Carnforth, 
Lancashire, UK). Varian (Oxford, Oxfordshire, UK) kindly supplied Bond Elut Jr. PSA 
anion exchange cartridges. 
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2.3 Monomaleimido Nanogold Labelling of Sulfhydryl Modified 
DNA 
2.3.1 Introduction to Monomaleimido Nanogold labelling 
Monomaleimido nanogold (MMN) has a molecular weight of approximately 15 KDa and 
contains a single maleimide ligand, which is covalently attached to an Au core containing 
~80 Au atoms. Only one maleimide functionality is present on the MMN conjugate, which 
reacts specifically with one sulfhydryl group on the biomolecule to provide stoichiometric 
labelling.95 The structure of the probe can be seen in Figure 2:1; details of its synthesis have 
been reported by Jahn96 and Hainfeld et al.,101 The maleimide functionality may react with 
amines above pH 7; therefore, all reactions were carried out at pH < 7 to ensure specific 
sulfhydryl labelling occurred. Since the maleimide functionality hydrolyses in solution, 
MMN was used immediately once dissolved.95 
 
 
                                                                                                                                                                                  
                                                             
N OO
  
Figure 2:1: Monomaleimido Nanogold. 
 
The reaction of MMN with sulfhydryl modified DNA is shown in the schematic in Figure 
2:2. Although the emphasis is on sulfhydryl labelled nucleic acids, sulfhydryl containing 
amino acids on peptides can also be labelled with MMN. 
 
 
 
 
 
 
84 
 
 
                                    
PO
O
N
O
SH
H
-
      +                      
N OO
 
 
 
 
 
 
                      
                                                                    
NS
P NO
O
O H
O
O
-
 
 
 
Figure 2:2: Reaction between sulfhydryl modified DNA and MMN. 
 
The reaction takes place in mild reaction conditions, typically below room temperature 
within 24 hours at pH ~6.5. 
 
2.3.2 Sulfhydryl Derivatisation of DNA 
Although sulfyhydryl modified oligonucleotides are commercially available, it will be 
necessary to incorporate the reactive group in-house if the technique is to have an 
application in bioanalysis. An article by Ghosh et al.,107 detailed a procedure for modifying 
the 5’ terminal phosphate of nucleic acids to a sulfhydryl group. The reaction steps are 
summarised below in Figure 2:3 and Figure 2:4.107 The actual nucleic acid modification 
was achieved using the method reported by Ghosh, however, two methods of separating the 
stage 1 and stage 2 products were investigated. The first method employed gel filtration and 
the second method used anion exchange SPE. The latter separation method also employed 
 HO 
 HO 
5’ sulfhydryl modified DNA MMN 
MMN-DNA conjugate 
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tris(carboxyethyl)phosphine (TCEP) as an alternative reducing agent to dithiolthreitol 
(DDT). Both methods will be discussed. 
 
Stage 1 of the derivatisation required 0.1 M imidazole, 0.15 M EDC and 0.25 M cystamine 
at pH 6.5. EDC and imidazole help form a reactive ester, which then facilitates the 
formation of a covalent bond between the terminal phosphate of the nucleic acid and the 
primary amine of cystamine. The reaction was allowed to proceed at 23 oC for 16 hours.  
 
Stage 1 
                             
PO
O
O
OH
-
                                                    
P NO
O
O H
S
S
NH2
-
 
 
 
Figure 2:3: Stage 1 of the sulfhydryl derivatisation reaction. 
 
Stage 2 of the reaction involved cleaving the disulfide on the cystamine residue to yield a 
reactive sulfhydryl group. Reduction was carried out with either DDT or TCEP. Both 
reagents resulted in cleavage of the disulfide bonds within 60 minutes, although it will be 
discussed later that TCEP was the preferred reducing agent. 
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Figure 2:4: Stage 2 of the sulfhydryl derivatisation reaction. 
 
Thus, 16 nmoles of 5’-phosphorylated 10 mer were added to 0.6 ml of a solution 
containing; 0.25 M cystamine, 0.15 M EDC and 0.1 M imidazole. The reaction mixture was 
incubated at 23 oC for 16 hours in a heated water bath. The resulting stage 1 product 
HO  HO 
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5’ cystamine modified oligonucleotide 5’ sulfhydryl modified  oligonucleotide 
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(oligonucleotide-cystamine derivative) was then purified on a Sephadex G-10 column to 
remove excess reagent from the product. The eluent used for purification consisted of    
0.15 M ammonium chloride and 1 mM EDTA, pH 6.3. The gel filtration purification was 
not used by Ghosh et al,107 but developed here to purify the stage 1 and stage 2 products. 
The gel filtration media and column was prepared by suspending 2 g of Sephadex G-10 
media in ~10 ml of deionised water. The suspension was allowed to stand for at least 3 
hours at room temperature, after which time the suspension was poured in one slow motion 
into a plastic column (1 cm diameter x 7 cm). Deionised water was passed through the 
column until the column bed level settled. Equilibration of the column with 5-10 column 
volumes of buffer (0.15 M ammonium chloride and 1 mM EDTA, ~pH 6.3) was then 
carried out prior to sample purification.  Sephadex G-10 has a molecular weight cut-off 
below 700 Da, resulting in the oligonucleotide (MW ~3019) eluting first near the void 
volume and the reactants being retained on the column. The stage 1 product was collected 
as it eluted from the column and was mixed with a reducing agent containing 0.1 M DTT, 
0.15 M ammonium chloride and 1 mM EDTA, pH 8.3. The reduction was carried out at   
23 oC for 1 hour. DTT cleaves the disulfide bond present in the stage 1 product 
(oligonucleotide-cystamine derivative) to produce the stage 2 product, namely the 5’-
sulfhydryl modified 10 mer. The stage 2 product (sulfhydryl modified oligonucleotide) was 
then separated on a Sephadex G-10 column as discussed above. 
 
During the gel filtration purification steps carried out on the stage 1 and 2 products, the 
column outlet was connected to the inlet of a variable wavelength UV detector. The UV 
detector outlet was then connected to the back of the ICP nebuliser, so both UV and MS 
data were collected during the purification of both steps. This was carried out to confirm 
the elution of the oligonucleotides. A schematic of the instrumentation set up is illustrated 
in Figure 2:5. The PQ ExCell ICP-MS instrument was employed during the gel filtration 
purification; refer to Table 2:1 for instrument parameters. The collision cell was employed 
with oxygen collision gas, so the oxides of P and S at m/z 47 and 48 respectively were 
detected. The P signal was monitored to confirm the elution of the oligonucleotide species 
and the S signal confirmed the elution of the stage 1 product (oligonucleotide-cystamine 
species) and excess unreacted cystamine and DTT in the reaction mixture.  
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Figure 2:5: Instrument set up. 
 
It was established that gel filtration was slow, time consuming and an inefficient method of 
sample purification. There was evidence that the excess cystamine was not being resolved 
from the DNA, this will be explained in more detail in the results section. As a result of 
these limitations, alternative separation procedures were investigated and anion exchange 
SPE was chosen for separation of the stage 1 and stage 2 product. An alternative reducing 
agent was also investigated.  
 
Anion Exchange Separation and TCEP Reduction. 
Anion exchange SPE was thought to be a good method of separation, since the modified 
oligonucleotide would be retained on the phase, whilst the excess reagents would be eluted 
with very little retention. This method of separation was less time consuming since the 
phase was pre-prepared and did not require extensive equilibration prior to use like gel 
filtration. Varian PSA Bond Elute Jr. phases were employed for the separation steps, the 
method is summarised in Figure 2:6. The Varian PSA phase was chosen because it 
consisted of ethylenediamine-N-propyl anion exchange resin, which contained two amine 
groups: primary amine (pKa 10.1) and a secondary amine (pKa 10.9), thus providing higher 
capacity.108 Highly polar compounds were not retained strongly on the phase due to its high 
carbon content, which provided good recovery for oligonucleotides.108  
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1) Phase conditioned with 2 ml methanol followed by 2 ml deionised water. 
   Deionised water conditioning step collected. 
 
 
2) Sample applied to the phase. 
Column effluent collected as sample was applied to the phase. 
 
 
3)  Phase washed with 2 ml deionised water. 
Wash fraction collected. 
 
 
4) Elution with 0.3 M citric acid + 0.1 M ammonium chloride or 1.5 M TMACl. 
             Elution fraction collected. 
 
Figure 2:6: Anion exchange SPE separation method for modified oligonucleotides. 
 
The column eluents resulting from steps 1-4 of the separation were all collected and 
analysed by UV/vis to confirm the presence of the oligonucleotide. The deionised water 
phase conditioning step (step 1) was analysed to ensure the phase was not contaminated 
with any absorbing species that may have interfered with DNA detection. A UV spectrum 
of the sample application fraction (step 2) confirmed that the analyte was not eluting 
immediately upon application to the phase. The eluent resulting from the water wash stage 
(step 3) confirmed that the oligonucleotides were retained and finally the eluent from step 4 
confirmed the elution of the nucleic acids from the phase. The above separation method 
was employed for both the separation of the stage 1 (oligonucleotide-cystamine species) 
and the stage 2 (sulfhydryl modified oligonucleotide) product. Eluents containing 1.5 M 
TMACl or 0.3 M citric acid and 0.1 M ammonium chloride were chosen, since both 
solutions had high ionic strength that was thought to be relatively ICP-MS compatible and 
sodium salts were avoided. 
 
DTT is commonly used for cleaving disulfide bonds to form the reactive sulfhydryl group. 
However, this reagent contains thiol groups, which would have competed with the thiolated 
DNA for maleimide, if not completely removed from the sample prior to labelling. As a 
result, TCEP was used in the second stage of the reaction. TCEP is an effective reducing 
reagent, resulting in cleavage of disulfide bonds and avoids the problems associated with 
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DTT. The structure of TCEP and its mechanism of action is shown in Figure 2:7. TCEP 
immobilised on agarose beads is more effective than DTT and it is not mandatory to 
remove the reducing agent before adding the MMN since it does not contain thiol groups. 
However, some studies have reported that the presence of TCEP does reduce the efficiency 
of maleimide-sulfhydryl cross-linking reactions to a certain degree.109 TCEP is also 
effective at a wider range of pH values, whereas DTT should only be used at pH >8.109 By 
employing TCEP immobilised on agarose beads, the oligonucleotides were reduced in one 
step and then easily removed from the immobilised reducing agent by centrifugation. Slow 
inefficient gel filtration methods were therefore avoided.  
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Figure 2:7: a) TCEP structure and b) mechanism for disulfide reduction.
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The stage 1 product (oligonucleotide-cystamine species) was prepared in the same way as 
discussed above (0.1 M imidazole, 0.25 M cystamine and 0.15 M EDC, 23 oC for 16 
hours). After the 16 hour reaction period, a 0.5 ml aliquot of the stage 1 product was 
separated on the SPE phase using the method outlined in Figure 2:6. Following separation, 
a 0.5 ml aliquot of the separated stage 1 product was then added to 0.5 ml immobilised 
TCEP gel and allowed to stand at room temperature for 10 minutes. The suspension was 
then centrifuged at 1000 rpm for 1 minute and the supernatant containing the reduced 
oligonucleotide was removed and applied to a conditioned PSA anion exchange cartridge. 
Separation and elution of the stage 2 product (sulfhydryl modified oligonucleotide) was 
then carried out according the procedure outlined in Figure 2:6. 
 
Since the reducing agent was immobilised on agarose beads, it was easily removed from 
the analyte and there was no chance of the MMN reaction being hindered by other thiols, as 
in the case of DTT. For each mole of disulfide bond broken, two moles of reactive 
sulfhydryl are produced (Figure 2:7). As a result, the anion exchange separation step was 
required to isolate the sulfhydryl modified oligonucleotide and remove the other half of the 
disulfide which also contained a sulfhydryl group. One potential limitation with this 
separation method is that the unreduced oligonucleotides may not be resolved from their 
sulfhydryl modified counterparts. Therefore, UV spectroscopy could not be used to 
calculate reaction efficiency. 
 
Ellman’s assay was employed in an attempt to confirm that sulfhydryl modified 
oligonucleotides were produced during the second stage of the reaction. This is a well 
documented assay that allows the concentration of sulfhydryl groups to be determined. The 
procedure used is outlined below and is a slight modification from the procedure suggested 
by Pierce Biotechnology.111 The S containing amino acid cysteine was used as a standard in 
the determination of free sulfhydryl groups present in the reduced oligonucleotide samples. 
By preparing a range of cysteine standards at a known concentration, a calibration curve 
was prepared and the concentration of sulfhydryl groups present in the second reaction was 
therefore determined. Cysteine hydrochloride standards were prepared in a 0.1 M sodium 
phosphate buffer containing 1 mM EDTA, pH 8. The standards were prepared in the 
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concentration range 1-20 µM. Ellman’s reagent (5,5’-dithiolbis(2-nitrobenzoic acid) or 
DTNB) was prepared at a concentration of 4 mg ml-1 in the sodium phosphate buffer.  
 
The mechanism of the assay is illustrated in Figure 2:8. DTNB (Ellman’s reagent) reacts 
with free sulfhydryl groups in solution to form a mixed disulfide by-product and thio-bis-
(2-nitrobenzoic acid) (TNB). The TNB product is yellow in colour and absorbs at 412 nm. 
Thus, by measuring the absorbance of the standard cysteine solutions containing DTNB at 
412 nm, calibrations were carried out. 
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Figure 2:8: Mechanism of Ellman's assay.
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The standard solutions were prepared by mixing 0.5 ml sodium phosphate buffer with    
250 µl cysteine standard solution and 50 µl DTNB. The solutions were mixed and allowed 
to stand for 15 minutes at room temperature, before the absorbances of the resulting 
standard solutions were measured at 412 nm. A calibration curve was then plotted. 
 
DTNB (Ellman’s Reagent) 
TNB 2- 
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The unknown solutions were also prepared by mixing 0.5 ml sodium phosphate buffer with 
250 µl sample and 50 µl DTNB. Incubation for 15 minutes at room temperature was also 
carried out for the samples to be determined. By calculating the concentration of sulfhydryl 
groups expected, the efficiency of the reaction could be determined.  
 
2.3.3 Method of Labelling 
2.3.3.1 Labelling of Di-nucleotides 
Di-nucleotides have a very important role in cancer research studies, which will be 
discussed in detail in Chapter 3. As a result, the MMN labelling method commenced with 
5’ thiolated di-nucleotides. Although di-nucleotides containing 5’ thiol functionality were 
commercially available, they were provided in the disulfide form. As a result, the disulfide 
bond required cleaving with the aid of a reducing agent to obtain the reactive sulfhydryl 
group. Thus, a 100 µl aliquot of 5’ disulfide di-nucleotide (100 µM) was added to 100 µl of 
reducing agent which contained: 0.1 M DTT + 1 mM EDTA + 0.15 M ammonium chloride, 
pH 8.3. The mixture was allowed to stand for one hour at room temperature before an 
aliquot of the reduced di-nucleotide was purified by gel filtration. A Sephadex G-10 gel 
filtration column (7 cm x 1 cm) was used to remove excess DTT. As stated previously, 
removal of excess DTT is necessary to avoid the reagent competing with the functionalised 
oligonucleotide for maleimide sites and adversely effecting the MMN labelling reaction.  
 
The gel filtration media and column used for DTT removal was prepared as discussed 
previously in section 2.3.2. The column outlet was connected to a variable wavelength UV 
detector with peristaltic pump tubing. A peristaltic pump operating at approximately       
200 µl min-1 pumped eluent from the column into the UV detector. The detector outlet was 
connected directly to the back of the ICP-MS nebuliser (see experimental set-up in Figure 
2:5). The column was equilibrated with 0.15 M ammonium chloride + 1 mM EDTA, pH 
6.3. After an adequate equilibration time, a 100 µl aliquot of the di-nucleotide (50 µM) + 
DTT mixture (0.1 M DTT + 0.15 M ammonium chloride + 1 mM EDTA, pH 8.3) was 
injected on the top of the column. The UV detector was set to 260 nm, whilst the PQ 
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ExCell ICP-MS measured m/z 47 and 48 (see Table 2:1 for operating conditions). Table 2:4 
summarises the gel filtration operating conditions.  
Table 2:4: Instrument operating conditions for di-nucleotide desalting. 
Parameter Setting 
Column flow rate 200 µl min-1 
Eluent 0.15 M ammonium chloride + 1 mM EDTA, pH 6.3 
UV detector wavelength 260 nm 
 
Once it was confirmed by ICP-MS that the di-nucleotide and DTT were resolved on the gel 
filtration column, the purified di-nucleotide was collected from the column outlet as it 
eluted, and added to MMN. The MMN was supplied lyophilised and was dissolved in     
200 µl deionised water to yield 6 nmoles of MMN in phosphate buffered saline (PBS-20 
mM phosphate, 150 mM NaCl), pH 6.5. The MMN contained phosphate buffer, which may 
interfere with the di-nucleotide phosphate signal, so the chromatographic method used for 
the MMN-DNA conjugate purification had to resolve the phosphate buffer from the di-
nucleotide. A 100 µl aliquot of the separated di-nucleotide fraction was added to 150 µl 
MMN and stored at 4 oC for approximately 20 hours. These reaction conditions were 
recommended by the manufacturer of the MMN 95 and similar conditions were employed 
by other research groups.92 Before the di-nucleotide was added to the MMN solution, a    
50 µl aliquot of MMN was taken and diluted 100 fold with deionised water and used as a 
retention time marker for HPLC-ICP-MS. In addition, a sample containing the di-
nucleotide only at a concentration of 10 µM was also prepared and used as a retention time 
marker. The HPLC operating conditions used for the separation of the conjugates are 
shown in Table 2:5; any amendments to the conditions shown will be stated were 
appropriate.  
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Table 2:5: HPLC conditions used in the purification of di-nucleotide-Au conjugates. 
Stationary phase TSKgel-DNA-NPR, 4.6 mm x 7.5 cm, 2.5 µM 
Mobile phase A: 5 mM or 20 mM Tris-HCl, pH 9 
B: 5 mM or 20 mM Tris + 0.1 M ammonium chloride, pH 9 
Gradient    Time (mins)                     %B 
           0                               0  
           3                               0 
          15                             100   
Flow rate 0.5-0.7 ml min-1 
Injection volume 10 µl 
Stop time 15 minutes 
Post time 4 minutes 
Wavelength 260 nm 
 
2.3.3.2 Labelling of 25 mer Oligonucleotides 
Thiol modified di-nucleotides were initially chosen in this investigation due to their 
relevance in cancer research studies (see Chapter 3). However, these short chain 
oligonucleotides were commercially supplied in the disulfide form, so a reduction step was 
necessary to yield the reactive sulfhydryl group. These sample preparation procedures, 
which were described above were long and tedious, so longer chain 25 mers were also 
investigated. The longer oligonucleotides were supplied as the reactive sulfhydryl form and 
were received in an inert Ar environment, to prevent re-oxidation of the sulfhydryl groups 
to the disulfide. Thus the DTT reduction step was not required. Using the pre-
functionalised oligonucleotides helped confirm that the labelling method was viable.  
 
The labelling procedure involved re-suspending the dried 5’ sulfhydryl modified 
oligonucleotide in deionised water to a concentration of 10 µM. The stock oligonucleotide 
solutions were stored in the freezer, whilst the 10 µM working solutions were stored in the 
refrigerator to avoid repetitive freeze-thawing and accelerated degradation of the nucleic 
acids. The refrigerated oligonucleotide solutions were used within one week of preparation 
due to long term instability once in solution.112 An 80 µl aliquot of 5’-thiol modified 25 
mer (10 µM) was mixed with 150 µl MMN (30 µM). The reaction mixture therefore 
contained 0.8 nmoles DNA (3.5 µM) and 4.5 nmoles MMN (19.6 µM), resulting in a 5.6 
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fold molar excess of MMN. The mixture was allowed to react for approximately 20 hours 
at 4 oC.  
 
The separation and analysis of the MMN-oligonucleotide conjugates was initially carried 
out using on-line anion exchange HPLC, but here the peaks containing the unbound and 
bound MMN were fraction collected off-line and then analysed by ICP-MS. There are 
several reasons for avoiding on-line separations with ICP-MS; the main reason being that 
the mobile phases used for anion exchange chromatography are not always compatible with 
ICP-MS due to the high salt content. High salt levels may cause the nebuliser to become 
blocked, as well as coating the multipoles and ion optics within the instrument. The basic 
HPLC conditions used for the separation of MMN-25 mer conjugates was identical to that 
outlined in Table 2:5. However, the mobile phases used were of higher ionic strength and 
the gradient was modified as shown in Table 2:6. 
Table 2:6: MMN-25 mer conjugate separation method. 
Stationary phase TSKgel-DNA-NPR Guard column 4.6 mm x 0.5 cm, 2.5 µM 
Mobile phase A:20 mM Tris-HCl, pH 8 
B:20 mM Tris + 0.1 M ammonium chloride + 0.3 M citrate 
pH 8 
Gradient Time (mins)                     %B 
         0                               10 
        10                              90 
        12                              90   
Flow rate 1 ml min-1 
Stop time 12 minutes 
Post time 4 minutes 
Injection volume 5 µl 
Column temperature Room temperature 
Wavelength 260 nm 
 
A TSKgel-DNA-NPR guard column with a 0.5 cm length phase was used for the separation 
of the conjugates. The short length phase resulted in speedier run times, and elution of the 
oligonucleotides occurred at lower salt concentrations than those used with the longer 
analytical column.  
 
96 
Optimisation of Reaction Conditions 
Once MMN tagging was achieved, it was necessary to establish the optimum reaction 
conditions. The reaction conditions outlined above were recommended by the 
manufacturer95 and were utilised by other researchers,92 but it was unknown whether the 
reaction proceeded better at slightly higher temperatures (without compromising the 
stability of the probe). The optimum reaction time was another factor that needed to be 
established. As a result, reaction optimisation experiments were carried out, which involved 
preparing two reactions, both containing 6 nmoles MMN (200 µl) and 1 nmole 5’ 
sulfhydryl 25 mer (10 µl). The final concentration of MMN and 25 mer in the reaction 
mixtures was 28.6 µM and 4.8 µM respectively. One of the reactions was stored at 4 oC and 
the other reaction was kept at room temperature. At time intervals of 1, 5, 10, 24, and 48 
hours after the reaction mixtures were prepared, a 30 µl aliquot was taken from the reaction 
vial and diluted to 300 µl with 20 mM tris-HCl, pH 8. The diluted aliquots were then 
separated by HPLC using the conditions outlined in Table 2:6 to resolve the bound and 
unbound MMN. Two further reactions were also prepared, both contained 2.25 nmoles 
MMN and 0.5 moles of DNA, resulting in a 4.5 fold molar excess of MMN. Again one 
reaction was stored at 4 oC and the other at room temperature. These two reactions were 
allowed to proceed for 65 hours before being diluted (50 µl reaction mixture to 500 µl tris-
HCl buffer), separated and fraction collected. During the separation step, the column 
effluent was collected between 0-0.5 minutes (fraction 1) and 7-7.5 minutes (fraction 2). 
These two fractions contained unbound MMN and DNA bound MMN respectively. The 
collected fractions were then diluted further before the Au was determined by ICP-MS. The 
PQ ExCell instrument was used for all Au determinations in the MMN labelling 
experiments.   
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2.4 Results of Monomaleimido Nanogold Labelling 
2.4.1 Sulfhydryl Derivatisation 
As stated in Section 2.3.2, both UV and ICP-MS data were obtained during the gel 
filtration purification of the stage 1 (oligonucleotide-cystamine species) and stage 2 
(sulfhydryl modified oligonucleotide) products of the sulfhydryl modification. The 31P16O 
signal obtained from the ICP-MS confirmed the elution of the unmodified oligonucleotide 
and the oligonucleotide derivatives. Likewise, the elution of the oligonucleotide-cystamine 
species (stage 1 product) could be further confirmed by the 32S16O signal, since the stage 1 
product contained both P and S. The elution of cystamine was also detected by the ICP-MS 
at m/z 48. Figure 2:9 shows the 31P16O and 32S16O ICP-MS data obtained during a stage 1 
purification step. The stage 1 reaction mixture was diluted 50 fold prior to injection on the 
column. It should also be noted that the two sets of data shown in Figure 2:9 were from the 
same sample; both the 31P16O and 32S16O signals were measured simultaneously during 
separation. 
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Figure 2:9: a) 
31
P
16
O signal intensity and b) 
32
S
16
O signal intensity during the stage 1 (oligonucleotide-
cystamine species) gel filtration purification step. Eluted with 0.15 M ammonium chloride and 1 mM 
EDTA, pH ~6.3, 200 µl injection volume. 
 
The 31P16O signal (Figure 2:9a) exhibited a peak between ~12-23 minutes which 
corresponded to the eluting 10 mer oligonucleotide. However, this peak actually appeared 
a 
b 
16 minutes 17.5 minutes 
17 minutes 
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to be two peaks co-eluting, the first peak at ~16 minutes and a second at ~17.5 minutes. 
The first peak at 16 minutes was likely to be the Stage 1 product (oligonucleotide-
cystamine species), since it had a larger molecular weight than the unmodified 10 mer. The 
second peak at 17.5 minutes was probably unmodified 10 mer, since this was the lighter 
oligonucleotide species. The 32S16O signal (Figure 2:9b) showed a small increase in 
response between 15-17.5 minutes and then a huge response between 17.5-30 minutes. The 
small rise in 32S16O signal intensity observed between 15-17.5 minutes corresponded to the 
first 31P16O peak at 16 minutes, which was thought to be the oligonucleotide-cystamine 
species. These two sets of data suggested that the stage 1 product was eluting between 15-
17 minutes, since the oligonucleotide-cystamine species contained both P and S. The 
excess S containing reagents eluted from approximately 18 minutes onwards. Note how the 
signal intensities of the two sets of data vary. The 31P16O counts were quite low compared 
to the huge 32S16O response, in which an excess of 500 000 counts per second (cps) was 
observed. This was due to the large excess of cystamine (9000 fold excess of cystamine) 
that was used in the reaction. The UV data supported the 31P16O data and is shown in 
Figure 2:10. 
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Figure 2:10: UV chromatogram during the stage 1 (oligonucleotide-cystamine species) gel filtration 
purification step. Eluted with 0.15 M ammonium chloride and 1 mM EDTA, pH ~6.3, 50 µl injection 
volume, 25 pmoles of oligonucleotide. 
 
Only one peak was observed in the UV chromatogram of the stage 1 purification step 
(Figure 2:10). However, the ICP-MS data suggested that more than one oligonucleotide 
species eluted from the column, with the stage 1 product eluting at approximately 16 
minutes. All three sets of data show that the modified oligonucleotide was not totally 
resolved from the excess cystamine in the reaction mixture. The lack of resolution was 
most obvious in Figure 2:10, where only one peak was observed at 260 nm. 
 
The stage 1 reaction was repeated but in the absence of EDC, the aim was to see what 
effect the reagent had on the first reaction step. Figure 2:11 shows the UV chromatogram of 
the stage 1 reaction mixture at 260 nm during separation of a Sephadex G-10 gel filtration 
column. 
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Figure 2:11: Chromatogram at 260 nm of the stage 1 product (oligonucleotide-cystamine species) in 
absence of EDC during gel filtration separation. Eluted with 0.15 M ammonium chloride and 1 mM 
EDTA, pH ~6.3, 50 µl injection volume, 25 pmoles oligonucleotide.  
 
Note how two peaks are present in the chromatogram shown in Figure 2:11. The first peak 
at 17 minutes was extremely small and corresponded to the retention time of the stage 1 
product (oligonucleotide-cystamine species), as shown by the 31P16O and 32S16O data in 
Figure 2:9. The second peak at 23 minutes corresponded to the excess reagents. Hence, it 
can be confirmed from this data that EDC is essential for the formation of the stage 1 
product.  
 
Figure 2:12 shows the ICP-MS data obtained for 31P16O and 32S16O during the gel filtration 
of the stage 2 product (sulfhydryl modified oligonucleotide). The 31P16O signal (Figure 
2:12a) revealed oligonucleotide elution between 13 and 25 minutes. However, like with the 
first stage product, the second stage product appeared to have more than one peak present, 
suggesting more than one type of oligonucleotide was eluting. The first peak at 16 minutes 
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was thought to be the stage 1 product (oligonucleotide-cystamine species), which had not 
been reduced by DTT, whilst the second co-eluting 31P16O peak at 21 minutes was thought 
to be the sulfhydryl modified 10 mer (stage 2 product). Therefore, the second 31P16O peak 
was required for the subsequent MMN labelling reaction. 
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Figure 2:12: a)
 31
P
16
O Signal intensity and b) 
32
S
16
O signal intensity during the gel filtration purification 
of the stage 2 product (sulfhydryl modified oligonucleotide). Eluted with 0.15 M ammonium chloride 
and 1 mM EDTA, pH ~6.3.  
 
a 
b 
16 minutes 
21 minutes 
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The 32S16O MS data (Figure 2:12b) revealed that the elution of excess DTT occurred at 
approximately 30 minutes, Suggesting the oligonucleotide and excess DTT were well 
resolved. As a result, DTT should not interfere with the MMN labelling reaction. Two other 
32S16O peaks were expected at approximately 16 and 21 minutes, corresponding to the stage 
1 and stage 2 modified oligonucleotides. Both these olignucleotide species would have 
contained S, but no signal was observed in the 32S16O chromatogram. One explanation for 
this is that the S concentration would have been too low for detection.  
 
The UV chromatogram corresponding to the stage 2 (sulfhydryl modified oligonucleotide) 
purification is shown in Figure 2:13. The first peak at ~15 minutes coincided with the first 
31P16O peak observed in the MS data, which was thought to be the unreduced 
oligonucleotide-cystamine derivative (stage 1 product). The second UV peak at ~20 
minutes coincided with the remaining 31P16O signal, which probably corresponded to the 
stage 2 product (sulfhydryl modified oligonucleotide). The third peak in the UV 
chromatogram at 28 minutes onwards corresponded to the excess DTT. Again this was in 
good agreement with the ICP data, which showed a very high signal for 32S16O eluting from 
the column from approximately 30 minutes onwards. 
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Figure 2:13: UV chromatogram at 260 nm of stage 2 (sulfhydryl modified oligonucleotide) gel filtration 
purification. 0.15 M ammonium chloride and 1 mM EDTA, pH ~ 6.3. 
 
Figure 2:12 and Figure 2:13 both show that more than one oligonucleotide species eluted 
from the phase. It has been established that the stage 1 product (unreduced oligonucleotide-
cystamine species) eluted at approximately 15 minutes and the stage 2 product (sulfhydryl 
modified oligonucleotide) eluted at ~21 minutes. However, the stage 1 oligonucleotide 
peak at 15 minutes was larger than the stage 2 oligonucleotide peak, suggesting that not all 
the stage 1 product was being reduced by DTT. The reason for this was attributed to the pH 
of the reducing DTT mixture. It has been documented that DTT is more effective at pH 
>8.109, 110 However, in the above experiments, the first stage reaction mixture was being 
eluted from the gel filtration column with a buffer at pH 6.3. The collected stage 1 species 
was then used directly in the reduction step. Although the DTT mixture was adjusted to pH 
8.5, the addition of the stage 1 species at pH 6.3 may have decreased the pH below 8. Thus, 
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the effectiveness of the DTT was compromised. To overcome this problem, the stage 1 
product (oligonucleotide-cystamine species) was eluted from the gel filtration column with 
a buffer at pH 8.3. The modified oligonucleotide fraction was then collected from the 
column and added to the DTT reducing solution, which was also at pH 8.3. Upon 
separating the stage 2 product, the second peak (sulfhydryl modified oligonucleotide) was 
larger than the first. The UV chromatogram for this separation is shown in Figure 2:14 and 
suggests that the pH of the reducing agent was critical, for maximum disulfide reduction, a 
pH >8 was required. 
 
 
 
Figure 2:14: UV chromatogram at 260 nm of the stage 2 (sulfhydryl modified oligonucleotide) reaction 
mixture after reduction with DTT at pH 8. 
 
Anion Exchange Separation of Modified Oligonucleotides 
Before the SPE separation method was applied to the sulfhydryl derivatised 
oligonucleotides, the retention and elution of unmodified oligonucleotides was assessed on 
the Varian PSA phase. Briefly, a solution containing 5 µM of unmodified 25 mer 
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oligonucleotide was prepared in deionised water, and the UV spectrum of the sample was 
taken between 200-400 nm. A 1 ml aliquot of the sample was then applied to a conditioned 
SPE phase, which was subsequently washed with 1 ml deionised water. Elution of the 
oligonucleotide was then achieved with 2 ml TMACl (1.5 M). Figure 2:15 shows the 
overlaid UV spectra corresponding to the column eluent resulting from the phase 
conditioning step, sample application step, deionised water wash and TMACl elution.  
 
Figure 2:15: Overlaid UV spectra of column eluents during various stages of a 25 mer oligonucleotide 
anion exchange SPE separation.  
 
From the UV data in Figure 2:15, it was calculated that 94% of the oligonucleotide was 
recovered from the phase during TMACl elution, confirming that the oligonucleotide was 
retained on the anion exchange phase, but more importantly the oligonucleotide was easily 
eluted with a high ionic strength mobile phase with good levels of recovery. Once it was 
confirmed that the phase was adequate at retaining oligonucleotides, and that the nucleic 
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acids could be eluted with relative ease, the separation method was applied to the 
sulfhydryl derivatised oligonuleotides.  
 
The stage 1 reaction mixture (oligonucleotide-cystamine species before reduction, 0.5 ml) 
was injected onto a conditioned SPE cartridge and the phase was washed with 2 ml 
deionised water to remove the excess un-reacted reagents. Elution of the modified 
oligonucleotide was then achieved using 1.5 ml buffer containing 0.1 M ammonium 
chloride and 0.3 M citric acid, pH 7. The eluent was originally 1.5 M TMACl (Figure 
2:15), but high background absorbance’s were encountered which was attributed to the 
reagent being contaminated. Therefore, the eluent was changed to 0.3 M citric acid and   
0.1 M ammonium chloride, pH 7. The wash step and oligonucleotide elution fractions were 
collected and analysed by UV/vis spectroscopy to confirm the elution of the reagents. 
Figure 2:16 shows the overlaid UV/vis spectra of the: phase conditioning step (step 1), 
sample application (step 2), deionised water wash step (step 3) and the oligonucleotide 
elution step (step 4). The spectrum from the phase conditioning step revealed that there was 
no absorbing species from the phase that may have interfered with the DNA detection. The 
spectrum corresponding to the sample application step (eluent collected during sample 
application) revealed that no analyte was eluted immediately upon application to the phase. 
The deionised water wash eluent had a very high absorbance below 300 nm, which was a 
consequence of the EDC and imidazole. Distinctive maxima at 257 nm can be seen in the 
citric acid, ammonium chloride elution step which corresponded to the oligonucleotide.  
 
109 
 
Figure 2:16: Overlaid UV spectra of column eluents during various stages of anion exchange SPE of the 
stage 1 product (oligonucleotide-cystamine species), DNA concentration ~9 µM. 
 
The separated oligonucleotide from the stage 1 reaction was collected and reduced with the 
TCEP reducing beads to form the reactive sulfhydryl oligonucleotides. The reduced 
oligonucleotides were then separated on the anion exchange SPE cartridges as discussed 
above. The overlaid UV spectra in Figure 2:17 shows the phase conditioning step, sample 
application, deionised water wash step and the citrate, ammonium chloride elution step 
which resulted in elution of the modified DNA. Anion exchange separation of the 
oligonucleotides appeared to be successful, however, from these spectra it could not be 
confirmed whether the phosphate groups were actually converted to the sulfhydryl form.  
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Figure 2:17: Overlaid UV spectra of column eluents during various stages of anion exchange SPE of the 
stage 2 product, DNA concentration ~2 µM. 
 
Figure 2:17 clearly shows that DNA was eluted in the citrate, ammonium chloride elution 
steps. The recovery of the oligonucleotide from the phase was calculated to be 100% and 
86% for the stage 1 and stage 2 separations respectively. This suggested that very little 
oligonucleotide was lost during the separations. However, the reaction efficiency for both 
stages was not calculated.  
 
Ellman’s assay was assessed for its suitability in confirming the presence of sulfhydryl 
groups in the sulfhydryl modified oligonucleotide sample. The concentration of sulfhydryl 
groups could then be calculated, allowing the reaction efficiency to be determined. The 
linearity of the cysteine calibration curves were quite poor, which was attributed to the very 
low absorbance readings obtained from the low concentration cysteine standards (typical 
absorbance readings ranged from 0.018-0.044 AU for a 1-20 µM cysteine calibration). In 
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all cases, the calculated concentration of sulfhydryl groups in the samples was much higher 
than expected. The procedure that was followed recommended preparing calibration curves 
in the concentration range 0.1-10 mM cysteine.111 Since the concentration of sulfhydryl 
groups in this particular investigation was anticipated to be much lower than 0.1-10 mM, 
the calibration was prepared in the range 1-20 µM cysteine. Therefore, it was decided that 
Ellman’s assay was not suitable for the determination of very low levels (µM range) of 
sulfhydryl groups used here, and that 1-20 µM was probably below the assay limit of 
detection, hence spurious results were obtained.111  
 
2.4.2 Labelling Results 
2.4.2.1 Labelling of Di-nucleotides 
As discussed in section 2.3.3.1, the disulfide modified di-nucleotides were reduced with 
DTT; the reduced oligonucleotides were then separated from excess DTT by gel filtration 
before being added to MMN. The separation of unbound MMN and MMN labelled di-
nucleotides in the resulting reaction mixture was carried out with the TSKgel-DNA-NPR 
analytical column (7.5 cm x 4.6 mm), which was coupled directly to an ICP-MS 
instrument. Prior to injection, a 100 µl aliquot of the di-nucleotide-MMN tagging mixture 
was diluted with the same volume of deionised water in a micro HPLC vial. The diluted 
reaction mixture was then injected directly onto the anion exchange column. Figure 2:18 
shows the HPLC-ICP-MS data, corresponding to 31P16O and 197Au signals observed during 
the separation of the MMN-di-nucleotide tagging reaction mixture.  
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Figure 2:18: 
197
Au and 
31
P
16
O signal intensity during separation of the MMN-di-nucleotide tagging 
reaction mixture. TSKgel-DNA-NPR 7.5 cm x 4.6 mm column, mobile phase A = 20 mM tris-HCl, pH 9, 
B = 20 mM tris + 0.3 M citrate and 0.1 ammonium chloride, pH 9. 0 mins = 0% B, 2 min = 0% B, 15 
min = 100% B, 17 min = 100% B. Flow rate = 0.7 ml min
-1
, 10 µl injection volume. 
 
From Figure 2:18, it appears that there were three Au peaks at 0.87, 1.27 and 6.67 minutes. 
However, it was realised that in fact there were only two Au peaks, the first two Au signals 
at 0.87 and 1.37 minutes were actually part of the same peak. The sample was not diluted 
enough before injection, hence the Au signal intensity exceeded the detector threshold    
(>5 000 000 cps), at the peak apex, which resulted in a signal intensity of zero being 
recorded around the peak apex, thus giving the appearance of two peaks. Therefore, the 
first Au peak (0.87 and 1.37 minutes peaks combined) was very broad with the width at the 
base ~5 minutes. The Au signal did not return to baseline level and even increased further 
at ~9 minutes. The erratic, elevated baseline and broad Au peak may have resulted from 
overloading the column with MMN. The Au peak at 6.67 minutes was not reproducible and 
could not be explained; suggesting that this signal was an artefact. At 1.25 minutes, a 
31P16O peak was observed. At this stage it was unknown whether the 31P16O peak was due 
to the di-nucleotide or the phosphate buffer that was present in the MMN. UV data was also 
197Au 
31P16O 
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collected during the separation, however, only the first Au peak at 0.87 minutes was 
detected by the UV detector. 
 
A lot of unanswered questions were raised from the experiment, namely, why was the Au 
baseline erratic, what was the identity of the 31P16O peak and the cause of the spurious Au 
peak at 6.67 minutes. As a result, the procedure was repeated again, but some amendments 
to the separation and detection method were made. The disulfide modified di-nucleotide 
was reduced and purified by gel filtration as discussed previously. But, to ensure the correct 
fraction was collected from the column during the separation of the di-nucleotide and DTT, 
the gel filtration column was connected to both a UV detector and ICP-MS. Thus, the UV, 
P and S signals were monitored simultaneously during purification to ensure that the 
correct oligonucleotide fraction was being used for MMN labelling. Figure 2:19 shows the 
elemental (31P16O and 32S16O) chromatograms, during the gel filtration separation of the 
sulfhydryl modified di-nucleotide and DTT. 
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Figure 2:19: 
31
P
16
O and 
32
S
16
O signal intensity during the gel filtration separation of sulfhydryl 
modified di-nucleotide and DTT. 
48SO 
47PO 
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The sulfhydryl modified oligonucleotide contained both P and S, Figure 2:19 confirmed 
that both P and S were present at approximately 16 minutes, suggesting that the 
olignucleotide eluted at this retention time. However, the S signal dramatically increased 
from 20 minutes onwards due to the excess DTT in the reaction mixture. As a result, great 
care was needed to ensure that the sulfhydryl modified di-nucleotide was collected but not 
the DTT. For this reason, the oligonucleotide fraction eluting between 11-16 minutes was 
collected for MMN labelling. A 100 µl aliquot of the reduced di-nucleotide was then added 
to 150 µl MMN. The reaction was allowed to proceed at 4 oC for approximately 24 hours. 
 
Before, the reaction mixture was separated and detected by HPLC-ICP-MS, it was diluted 
50 fold in 5 mM tris-HCl and the separation parameters were modified. The ionic strength 
of the HPLC mobile phase was reduced (mobile phase A = 5 mM tris-HCl, pH 9, mobile 
phase B = 5 mM tris + 0.1 M ammonium chloride, pH 9) to ensure that the di-nucleotide 
was retained on the anion exchange resin. The previous experiment resulted in a 31P16O 
peak at 1.25 minutes (Figure 2:18). If this peak was due to the di-nucleotide, then it eluted 
very quickly, but more importantly, it eluted at the same time as the MMN resulting in no 
separation. Reducing the mobile phase ionic strength should ensure that the oligonucleotide 
was retained for longer and thus resolved from the unbound MMN.  
  
The 197Au and 31P16O chromatograms from the repeated tagging experiment are shown in 
Figure 2:20. A large 197Au peak was observed at approximately 1.3 minutes, which 
corresponded to the free unbound MMN. As expected, the MMN had no retention on the 
anion exchange phase, since the neutral nano-particle had no interaction with the positively 
charged amine groups on the non-porous resin. After elution of the unbound MMN, the Au 
signal returned to baseline, but rose again after ~9 minutes and continued rising throughout 
the separation. At 11.8 minutes a small Au peak was observed, which was initially thought 
to correspond to the MMN-di-nucleotide conjugate. However, it was discovered that the 
unlabelled di-nucleotide eluted at 12.8 minutes, suggesting the Au peak at 11.8 minutes 
was not due to the bound di-nucleotide. In addition, a similar Au peak was also observed in 
the blank injection at the same retention time, further confirming that the Au peak at 11.8 
minutes was not due to the labelled oligonucleotide. The large 31P16O peak at 
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approximately 13 minutes was due to a contaminant, either on the column or in the 
injection system. This large signal was observed at exactly the same time in every injection 
and co-eluted with the di-nucleotide. This definitively confirmed the Au peak at 11.8 
minutes was not attributed to the MMN labelled di-nucleotides. 
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Figure 2:20: ICP-MS data for the MMN-di-nucleotide tagging reaction mixture. TSKgel-DNA-NPR  
7.5 cm x 4.6 mm column. Mobile phase A = 5 mM tris-HCl, pH 9 B = 5 mM tris + 0.1 M ammonium 
chloride, pH 9. 0 min = 0% B, 3 min = 0% B, 15 min = 100% B. Flow rate = 0.5 ml min
-1
. 10 µl injection 
volume.  
 
Although the above tagging reaction mixture was diluted 50 fold prior to HPLC-ICP-MS 
analysis, a response exceeding 200 000 counts per second was still obtained for the Au 
peak at 1.3 minutes. Therefore, the rising baseline from 9 minutes onwards could have 
resulted from column overloading. The column was cleaned and repeatedly flushed with 
both high ionic strength eluents, and eluents containing 20% organic solvent in an attempt 
to remove any retained material from the phase. The experiment was then repeated with 
more diluted reaction mixtures in an attempt to avoid overloading the column and elevating 
the baseline.  
197Au 
31P16O 
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The tris-HCl mobile phase was also reconsidered, since it is known that the maleimide 
ligand can become reactive towards primary amines above pH 7. Tris-HCl base 
(tris(hydroxymethyl)aminomethane) contains a primary amine and was used as the HPLC 
eluent at pH 9 throughout the study. The possibility of the tris-HCl buffer reacting with the 
unbound MMN was considered, alternatively, the high pH could have degraded the probe. 
The manufacturer of the probe confirmed that MMN was stable in the presence of amines 
at high pH values once MMN was bound to sulfhydryl groups, hence this should not have 
been an issue. In addition, the maleimide ligand on any unbound MMN would have 
hydrolysed, hence not reacting with the tris base. Despite the manufacturer’s reassurance 
that tris-HCl was suitable for conjugate separation, the separation was repeated using bicine 
buffer (5 mM bicine, pH 9) in place of tris-HCl.  Bicine contains a tertiary amine so should 
not have any reactivity towards MMN. In addition, the pKa value and buffering range of 
bicine is similar to tris-HCl.  Despite these amendments to the procedure, a small rise in Au 
background throughout the separation was still observed, although not as pronounced as 
when tris-HCl was used in the eluent. A key finding was that the small Au peak that was 
previously observed at 11.8 minutes, and was initially thought to be the MMN-di-
nucleotide conjugate, was observed during the separation of the MMN retention time 
marker (no oligonucleotide present). The chromatograms of the MMN retention time 
marker and MMN-di-nucleotide reaction mixture, using the bicine mobile phase are shown 
Figure 2:21.  
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Figure 2:21: a) Au signal during the injection of the MMN retention time marker. b) Au signal intensity 
during separation of the MMN-di-nucleotide tagging reaction mixture. Bicine was employed as an 
eluent for both injections.  
a 
b 
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Despite attempts to ensure the sample preparation procedure was adequate for Au labelling, 
the MMN-di-nucleotide tagging experiments were unsuccessful. The limiting factor to 
success was thought to be the sample preparation procedure, which involved several steps; 
reduction of the disulfide bond with DTT, followed by removal of DTT by gel filtration. 
ICP-MS was used in conjunction with UV detection to ensure the correct olignucleotide 
fraction was being used for MMN labelling. However, gel filtration is a relatively 
inefficient method of sample purification; even trace quantities of DTT in the collected di-
nucleotide fraction may have adversely affected the maleimide-sulfhydryl coupling. Thus, 
the gel filtration separation may not have been sufficient for DTT removal. Reoxidation of 
the sulfhydryl group to yield the disulfide may be another factor that was resulting in poor 
tagging results. Reformation of the disulfide bond can occur by exposing the 
oligonucleotide to the atmosphere. Trace metal ions can also aid reformation of the 
disulfide, although 1 mM EDTA was added to the gel filtration eluent and reaction buffer 
to complex any divalent metal ions that could have potentially reoxidised the 
oligonucleotide. The oligonucletides had an approximate retention time of 20 minutes. The 
formation of disulfide bonds between oligonucleotides to produce di-nucleotides bridged 
by a disulfide bond would have rendered the di-nucleotides un-reactive upon elution. 
 
2.4.2.2 Labelling of 25 mer Oligonucleotides 
The 25 mer labelling reactions were more successful than those for the di-nucleotides. The 
25 mer oligonucleotides used in this particular stage of the investigation were supplied in 
the reactive sulfhydryl form, instead of the disulfide form as in the case of the di-
nucleotides. As a result, the 25 mers did not require additional sample preparation. Initially, 
a sample of unmodified 25 mer (containing no MMN) containing the same base sequence 
as the sulfhydryl modified 25 mer was injected onto the TSKgel-DNA-NPR guard column, 
to establish the retention time. In addition, a MMN retention time marker was injected to 
establish the retention time of the unbound MMN. The retention times of unbound MMN 
and 25 mer were 0.10 and 6.98 minutes respectively. The UV chromatograms of both 
reagents can be seen in Figure 2:22. Citric acid has a residual absorbance at 260 nm, 
consequently the UV baseline increased during gradient elution due to the increasing 
proportion of citric acid. 
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Figure 2:22: a) Unbound MMN (3 µM). b) Unlabelled and unmodified 25 mer oligonucleotide (10 µM). 
Both samples eluted from a TSKgel-DNA-NPR guard column with 20 mM tris-HCl, pH 9 (A) and 20 
mM tris + 0.3 M citrate and 0.1 M ammonium chloride, pH 9 (B). Gradient = 10% B at 0 min, 90% B 
at 10 min and 90% B at 12 min. Flow rate = 1 ml min
-1
. Wavelength = 260 nm. 
 
The UV chromatogram of the tagging mixture is shown in Figure 2:23. Note that the peak 
corresponding to unbound MMN appeared at 0.13 minutes as expected, but an additional 
small broad peak was observed at 7.06 minutes, which was thought to correspond to the 
MMN-25 mer conjugate. This retention time was slightly later than the unbound 25 mer 
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(6.99 minutes), but if the oligonucleotide was covalently bound to a 15 KDa probe, then it 
is not unrealistic to expect a slight shift in retention time.  
 
Figure 2:23: Chromatogram of the MMN-25 mer tagging reaction mixture eluted from a TSKgel-DNA-
NPR guard column with 20 mM tris-HCl, pH 9 (A) and 20 mM tris + 0.3 M citrate and 0.1 M 
ammonium chloride, pH 9 (B). Gradient = 10% B at 0 min, 90% B at 10 min and 90% B at 12 min. 
Flow rate = 1 ml min
-1
. Wavelength = 260 nm. 
 
The MMN-25 mer reaction mixture was injected onto the column again, but the following 
fractions were collected from the column outlet during elution: 0-3 minutes (fraction 1) and 
7-9 minutes (fraction 2). These fractions were collected during the following injections and 
separations; blank, unmodified 25 mer, MMN only and tagging reaction mixture 
separation. Fractions were collected between 0-3 minutes and 7-9 minutes because these 
time frames correspond to the elution of the unbound MMN and MMN-25 mer conjugate 
respectively. The fractions were diluted accordingly and analysed by ICP-MS. The 
summarised data is shown in Table 2:7, which shows that significant Au counts were 
observed in the tagging sample fractions; ~100 000 and 3300 cps were obtained for 
fractions 1 and 2 respectively. The Au signal in each of the tagging sample fractions was 
significantly higher than the signal observed in the blank injection fractions. 
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Table 2:7: Summarised ICP-MS data for HPLC fractions collected during elution of the MMN-25 mer 
samples. 
Sample 
Fraction 1:  0-3 min 
Au (cps) 
Fraction 2:  7-9 min 
Au (cps) 
Blank 300 204 
MMN retention time marker 52492  
25 mer retention time marker  96 
Reaction mixture 96172 3349 
 
The chromatogram corresponding to the MMN-25 mer mixture, shown in Figure 2:23 
revealed that the majority of the MMN was unbound, hence it eluted in the void volume at 
0.13 minutes. ICP-MS data confirmed that the peak at 7.06 minutes contained significant 
Au counts and therefore corresponded to the MMN-25 mer conjugate. Unfortunately, data 
was not collected for fraction 2 of the MMN retention time marker and fraction 1 of the 25 
mer retention time marker. 
 
Once nano-particle labelling of the DNA was indicated, it was necessary to calculate the 
efficiency of reaction. It is important to obtain maximum labelling efficiency to enable 
maximum signal enhancement and therefore sensitivity. In the above experiment, the MMN 
was in a 5.6 fold molar excess of DNA, and only one MMN probe will bind to a DNA 
molecule giving a 1:1 labelling ratio: 
 
Reaction: DNA + AuR →   AuP (fraction 1) + C (fraction 2) 
   No. moles:      1 +  5.6  →         4.6          +  1 DNA + 1 Au   
 
Where: 
DNA = sulfhydryl modified DNA added to the reaction. 
Au = free MMN. Superscript R refers to the reactant MMN and P refers to the MMN upon 
completion of the reaction. 
C = MMN-DNA conjugate formed during the reaction. 
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The ratios of Au signal intensities for the two collected fractions were compared in order to 
calculate the labelling efficiency. If the reaction was 100% efficient, then the mole ratio of 
Aup to C would be 4.6. e.g. 
 
Au Mole Ratio 64
1
64
.
.
C
Au p
===  
 
Therefore, 4.6 times as many Au counts should have been observed in fraction 1 (Aup) 
compared to fraction 2 (C). In the above case, 96 172 cps and 3 349 cps of Au were 
observed in the first and second fractions of the reaction mixture respectively. Fraction 1 
and 2 consisted of 3 ml and 2 ml respectively, therefore, if the appropriate dilution factors 
are applied, 43.08 times as many Au counts were observed in fraction 1 (Aup), so the 
observed Au ratio becomes: 
Observed Au Mole Ratio 0843
672232
96172
.
.C
Au p
===  
 
Once the Au ratios corresponding to 100% labelling and observed labelling are calculated, 
the labelling efficiency can be established by comparing the two ratios; 
 
% Labelling Efficiency %.x
.
.
6810100
0843
64
==  
 
Therefore ~1/10th, or 10.7% of the DNA was successfully labelled in the above example. 
 
The relative responses of Au and P by ICP-MS also have to be considered, and the 
enhancement in signal has to be calculated to demonstrate that elemental labelling does 
improve biomolecule detection by ICP-MS. Since DNA contains phosphate groups, 
detection is possible through P measurement, but as already discussed, P measurement by 
ICP-MS does have its limitations. In the above experiment, the oligonucleotide contained 
25 P atoms. If each labelled oligonucleotide contained 80 Au atoms, a P:Au ratio of 24:80 
or 1:3.3 was achieved. Therefore, 3.3 times as many Au atoms were present on each 
labelled oligonucleotide compared to P. However, the relative sensitivities of P and Au 
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have to be considered, which was determined by ICP-MS. Briefly, two calibration curves 
were prepared, one for Au and the other for P. The gradients of the Au and P calibration 
curves were 12 421 and 101 respectively (x axis expressed as ng ml-1). Thus, the Au 
gradient was 123 times greater than that of P, or it can be said that Au gave 123 times 
greater signal than P, proving that Au has a greater sensitivity than P when measured by 
ICP-MS. But, each labelled oligonucleotide contained 3.3 times more Au atoms than P. As 
a result, the 123 Au enhancement factor can be multiplied by 3.3 to give 406, 
demonstrating that 406 times greater sensitivity was obtained when measuring Au labelled 
25 mer oligonucleotides compared to measuring P alone. If the 406 enhancement factor is 
multiplied by the 10.7% labelling efficiency (calculated above), a 43 fold greater signal was 
obtained when measuring MMN labelled 25 mers compared to P. This calculation 
demonstrates that even low labelling efficiencies can result in significant signal 
enhancement and could be used to obtain lower limits of detection. 
 
The above calculated signal enhancement factor was applicable to 25 mers, but it should be 
considerably greater for smaller nucleic acids such as the di-nucleotides. Di-nucleotides 
contain two P atoms, thus if these short chain nucleic acids were labelled with 80 Au 
atoms, then there would be 40 times as many Au atoms compared to P. If the 123 Au 
enhancement factor is then multiplied by the factor of 40, potentially 4920 times greater 
response would be obtained when detecting Au labelled di-nucleotides by ICP-MS 
compared to measuring P alone. In the case of di-nucleotides which only contain two P 
atoms, the limits of detection when measuring P alone would be quite poor due to the low 
number of P atoms per nucleic acid, so the signal enhancement achieved by Au labelling 
would be more beneficial to short chain nucleic acids.  
 
Optimisation of Reaction Conditions 
The MMN labelling samples were stored for various periods of time, at either room 
temperature or 4 oC, and then separated by HPLC and the fractions were collected from the 
column outlet at, 0-0.5 minutes (fraction 1) and 7-7.5 minutes (fraction 2) during elution. 
Fractions 1 and 2 corresponded to the unbound MMN and MMN-DNA conjugates 
respectively. A blank injection consisting of 20 mM tris-HCl sample solvent was also 
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fraction collected at 0-0.5 minutes and 7-7.5 minutes, to establish the background Au 
counts on the column. The Au signal intensities for the blank, reaction samples and 
retention time markers are summarised in Table 2:8. The unbound MMN eluted within 
fraction 1 and any MMN labelled 25 mer should have eluted in fraction 2. Hence, the Au 
signal intensity in each fraction was determined to establish the MMN labelling efficiency. 
Table 2:8: 
197
Au signal intensity for the MMN optimisation reactions.  
Sample Fraction 1Au signal (cps) Fraction 2 Au signal (cps) 
Blank  195.34 227.00 
25 mer only 95.67 139.33 
Nanogold only 4484.70 211.34 
4 
o
C reactions   
1 hour 38616.81 452.34 
5 hour 57660.14 749.02 
10 hour  77733.93 619.35 
24 hour 83788.01 674.35 
48 hour  71604.05 730.35 
65 hour 29888.58 480.01 
Room temperature reactions   
1 hour 47996.83 423.01 
5 hour 36819.07 842.03 
10 hour  61581.46 784.36 
24 hour 72449.58 1121.38 
48 hour  81653.37 1023.04 
65 hour 19100.43 455.01 
 
All of the above samples contained Au in fraction 2 (DNA-MMN conjugate fraction) that 
were above the background Au signal. The room temperature reactions generally gave 
higher Au counts than the lower temperature reactions, with the exception of the 1 and 65 
hour samples. The Au counts presented in Table 2:8 were relatively low. A 2% aqua regia 
solution was aspirated between samples to aid Au wash out from the sample introduction 
system. Aqua regia was chosen because Au is very soluble in this acid; hence it should be 
effective at minimising carry over between samples. However, it was noted that the Au 
signal intensity increased during the aqua regia wash, suggesting that some Au was 
adhering to the walls of the sample introduction system and not being measured, resulting 
125 
in relatively low signal intensities for the labelled conjugates, as shown in Table 2:8. Thus, 
when aqua regia was aspirated, the deposited Au was being removed from the sample 
introduction system. As a result, the above Au signal intensities for the two sets of fractions 
may not be accurate thus effecting the reaction efficiency calculations.  
 
The very high Au backgrounds that were observed during the acid wash did not decrease 
over time as expected. This suggested that the Au contamination was due to the sample 
bottles or reagents rather than the sample introduction system. The polypropylene sample 
bottles were therefore soaked in 5-10% aqua regia before use. This had the desired effect 
of removing residual Au from the bottles prior to analysis and reduced the background Au 
signal upon acid aspiration. It has also been reported that the S containing amino acid, 
cysteine is effective at complexing residual Au on the surfaces of sample introduction 
systems, and improving Au wash out between samples.106 Gold has high affinity for S since 
Au is a soft Lewis acid and S a soft Lewis base. A 10 mM cysteine solution was prepared 
and aspirated, which resulted in the Au signal increasing. This was again due to the 
cysteine complexing to Au in the sample introduction system and aiding wash out. Various 
wash out procedures containing aqua regia and cysteine were investigated; the most 
effective procedure involved aspirating both 5% aqua regia followed by 10 mM cysteine 
between samples. In addition, spiking Au solutions with aqua regia (2-5% acid) improved 
Au signal intensity. This was presumably because the acid stabilised the analyte in solution.  
 
The above analysis was repeated, but the collected fractions were diluted 20 fold with 5% 
aqua regia prior to ICP-MS determination. Gold standards were also prepared at a 
concentration range of 1-3 ng ml-1 in a 5% aqua regia matrix to allow quantification of Au 
in each fraction. The Au signal intensities for each fraction are shown in Table 2:9 and 
were used to calculate the labelling efficiency of each reaction. The labelling efficiency was 
calculated in the same way to that detailed above (Chapter 2.4.2.2), namely, the observed 
and 100% labelling Au ratio were calculated and used to calculate overall labelling 
efficiency. The dilution factors were considered; hence the appropriate dilution factors were 
applied to the Au counts, to ensure the ratios were calculated using equivalent signal 
intensities. The reaction stoichiometry then had to be considered. The majority of 
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optimisation samples contained 6 nmoles of MMN and 1 nmole of DNA, therefore this 
stoichiometry will be used as an example: 
 
Reaction:  DNA  +  AuR  →        AuP (fraction 1)  + C (fraction 2) 
No. nmoles:  1         +   6              5              + 1 DNA+1 Au 
 
Since, 1 nmole of DNA was present in the reaction; the maximum number of moles of 
MMN in the conjugate fraction was 1 nmole, since MMN binds to thiol containing 
compounds in a 1:1 stoichiometry. The data for each sample is shown in Table 2:9. 
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Table 2:9: Reaction optimisation results and corresponding reaction efficiencies. 
Sample 
Overall 
dilution 
factor 
Au 
counts 
(cps) 
nMoles 
of Au  in 
Reaction 
Expected 
Au
p
/C 
Ratio 
Observed 
Au
p
/C 
Au Ratio 
Labelling 
Efficiency 
(%) 
Blank Fraction 1 200 471.71   3.1566  
Blank Fraction 2 201 149.43         
25 mer only Fraction 1 202 118.97   0.9638  
25 mer only Fraction 2 200 123.43         
Nanogold Only Fraction 1 201 12905.20   40.9036  
Nanogold Only Fraction 2 202 315.50         
1hr 4 degrees Fraction 1 844 39693.58 6 5 156.1425 3.20 
1hr 4 degrees Fraction 2 200 1072.27         
1hr RT Fraction 1 847 40935.72 6 5 143.7576 3.48 
1hr RT Fraction 2 200 1205.08         
5hr 4 degrees Fraction 1 816 52646.08 6 5 185.0718 2.70 
5hr 4 degrees Fraction 2 202 1148.81         
5hr RT Fraction 1 820 41294.20 6 5 97.7066 5.12 
5hr RT Fraction 2 201 1721.17         
10hr 4 degrees Fraction 1 809 35638.86 6 5 120.3896 4.15 
10 hr 4 degrees Fraction 2 200 1198.05         
10 hr RT Fraction 1 818 38290.48 6 5 142.6340 3.51 
10hr RT Fraction 2 201 1094.34         
24hr 4 degrees Fraction 1 821 24523.80 6 5 123.0922 4.06 
24 hr 4 degrees Fraction 2 200 817.89         
24 hr RT Fraction 1 867 22545.08 6 5 75.9091 6.59 
24 hr RT Fraction 2 200 1289.86         
48 hr 4 degrees Fraction 1 828 22807.83 6 5 161.4230 3.10 
48 hr 4 degrees Fraction 2 200 585.55         
48 hr RT Fraction 1 808 26078.04 6 5 152.8676 3.27 
48 hr RT Fraction 2 202 683.55         
65 hr 4 degrees Fraction 1 811 12726.30 2.25 3.5 290.0989 1.21 
65 hr 4 degrees Fraction 2 201 176.83         
65 hr RT Fraction 1 801 13106.98 2.25 3.5 272.2664 1.29 
65 hr RT Fraction 2 200 192.80         
 
Very low Au counts were observed in the blank and retention time markers. This was true 
for both fractions, again suggesting that the observed Au in fraction 2 of the optimisation 
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samples was due to the MMN-DNA conjugate.  The calculated labelling efficiencies ranged 
from 1.21-6.59%, with the highest labelling efficiency corresponding to the 24 hour room 
temperature reaction. Generally, the room temperature reactions gave higher labelling 
efficiencies compared to those reactions stored at 4 oC. This observation was expected, 
since ambient room temperature would not have compromised the stability of the MMN 
probe and higher temperatures generally favour faster reaction times. The 10 hour reactions 
were the only exception to this rule, where the lower temperature reaction gave a slightly 
higher labelling efficiency.  
 
The data presented in Table 2:9 does not display any trends. It was expected that the 
labelling efficiency would gradually increase with increasing reaction time, until a plateau 
was reached and the efficiency would remain fairly constant. Instead of the expected trend, 
the labelling efficiencies were quite variable as illustrated in Figure 2:24, which shows 
graphically the variation in labelling efficiencies with reaction time. The efficiency of the 
room temperature reactions initially increased with reaction time, but then decreased at 10 
hours, followed by a large increase in efficiency at 24 hours, where the maximum labelling 
efficiency was observed.  
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Figure 2:24: MMN labelling efficiency with time. 
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The highest labelling efficiency for the 4 oC reactions was observed at 10 hours with     
4.15% labelling achieved. The 65 hour reactions gave much lower labelling efficiency 
values (1.21-1.29%). These two samples were taken from different reactions which only 
contained a 4.5 fold excess of MMN (6 fold excess of MMN was used in 1-48 hour 
reaction mixtures), hence these reactions were not included in Figure 2:24. It is possible 
that the lower molar excess of MMN resulted in lower labelling efficiencies. Alternatively, 
these two reactions may have been compromised upon preparation resulting in poor 
reaction yields.  
 
Despite investigating reaction time and temperature, poor labelling yields were still 
observed. The labelling efficiency values in Table 2:9 are much lower than those seen in 
the calculation on page 121, where 10.7% MMN labelling was achieved. In summary, the 
reaction does not appear to be controlled as illustrated in Figure 2:24, indicating that 
unknown factors are effecting the reaction. Further investigation into this reaction is 
required to obtain reproducible yields. These experiments were carried out with sulfhydryl 
modified 25 mers which did not require lengthy sample preparation prior to labelling. 
Although some success had been obtained in the initial experiments, poor yields prompted 
the decision to seek alternative methods of elemental labelling.  
   
Although calibration standards were prepared in order to quantify the Au contained in each 
fraction, this information was not employed in the calculation of labelling efficiencies. 
However, the standards were employed to check the response of the instrument to Au and 
also to check the instrument for signal drift during the analyses.  
 
One potential limitation of the anion exchange separation method is that the unbound 
MMN species eluted first in the void volume, followed by the MMN-DNA conjugate. It is 
possible that the Au response observed in the second fractions (MMN-DNA conjugate 
fraction), contained residual Au from the unbound MMN. This is plausible especially since 
the main limitation of Au is its ‘sticky’ nature, which results in carry over between samples. 
Although the blank, 25 mer oligonucleotide and MMN retention time markers exhibited 
low Au levels in the second fractions (Table 2:9), indicating that this was not the case, it 
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may be worth investigating this aspect of the separation to ensure any Au present in the 
second fraction is due to MMN-DNA and not residual Au remaining in the column from 
the unbound MMN species. Since cysteine and acid solutions were shown to improve Au 
wash out and reduce memory effects, it may be beneficial to add these to the mobile phase 
to aid Au wash out from the stationary phase. Conversely, a reversed phase separation 
should result in the MMN-DNA conjugate eluting first (highly charged species), followed 
by the less charged unbound MMN. This order of elution would prevent residual Au from 
unbound MMN being mistaken for Au corresponding to MMN-DNA, since the MMN-
DNA species is eluted first. 
 
2.4.3 Monomaleimido Nanogold Labelling Summary 
Preliminary results indicated that thiol modification did take place on 5’ phosphorylated 
oligonucleotides that were treated in-house with EDC, imidazole and cystamine. However, 
more analysis is required to confirm that efficient sulfhydryl modification was achieved. 
The presence of the reactive group could be confirmed with organic mass spectrometry, 
since structural information can be easily obtained, although this was not attempted here it 
should be considered for future development.  
 
The labelling of the sulfhydryl modified di-nucleotides with MMN proved to be difficult 
and very little success was achieved. The problems were attributed to the lengthy and 
difficult sample preparation procedures which involved cleaving the disulfide modification 
with DTT and separating the reactive di-nucleotide from excess DTT by means of gel 
filtration. As a result of these difficulties alternative reducing agents and separation 
methods were investigated. 
 
More success was achieved with the labelling of sulfhydryl modified 25 mers, these longer 
oligonucleotides were provided in the reactive sulfhydryl form. Although the results 
suggested that these nucleic acids were labelled with MMN, the labelling efficiency was 
very low. Investigations aimed at establishing the optimum reaction time and temperature 
for labelling were carried out. Unfortunately, poor labelling efficiencies were again 
calculated for the MMN reactions and the reaction yields were highly variable. The anion 
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exchange separation of bound and unbound MMN also needs to be investigated further to 
ensure all the Au is eluted from the anion exchange phase. 
 
The ‘sticky’ nature of Au meant that appropriate wash solutions were required to minimise 
carry over between samples. A combination of aqua regia and cysteine proved to be 
effective at removing Au from the surfaces of the sample introduction system. It may be 
beneficial to employ this combination of wash solutions in conjunction with the anion 
exchange column to prevent Au build up on the phase. 
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2.5 Streptavidin FluoroNanogold Labelling of Biotinylated DNA 
2.5.1 Introduction to Streptavidin FluoroNangold Labelling 
Streptavidin FluoroNanogold (SFNG) consists of a nanogold particle containing 
approximately 80 Au atoms, which is covalently bound to a streptavidin protein and an 
Alexa Fluor 488 dye. Each streptavidin protein contains an average of one Au nano-particle 
and between 2-3 Alexa Fluor 488 fluorophores.95 The molecular weight of SFNG is 
approximately 75 KDa, with the streptavidin protein contributing 60 KDa of the total mass. 
The probe is illustrated Figure 2:25.95 
 
 
Figure 2:25: Alexa Fluor - 488 Streptavidin FluoroNanogold. 
 
Streptavidin has extremely strong affinity for biotin, which is a water soluble vitamin. 
Association constants in the order of 1013 M-1 have been reported between these two 
species, in what is the strongest known non-covalent biological interaction.113 The 
exceptionally high association constants of these two molecules makes them ideal linkers 
for nano-particle labelling.90, 114, 115 Streptavidin is a tetrameric protein containing four 
biotin binding sites, however, only one or two of the biotin binding sites will potentially be 
accessible on the SFNG probe. This is due to steric hindrance, namely, the nanogold and 
Alexa Fluor dye will block some of the biotin binding sites on the protein.95 The reaction 
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between biotinylated DNA and SFNG is summarised in Figure 2:26. This reaction is 
straightforward, with SFNG-DNA conjugates forming below room temperature within 24 
hours.  
 
 
Figure 2:26: Streptavidin FluoroNanogold labelling of biotinylated DNA. 
 
2.5.2 Biotinylation of DNA 
The work in this section focuses on the labelling of biotinylated DNA with a SFNG probe. 
As in the case of sulfhydryl modified oligonucleotides, biotinylated oligonucleotides are 
commercially available, but for there to be a viable labelling method with an ultimate 
application, the DNA has to be modified to incorporate the reactive biotin group. This 
section outlines a potential method for the biotinylation of 5’ phosphate groups on nucleic 
acids. The modification procedure was obtained from Pierce Biotechnology,116 but similar 
biotinylation methods have been reported elsewhere.117 The DNA biotinylation route is 
shown in Figure 2:27. 
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Figure 2:27: Biotinylation of DNA 5' phosphate. 
 
Following modification, the biotinylated DNA needs to be separated from excess reagent. 
This could potentially be achieved using anion exchange SPE, since the DNA will be 
retained on the charged phase and the excess reagent eluted. However, the SPE method 
would not necessarily separate the biotinylated DNA from the unmodified DNA.  
 
Upon biotinylation, the distance between the biotin moiety and the terminal 5’ phosphate 
group would be 18.9 Å.118 This spacer arm is intended to minimise any steric effects that 
may occur during the labelling reaction. If more than one biotinylated DNA molecule binds 
to one streptavidin protein, it is possible that steric restraints may effect the labelling 
reaction. However, any steric effects should be minimised by having an 18.9 Å spacer 
between the biotin and DNA. 
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2.5.3 Method of Labelling 
Since the affinity between biotin and streptavidin is very strong, the labelling method was 
straight forward and did not involve complicated and lengthy sample preparation 
procedures. In addition, both the SFNG and biotinylated DNA were stable in solution, 
which made sample handling easier. SFNG labelling of biotinylated DNA was achieved by 
adding the DNA to an excess of SFNG. The reaction mixture was then left for 
approximately 24 hours at 4 oC to allow the reaction to proceed. 
 
2.5.4 Methods of Separation 
Once the labelling reaction was complete, a separation procedure was necessary to resolve 
the SFNG-DNA conjugate from the unbound SFNG. Numerous modes of separation were 
investigated for this labelling strategy. Each one will be discussed along with the 
advantages and disadvantages of each. 
 
2.5.4.1 Gel Filtration 
Gel filtration is a liquid phase separation operating at low pressures. Gel filtration separates 
species according to size, thus the technique works by size exclusion. The stationary phase 
consists of a porous carbohydrate-polymer matrix. Larger molecules cannot fit within the 
stationary phase pores and are therefore excluded and eluted from the phase. Conversely, 
small molecules infuse within the pores and are retained on the phase. This results in a 
sieving effect, where larger molecules are eluted first followed by small molecules.119, 120 
The phases used in gel filtration are relatively stable at a range of pH values.  
 
There are many types of phase available each having different selectivity’s (different 
molecular weight ranges) and molecular weight cut-off points. The media used to separate 
SFNG-oligonucleotide conjugates from unbound material was Superdex-75. This media is 
composed of cross-linked dextran and agarose and has an average particle size of 34 µm, 
and an optimum molecular weight separation range of 3000-70 000 Da. Species falling 
within this molecular weight range will be successfully separated; however, molecules with 
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a molecular weight exceeding 100 000 Da will not be retained in the pores and therefore 
eluted in the void volume. Thus, the exclusion limit of Superdex-75 is 100 000 Da. 
  
Superdex-75 was chosen because the oligonucleotide molecular weight was towards the 
bottom end of the media’s optimum molecular weight range and the molecular weight of 
the bound SFNG-DNA conjugates was towards the top end of the optimum separation 
range. As a result, the free and bound oligonucleotides should separate. The molecular 
weights of the species involved in the tagging experiment are summarised in Table 2:10. 
Table 2:10: Molecular weight of SFNG, biotinylated oligonucleotides and SFNG conjugates. 
Species Molecular weight 
SFNG ~75 500 
18 mer biotinylated oligonucleotide 6145 
18 mer oligo-SFNG conjugate ~81 600-87 790* 
24 mer biotinylated oligonucleotide 8000 
24 mer oligo-SFNG conjugate ~83 500-91 500* 
 
*The molecular weight of the SFNG- oligonucleotide conjugates depends on the number of 
oligonucleotides bound to the streptavidin protein. Only one or two biotinylated 
oligonucleotides will bind to SFNG due to steric restraints. 
 
Superdex-75 was supplied as a suspension in a 20% ethanol solution. The media was 
already pre-swollen and was prepared as follows: 
• The required amount of Superdex suspension was filtered using a glass filter to 
remove the ethanol.  
• 5-10 column volumes of deionised water were used to wash the media. 
• The media was then re-suspended in deionised water. The resulting suspension 
contained approximately 50% settled media and 50% water.  
• 200 µl of TWEEN-20 was added to the Superdex suspension. 
• The suspension was mixed gently by swirling the beaker. 
• The suspension was poured into a packing reservoir, which was attached to a 30 cm 
x 1 cm column. The suspension was poured in one slow, smooth motion.  
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• A peristaltic pump (Minipuls 2, Gilson) was connected to the column outlet and set 
to pump at ~0.20 ml min-1.  
• The column was left to pack at this flow rate for 2-3 hours or until the column bed 
had settled. The column was topped up with deionised water at regular intervals to 
ensure the media did not run dry. 
• Deionised water was then pumped through the column for a further 3 hours at    
0.20 ml min-1. 
 
Once the column bed had settled, the column was ready for equilibration with the elution 
buffer, followed by sample separation. 
 
2.5.4.2 Anion Exchange HPLC 
This mode of separation operates on charge interaction. A positively charged stationary 
phase was employed, which resulted in retention of the negatively charged phosphate 
groups on DNA. Likewise the SFNG was also retained due to the carboxylic and sulfonic 
acid groups on the fluorophore. It also was expected that streptavidin contributed to the 
retention of SFNG due to the carboxylic acid groups on the amino acids. However, it was 
hoped that a method could be developed to resolve the unbound SFNG from the SFNG-
DNA conjugate. The TSKgel-DNA-NPR analytical column was used for anion exchange 
separation (see Appendix 1 for details). The anion exchange stationary phase consisted of a 
non-porous resin, which was chosen since it does not possess intra-particular voids that 
would cause the high molecular weight molecules to be excluded. As a result, non-porous 
resins enable relatively quick, high resolution separations of high molecular weight 
molecules. This phase had a relatively low capacity due to the lack of intra-particular voids; 
therefore, small injection volumes were used to prevent overloading the column. This phase 
was used for all anion exchange separations, but numerous mobile phases were 
investigated.  
 
There were two criteria for the choice of mobile phase; firstly it was important that the 
mobile phase eluted both the DNA and SFNG. Secondly, the mobile phase had to be 
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compatible with ICP-MS. The basic HPLC parameters are outlined in Table 2:11. Any 
amendments to the chromatography conditions will be stated where appropriate.  
 
The HPLC separation optimisation was carried out off-line to the ICP-MS, as a result UV 
data was initially obtained and not ICP-MS data. The Alexa Fluor-488 dye and nanogold 
both have very high absorption coefficients, for example, at 280 nm the nanogold particle 
has an absorption coefficient of approximately 3 x 105 dm3 mol-1 cm-1. As a result, the 
probe should be easily detected by the UV detector allowing off-line chromatography 
optimisation prior to elemental analysis.  
Table 2:11: HPLC parameters employed for the anion exchange separation of the SFNG and SFNG-
DNA conjugates. 
Parameter Setting 
Stationary phase TSKgel-DNA-NPR, 7.5 cm x 4.6 mm, 2.5 µm. 
Mobile phase Variable 
Flow rate 0.7 ml min-1  
Detection wavelength 257 nm  
Gradient Variable 
Stop time Variable 
Post time Variable 
Injection volume 5 µl 
Column temperature Room temperature 
 
Solutions containing unbound SFNG were initially injected onto the HPLC phase to 
establish the retention time of the probe. The mobile phases investigated where as follows: 
• 20 mM Tris-HCl, pH 9 with a gradient of 20 mM Tris-HCl + 50 mM trisodium 
citrate + 0.5 M TMACl, pH 9 
• Phosphorus buffered saline (20 mM sodium phosphate, 150 mM sodium chloride), 
pH 7.2 
• pH gradient (25 mM Tris-HCl, pH 9 and 25 mM sodium phosphate + 25 mM 
trisodium citrate, pH 3) 
• 20% DMSO in 25 mM trisodium citrate, pH 9 isocratic 
• 50 mM ammonium sulfate, pH 3 isocratic 
• 20% acetonitrile in 100 mM triethylammonium acetate, pH 7 isocratic. 
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2.5.4.3 Immobilised Metal Affinity Chromatography 
Another mode of chromatography investigated in this particular project was immobilised 
metal affinity chromatography (IMAC). In this mode of affinity chromatography, the metal 
(usually a divalent or trivalent transition metal) is immobilised on agarose beads. The 
biomolecule, which may be DNA or proteins interacts with the immobilised metal and is 
therefore retained on the phase. The retained biomolecule can be eluted with a competing 
compound or by adjusting the pH of the elution buffer. There have been many reports in the 
literature regarding the use of IMAC for biomolecule  separations.121-125  
 
The choice of metal determines the selectivity of the phase, which depends on the part of 
the analyte that is to be retained on the column. Iron(III) and Ga(III) are hard Lewis acids 
and therefore interact with hard Lewis bases, such as phosphate groups on the biomolecule. 
However, Ni(II), Cu(II) and Zn(II) are softer Lewis acids and interact with the nitrogen 
bases on the imidazole rings of purine nucleobases. Iron(III) was chosen in this 
investigation, so the DNA was retained due to the presence of the phosphate backbone. The 
stationary phase was prepared as described below and was a slight modification of the 
procedure reported by Hart et al.126 It was hoped that the oligonucleotides would be 
retained due to the phosphate groups, but the SFNG would have little retention resulting in 
an easy separation method.  
 
Fe(III)-NTA-Agarose Phase Preparation 
• Ni(II)-NTA-Agarose (750 µl) was placed into a micro centrifuge tube. To this, the 
same volume of deionised water was added. The suspension was shaken manually 
and then centrifuged at 6000 rpm for 5 minutes.  
• The supernatant was discarded and then the above step was repeated twice more to 
wash the agarose.  
• The agarose beads were then washed three times with 750 µl of 0.1 M EDTA in      
1 M sodium hydroxide. During these wash steps the EDTA complexed to the NTA-
agarose bound Ni, thus removing the metal from the agarose beads. 
• A 750 µl volume of deionised water was used to wash the stripped beads followed 
by a 750 µl aliquot of 0.1 M acetic acid. The supernatant was again discarded. 
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• The Fe(III) was then introduced to the phase by adding 750 µl of a solution 
containing 0.1 M iron(III) chloride in 0.1 M acetic acid. The mixture was again 
shaken, centrifuged and the supernatant discarded.  
• An acetic acid wash was carried out after the modification, followed by three further 
deionised water wash steps. 
• The Fe(III)-NTA-agarose beads were re-suspended in 750 µl deionised water and 
split into three equal fractions each containing approximately 0.5 ml of suspension. 
One fraction was used as a blank/control sample (control sample consisted of 
deionised water only), the second for an oligonucleotide sample and the third for a 
SFNG sample. 
• The excess water was removed from the beads and 0.4-0.5 ml of sample was 
applied to the Fe(III)-NTA-agarose phase. 
• The loaded beads were shaken and allowed to stand for two hours at 4 oC, with 
shaking every 30 minutes. 
 
After the two hour incubation time, the suspension containing the IMAC phase and sample 
were poured into a small gel filtration column. The column was connected to a vacuum 
manifold. The excess liquid in the column was allowed to drain away. The column eluent 
was collected and kept for UV/vis analysis. The phase was then washed with three 0.5 ml 
aliquots of deionised water followed by three 0.5 ml aliquots of 0.1 M sodium hydroxide. 
The column eluent was collected during each wash and elution step and UV/vis was used to 
determine where the two species of interest eluted.  
 
2.5.4.4 Reversed Phase HPLC 
Reversed phase HPLC (RP-HPLC) employs a non-polar stationary phase and polar mobile 
phases containing various proportions of organic solvent. The mode of separation is based 
on hydrophobic interaction. Non-polar molecules have more interaction with the non-polar 
phase and are therefore retained on the column and exhibit longer retention times. In 
contrast, polar species have less affinity with the stationary phase and more interaction with 
the polar mobile phase and are eluted first. The strength of the mobile phase is increased by 
adding greater amounts of organic modifier, which has the effect of eluting the non-polar 
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species from the stationary phase. Consequently, the elution strength of the mobile phase is 
increased by raising the proportion of organic solvent in the eluent. Reverse phase 
separations can be coupled to ICP-MS more easily than most other modes of 
chromatography, there are several reasons for this. Firstly, the mobile phase consists of 
aqueous solvents which are ICP-MS compatible. Although organic modifiers are used in 
reversed phase chromatography, they can be used in conjunction with ICP-MS providing 
the content is kept relatively low (<15%). Alternatively, the organic solvent can be easily 
removed by evaporation prior to ICP-MS analysis. In addition, HPLC flow rates are 
typically 0.5-1 ml min-1, which is compatible with nebuliser flow rates.  
 
A C18 column was used for all SFNG reversed phase separations. Mobile phases 
containing various proportions of methanol and acetonitrile in deionised water were 
assessed for their suitability in eluting the SFNG species from the phase. In addition to RP-
HPLC being compatible with ICP-MS, the charged SFNG probe should have very little 
interaction with the non-polar stationary phase, thus providing easier separation with good 
levels of recovery. This is a contrast to anion exchange chromatography where SFNG 
appeared to be retained quite irreversibly on the charged anion exchange phase (see results, 
section 2.6.1.2). 
 
A HP 1090 Series 2 HPLC instrument with diode array UV detection, operating off-line to 
ICP-MS was initially employed to establish the retention times of the unlabelled 
oligonucleotides and SFNG. Once it was established that the two species had different 
retention times, the separation was carried out on-line with ICP-MS. The Element 2XR 
ICP-MS instrument was employed for the determination of Au in the SFNG/DNA samples.  
The basic HPLC parameters are outlined in Table 2:12, whilst Table 2:2 summarises the 
ICP-MS operating conditions. 
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Table 2:12: Basic HPLC operating parameters for the C18 separation of SFNG and SFNG-DNA 
conjugates. 
Parameter Setting 
Stationary phase Hypersil C18, 250 mm x 4.6 mm (120 Å) or Waters µBondapak C18 
300 mm x 3.9 mm, 10 µm (125 Å). 
Mobile phase Acetonitrile/water or methanol/water of varying proportions 
Flow rate 0.6 - 1 ml min-1  
Detection wavelength 280 nm  
Gradient Variable 
Stop time Variable 
Post time Variable 
Injection volume 10 µl  
Column temperature Room temperature 
 
The Element 2XR instrument was operated in speed scanning mode for all 
chromatographic data acquisitions. The resulting Au chromatograms were exported as an 
Xcalibur file and then opened with the Xcalibur program (Version 2.0, Thermo Finnigan, 
San Jose, California, US), which was employed to process ESI-MS data on the LTQ linear 
ion trap mass spectrometer. This allowed the Au chromatograms, which were obtained on 
the Element to be integrated, thus peak areas and retention times were accurately obtained 
for each Au chromatogram. In addition, the chromatographic data was also exported as a 
text file and subsequently opened in Microsoft Office Excel, which simply allowed the 
chromatographic data to be viewed without the need for the Xcalibur viewing software.   
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2.6 Results of Streptavidin FluoroNanogold Labelling 
2.6.1 Methods of Separation 
2.6.1.1 Gel Filtration 
Unfortunately, gel filtration was found to be unsuitable for the separation of SFNG from 
SFNG-DNA conjugates due to the poor resolving power of the technique. The longest 
oligonucleotides (24 mer) had a molecular weight of ~8 000 Da, therefore, if two 24 mers 
bound to each streptavidin protein; the corresponding conjugate would have a MW ~91 500 
Da and the unbound SFNG MW ~75 500 Da. This small molecular weight difference (1.2 
fold difference in MW) resulted in partial resolution, which would have resulted in difficult 
quantification. Ultimately, baseline resolution of the two species was required for 
quantitative analysis. This implies that for gel filtration to be successful in purifying these 
conjugates, an excess of biotinylated oligonucleotide was required in the tagging reaction 
mixture, so when the reaction has gone to completion, there should be no free SFNG, but 
an excess of unbound oligonucleotide. It should be reasonably straight forward to separate 
the excess free oligonucleotide (MW~6 000-8 000 Da) from the much heavier SFNG-DNA 
conjugates (MW ~81 600-91 500 Da). Even though the use of gel filtration is possible, the 
species to be labelled has to be in excess and not the probe which negates quantification. 
 
In addition, problems were encountered when packing the media into columns. It was 
difficult to obtain an even column bed. The performance of the column was tested with 
both blue dextran and acetone. Blue dextran was used to establish the void volume of the 
column. The average molecular weight of the dextran was ~2 x 106, thus it was totally 
excluded from the phase. Acetone was used to establish the efficiency of the column, which 
was achieved following the procedure outlined by the manufacturer.120 Breifly, the column 
outlet was connected to a UV detector and integrator as described previously. The acetone 
peak was then used to calculate the column efficiency using the equation below.120 
 
N/m = 5.54(Ve/W½)
2 1000/L 
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Where: 
N/m = Number of theoretical plates per meter. 
Ve = Elution volume (ml) 
W½ = Peak width at half height (ml) 
L = Height of Superdex bed (mm) 
 
For Superdex media, efficiency values of approximately 10 000 N/m should be obtained.120 
However, the best value achieved was 382 N/m. As a result of these problems and other 
limitations it was decided to look for alternative methods for separation.  
 
2.6.1.2 Anion Exchange HPLC 
Several mobile phases were assessed for their suitability for SFNG elution from the anion 
exchange phase. The basic chromatographic conditions used were kept constant throughout 
this part of the investigation and are shown in Table 2:11 in the method section. The first 
phase to be investigated was: 
A: 20 mM Tris-HCl, pH 9  
B: 20 mM Tris-HCl + 0.5M TMACl + 50 mM trisodium citrate, pH 9 
 
Gradient elution was employed with mobile phase B gradually increasing throughout the 
separation. The buffers used in this mobile phase should be compatible with ICP-MS. The 
ionic strength of the eluent was very high, owing to the presence of citrate, which has a 
triple negative charge. It was hoped that the high ionic strength eluent would be sufficient 
to elute the highly charged SFNG from the anion exchange phase. However, SFNG failed 
to elute with this mobile phase. As a result, the retention mechanism was thought to have 
some hydrophobic character rather than just ionic, thus 10% acetonitrile was added to 
mobile phase B. The high ionic strength phase containing organic solvent also failed to 
elute SFNG.  
 
Phosphorus buffered saline (PBS) was the next mobile phase to be investigated. SFNG was 
supplied in a solution containing 20 mM phosphate buffer and 150 mM sodium chloride at 
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pH 7.4. The probe was soluble and stable in this buffer, so mobile phases containing the 
following were prepared: 
A: 20 mM sodium dihydrogen phosphate, pH 7.2 
B: 20 mM  sodium dihydrogen phosphate, 0.5 M sodium chloride, 5.4 mM 
potassium chloride, pH 7.2 
 
Gradient elution was again carried out with a gradual increase of mobile phase B. SFNG 
did not appear to elute using the mobile phases outlined above. However, when the column 
was removed from the instrument and reconnected in the reverse flow direction, a huge 
absorbance was observed. Upon further inspection, it appeared that the signal slowly 
decreased over a period of ~12 minutes, suggesting that the signal was not due to the 
SFNG, but probably due to deposited material and contaminants on the top of the column.  
 
All previous anion exchange chromatography had been conducted with an escalating 
gradient of salt, thus increasing ionic strength in an attempt to elute the analyte. However, 
pH gradients had not yet been investigated. Anion exchange separation of proteins can be 
carried out using pH gradients as reported elsewhere,127, 128 and it was used in this study for 
the elution of SFNG. This method of elution involved using an initial mobile phase with a 
higher pH, and then gradually decreasing the mobile phase pH to the same pH as the 
protein isoelectric point (pI). At this stage, the positive and negative charges on the protein 
are balanced, so the protein net charge is zero and SFNG should elute. The buffers used to 
create a pH gradient were as follows: 
A: 25 mM Tris-HCl, pH 9 
B: 25 mM sodium dihydrogen phosphate, 25 mM trisodium citrate, pH 3 
 
The above buffers produced a gradient starting from pH 9 and decreasing to pH 3. The pKa 
values and buffering ranges of all three buffers overlapped, and therefore created a 
decreasing pH gradient throughout the elution. At pH 9, all the streptavidin carboxylic acid 
groups would have been ionised and therefore interacted with the anion exchanger. When 
the mobile phase composition gets to ~pH 5.5, the protein will have a net charge of zero, 
since this is the streptavidin isoelectric potential (pI). However, the mobile phase was taken 
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down to pH 3, which is two pH units below the protein pI. At pH 3 all the amine and acid 
groups on the protein were protonated, resulting in a net positive charge, which should 
result in SFNG elution. Despite efforts to elute the probe with pH gradients, no signal was 
observed.  
 
The manufacturer of SFNG was contacted and their advice was requested with respect to 
the chromatographic separation of the conjugate.95 After obtaining advice, a mobile phase 
containing 20% DMSO in 25 mM trisodium citrate, pH 9 was tested. DMSO solubilises the 
Alexa Fluor-488 fluorophore, so it was thought that DMSO was a good solvent to use in 
conjunction with the probe. No peaks were observed when the SFNG was injected into the 
column, however, the mobile phase was diluted two fold and the SFNG was re-injected. 
The aim of this was to weaken the mobile phase eluent strength and confirm that the probe 
was not eluting in the void volume and being masked by noise at the start of the injection. 
However, this was not the case and yet again, nothing was observed.  
 
Since none of the above mobile phases had successfully eluted the SFNG, degradation of 
the probe in solution was a consideration. However, even if the SFNG had dissociated in 
solution, the fluorophore and aromatic amino acids would have still been present resulting 
in some UV response. This suggested that the SFNG was being retained almost irreversibly 
on the phase. 
 
One anion that had not been investigated was sulfate. The sulfate anion is a very strong 
eluent in anion exchange chromatography; therefore, a buffer containing 50 mM 
ammonium sulfate at pH 3 was prepared. The mobile phase had a very high ionic strength 
and the pH was below the pI point of streptavidin, so the protein part of the probe should 
not have had any interaction with the phase using this eluent. The first blank injection 
carried out with this eluent resulted in a large peak with a retention time of 9 minutes. This 
huge absorbance was probably due to built up contamination on the column which was 
eluted with the strong eluent. A further blank injection did not give the same result. The 
SFNG injection exhibited a flat baseline, although a small peak in the baseline was 
observed at 10.4 minutes. Further SFNG injections gave a small peak at 10.4 minutes, 
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however, if this was due to the SFNG, the signal was very weak and the possibility of a 
contaminant in the sample was considered.  
 
Ion-pair HPLC was then investigated. The same chromatographic conditions detailed in 
Table 2:11 were employed, but the mobile phase consisted of 100 mM 
triethylamammonium acetate in 20% acetonitrile, pH 7 (isocratic). A response was 
observed at ~0.5 minutes, although the signal was weak and no better than that observed 
with the ammonium sulfate mobile phase. 
 
Although a lot of work was conducted with SFNG and anion exchange separations, no real 
success was obtained. It was concluded that the sulfonic acid groups on the Alexa Fluor-
488 dye were retained irreversibly on the anion exchange resin. Although a very small 
amount of SFNG may be eluted with a high ionic strength mobile phase, the recoveries 
would have been very small. Hence, alternative methods of separation were again 
investigated. 
 
2.6.1.3 Immobilised Metal Affinity Chromatography 
The column eluents collected from the phase during the separation procedure were scanned 
with a UV spectrometer between 200-400 nm for oligonucleotide detection, and            
200-600 nm for SFNG detection. Figure 2:28 shows the spectra of both the oligonucleotide 
and SFNG before they were applied to the phase. The oligonucleotide yielded a maximum 
at 256.40 nm, whilst SFNG gave an absorbance at 493.20 nm, which corresponded to the 
Alexa Fluor 488 absorbance (ε490 nm = 71 000 cm
-1
 M
-1).129 However, a stronger absorbance 
was observed at approximately 260-280 nm for SFNG, corresponding to the nanogold 
particle, which as stated previously has an absorption coefficient of ~3 x 105 at 280 nm. 
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Figure 2:28: a) 10 µM 25 mer oligonucleotide spectrum before IMAC separation. b) SFNG spectrum 
before IMAC separation (0.18 µM nanogold and ~ 0.85 µM Alexa fluor-488). 
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One set of IMAC beads was used as a control in which deionised water was added to the 
phase. The aim of the control was to ensure no background absorbance from the phase was 
effecting the UV/vis detection of DNA or SFNG. The UV data from the control column 
fractions did not reveal any significant absorbance that would potentially interfere with the 
DNA or SFNG detection. 
 
The deionised water column eluents from the oligonucleotide and SFNG loaded IMAC 
phases did not reveal any absorbance, thus confirming that both the oligonucleotides and 
SFNG were retained on the IMAC phase. The three sodium hydroxide elution steps did 
result in oligonucleotide elution, which was shown by absorbance maxima at 256 nm. The 
overlaid spectra in Figure 2:29 show the first, second and third sodium hydroxide elution 
steps of the oligonucleotide from the IMAC phase. Recovery calculations revealed that 
approximately 90% of the oligonucleotide was recovered from the phase with sodium 
hydroxide elution. Recoveries of 55.3%, 27% and 9.3% were obtained in the first, second 
and third sodium hydroxide wash steps respectively.  
 
Figure 2:29: Overlaid spectra of the three sodium hydroxide elution steps for DNA elution from the 
IMAC phase. 
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Figure 2:30 shows the overlaid spectra corresponding to the three sodium hydroxide elution 
steps of SFNG from the IMAC phase. The spectra exhibit absorbance at 494 nm 
corresponding to the fluorophore, although the absorbance was very weak. The nanogold 
absorbance at 280 nm gave a better indication of elution than the Alexa Fluor 488 dye. 
Further sodium hydroxide elution fractions did not show any sign of the probe. It should be 
noted that the Alexa Fluor dye was only present at a concentration of ~0.85 µM in the 
original sample. Hence after sodium hydroxide elution, the fluorophore concentration and 
absorbance would have been very weak. 
 
 
Figure 2:30: Overlaid spectra for the three sodium hydroxide elution steps of SFNG from IMAC phase. 
 
It can be concluded from these experiments that both the oligonucleotides and SFNG were 
retained on the Fe(III)-NTA-agarose phase, but co-eluted with base under the conditions 
used. However, it may be the case that the two species had different affinities to the phase, 
if so, different concentrations of base may successfully resolve the two species, resulting in 
separation of bound and unbound SFNG. The IMAC phase contained Fe(III), which has 
affinity for hard bases such as phosphate groups. If the streptavidin protein contained 
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phosphorylated amino acids, then these would also be retained on the IMAC phase. 
However, if the specificity of the phase is altered by changing the immobilised metal to 
Ni(II), then the streptavidin may not be retained, but DNA should still display retention due 
to the imidazole groups on the purine rings interacting with Ni(II). This aspect has yet to be 
investigated.  
 
A further consideration is that the eluent has to be compatible with ICP-MS; hence 
alternative bases to sodium hydroxide will have to be found. Tetramethylammonium 
hydroxide (TMAH) or tetramethylammonium chloride (TMACl) may be suitable for the 
elution of the oligonucleotide conjugates from the IMAC phase. Due to lack of time IMAC 
separation was not pursued any further. 
 
2.6.1.4 Reversed Phase HPLC 
Mobile phases consisting of methanol-water and acetonitrile-water mixtures were used in 
an attempt to elute SFNG from a C18 phase. SFNG should have very little, if any retention 
on a non-polar C18 reverse phase column. As a result, the probe should be successfully 
eluted with high levels of recovery using mild conditions. Although organic solvents were 
used, they can be easily removed prior to ICP analysis, or the HPLC flow can be split post 
column to minimise the solvent flow to the plasma. Initially solutions containing SFNG or 
oligonucleotide only were injected onto the C18 column to establish the retention times of 
the two species.  
 
Initial tests employed an isocratic acetonitrile-water (50:50) mixture to elute SFNG from a 
C18 guard column. A UV response was obtained which was attributed to the elution of 
SFNG. As a result, the same sample was injected onto a C18 analytical column (Hypersil 
C18 column 250 mm x 4.6 mm) and additional peaks were observed in the SFNG 
chromatogram when compared to the blank injection, which were again attributed to SFNG 
eluting from the phase. Additional peaks at 1.27 and 1.82 minutes were observed in the 
SFNG chromatogram. However, these peaks eluted very quickly suggesting that there was 
very little interaction between the probe and stationary phase. As a result, the eluent 
strength was decreased by employing an isocratic methanol-water mixture (50:50). Upon 
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eluting the SFNG with the weaker solvent, a peak was observed at 1.94 minutes. The 
methanol content was reduced further so the mobile phase contained 35% methanol, which 
resulted in the SFNG eluting at 2.39 minutes. A sample containing 5’ biotinylated 24 mer 
was also injected on the column and eluted using the isocratic 35% methanol mobile phase, 
and a retention time of 1.45 minutes was observed. The chromatograms of the biotinylated 
24 mer and SFNG, eluted with 35% methanol are shown in Figure 2:31. 
 
 
 
Figure 2:31: a) 5' biotinylated 24 mer retention time marker. b) SFNG retention time marker. Both 
species eluted from a Hypersil C18 column (250 mm x 4.6 mm) with 35% methanol isocratic elution. 
Flow rate = 0.6 ml min
-1
, 10 µl injection volume. 260 nm detection wavelength. 
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The peak at 1.36 minutes displayed in Figure 2:31b was also observed in the blank 
injection and therefore not attributed to SFNG. The baseline in Figure 2:31b exhibited a 
negative absorbance at 3 minutes. This suggests that there was a positive absorbance from 
the mobile phase, which was removed upon eluting the SFNG, no explanation could be 
given since the mobile phase only consisted of methanol and water. Once it was established 
that the SFNG and unbound oligonucleotide had different retention times, a SFNG-DNA 
reaction mixture was prepared. Briefly, 125 µl SFNG (1.33 µM streptavidin) was added to 
68 µl biotinylated 24 mer oligonucleotide (5 µM). Hence the reaction mixture contained; 
0.34 nmoles biotinylated 24 mer and 0.17 nmoles streptavidin, which equated to 0.67 
nmoles of biotin binding sites (total of four biotin binding sites per streptavidin). A two 
fold excess of biotin binding sites was present in the reaction mixture. The tagging reaction 
mixture was placed in the refrigerator for 24 hours at 4 oC.95 After 24 hours, a 100 µl 
aliquot was taken and 55 µl of methanol was added to the aliquot. This was done to ensure 
the sample solvent and mobile phase compositions were matched in terms of organic 
solvent content. The sample was then injected and the isocratic mobile phase consisting of 
35% methanol in water was used to separate the mixture. Figure 2:32 shows the tagging 
reaction mixture chromatogram, where three main peaks were observed at; 1.42, 2.55 and 
3.04 minutes. The peaks at 1.42 and 2.55 minutes were thought to be the biotinylated 24 
mer and the unbound SFNG respectively, since these retention times were consistent with 
those seen for the retention time markers (see Figure 2:31). The additional peak at 3.04 
minutes was thought to be the SFNG-DNA conjugate. Three peaks were expected, 
however, the identity of the two remaining smaller peaks at 1.81 and 2.34 minutes were 
unknown. 
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Figure 2:32: Chromtogram of the SFNG-biotinylated DNA reaction mixture, eluted from a Hypersil 
C18 column (250 mm x 4.6 mm) with 35 % methanol, isocratic elution, 0.6 ml min
-1
 flow rate, 10 µl 
injection volume. 260 nm detection wavelength. 
 
Once it was established that the SFNG-DNA labelling mixture gave additional peaks to 
those seen in the SFNG and 24 mer retention time marker chromatograms, the sample was 
injected again, but fractions were collected from the column outlet at the following time 
periods throughout the separation; 1.2-1.7 minutes, 2.3-2.8 minutes and 3-3.5 minutes. 
These three fractions were denoted fractions 1, 2 and 3 respectively. The same fractions 
were also collected during injection and elution of the retention time markers and the 
sample blank (35% methanol). Each of the collected fractions consisted of 300 µl           
(0.6 ml min-1 flow rate which was collected for a total of 0.5 minutes in each fraction), but 
contained approximately 35% methanol. Once all the fractions had been collected, the 
methanol was allowed to evaporate. This was achieved by placing the samples in a heated 
(50 oC) water bath with a gentle stream of argon flowing over the collected fractions. The 
removal of methanol was necessary to ensure the samples were ICP-MS compatible. Also, 
by removing the organic solvent, the standards did not have to be matrix matched with the 
samples in terms of solvent content.   
 
Once the samples had been evaporated down to near dryness, they were reconstituted with 
water to a volume of 0.5 ml. Further dilutions were carried out on the re-suspended samples 
with 2% hydrochloric acid prior to ICP-MS analysis. Gold calibration standards               
(10 pg ml-1–1000 pg ml-1) were also prepared in 2% hydrochloric acid. These samples were 
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analysed on the Element 2 XR ICP-MS and the Au in each fraction was quantified. Table 
2:13 summarises the data and shows the Au concentration in each of the collected fractions. 
Table 2:13: Au concentrations in separated fractions. 
Sample Au conc. (ng ml
-1
) 
Blank fraction 1 0.22 
Blank fraction 2 0.08 
Blank fraction 3 0.10 
  
24 mer only fraction 1 0.12 
24 mer only fraction 2 0.13 
25 mer only fraction 3 0.16 
  
SFNG only fraction 1 0.67 
SFNG only fraction 2 1.08 
SFNG only fraction 3 0.52 
  
SFNG-DNA fraction 1 5.67 
SFNG-DNA fraction 2 2.28 
SFNG-DNA fraction 3 1.39 
 
The Au concentrations were relatively low in the blank and 24 mer oligonucleotide 
(retention time marker) fractions as expected. However, the second fraction of the SFNG 
retention time marker had elevated Au levels which confirmed that the unbound SFNG 
eluted between 2.3-2.8 minutes, which was consistent with the UV data (Figure 2:31b). The 
third peak at 3 minutes in the SFNG-DNA labelling mixture (Figure 2:32) was thought to 
be the conjugate. However, this fraction proved to contain the least amount of Au of all the 
tagging fractions. The first fraction contained the most Au, suggesting that the SFNG-DNA 
conjugate eluted between 1.2-1.7 minutes. One explanation is that the SFNG-DNA 
conjugate was so large (up to 91 500 Da) that it was totally excluded from the porous C18 
phase, thus eluting very quickly. The conjugate would also be highly charged due to the 
presence of the additional DNA molecules, also explaining why the conjugate would have 
very little retention on the C18 phase. It should also be noted that more than one biotin 
binding site on the streptavidin molecule may be available for binding, thus more than one 
conjugate species may be formed during the reaction. The SFNG probe could have one or 
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two biotinylated DNA molecules bound to the streptavidin protein, resulting in two 
potential conjugate species, each having different molecular weights and charges. Hence, 
the two additional peaks (1.81 and 2.34 minutes) observed in the tagging chromatogram 
(Figure 2:32) could also be conjugates. 
 
The next step was to carry out the separation on-line with ICP-MS. However, the methanol 
content in the mobile phase had to be reduced from 35% to less than 10%. There were two 
reasons for reducing the amount of organic modifier in the mobile phase. Firstly, 35% 
organic solvent could potentially make the plasma unstable and the high organic matrix 
may have suppressed Au ionisation. In addition, carbon deposition around the sampler cone 
will be more pronounced with higher organic solvent content resulting in signal drift and 
reduced sensitivity. The separation method was therefore modified so the mobile phase 
contained 5% methanol. The low level of organic solvent did not adversely affect the 
plasma and carbon deposition was minimal. Isocratic elution is preferred when using 
HPLC-ICP-MS, since the mobile phase composition remains constant resulting in constant 
plasma conditions. In contrast, gradient elution involves changing the mobile phase 
composition. Thus, the plasma conditions are also constantly changing with the changing 
matrix, which can result in varying signal intensities due to suppressed or enhanced analyte 
ionisation during the separation. 
 
Before the separation was carried out on-line, the effect of 5% methanol on Au signal 
intensity was established. Initially two solutions containing 1 ng ml-1 115In were prepared; 
one solution was prepared in 2% hydrochloric acid and the other was prepared in 5% 
methanol. The resulting signal intensity for In was 2.5 x 106 cps and 750 000 cps in the 
hydrochloric acid matrix and 5% methanol matrix respectively. Hence, a 33% reduction in 
115In signal was observed in the methanol matrix. Initially this was attributed to the 
increased matrix levels in the plasma having a cooling effect and thus reducing In 
ionisation. Two further solutions both containing Au at a concentration of 0.50 ng ml-1 
were also prepared. Again one solution was prepared in 2% hydrochloric acid and the other 
was prepared in 5% methanol. Unlike the In signal, signal intensities of 97 692 cps and  
116 111 cps were observed for the Au solutions in the hydrochloric acid and methanol 
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matrix respectively, resulting in a 19% increase in Au sensitivity in the presence of 
methanol. This was quite unexpected, since it was initially thought that the organic matrix 
would suppress Au ionisation resulting in reduced sensitivity. However, there have been 
numerous reports of carbon enhancing the signal intensity of elements having high first 
ionisation potentials (generally those elements with first ionisation potentials between 9-11 
eV).130-134 Such reports have concentrated on the signal enhancement for Se and As. It is 
now common practise to introduce carbon (either as a gas or organic solvent) to the sample 
introduction system when analysing Se or As to enhance sensitivity.130, 135, 136 Rodushkin et 
al.,137 and Allain et al.,133 reported that Au signal intensity (amongst other elements) was 
enhanced in the presence of carbon.137 Carbon induced enhancement has been explained by 
charge transfer reactions in the plasma, where carbon ions transfer charge to analyte ions 
which have a lower ionisation potential than carbon itself (11.3 eV).131 The proposed 
charge transfer mechanism was described by Hu et al.,132 and is summarised below. 
 
M + C+ → M+ + C 
Enhancement in signal has also been attributed to reduced surface tension due to the 
presence of organic solvent, which improves sample uptake and nebulisation efficiency.130 
Since the In signal intensity dramatically decreased in the presence of 5% methanol and the 
Au signal increased, it was unlikely that reduced surface tension was responsible for 
increasing Au signal in the above case, but rather attributed to the charge transfer 
mechanism.131, 132 In addition, volatile solvents are known to expand in the plasma and thus 
widen the central channel. Liu et al.,131 suggested that lighter elements diffuse more rapidly 
through the already expanded central channel than heavier analyte ions, thus a decreasing 
signal intensity is observed for lighter ions compared to heavier species.131 This argument 
would explain why the 115In signal decreased in 5% methanol, but the heavier 197Au signal 
intensity did not. In any case, the enhancement in analyte signal by the HPLC mobile phase 
was an advantage. 
 
The coupling of the HPLC and ICP-MS involved inserting a T-piece between the column 
exit and nebuliser. This enabled the eluent flow to be split, so only 200-300 µl min-1 of 
solvent entered the nebuliser. Figure 2:33 shows a schematic of the LC coupling and 
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illustrates how the mobile phase flow can be split with the aid of a T-piece. The aim was to 
limit the amount of organic solvent entering the plasma. The lengths of Teflon tubing used 
to connect the column to the nebuliser are shown in Figure 2:33; the internal diameter of 
the tubing was 150 µm. Both the lengths and diameters of tubing determine the proportion 
of flow splitting, a small internal diameter was required to minimise band broadening and 
ultimately retain resolution. A Waters µBondapak C18 column (300 mm x 3.9 mm) was 
employed for the HPLC-ICP-MS analysis of the SFNG-DNA reactions. 
 
Figure 2:33: Schematic showing the coupling of a HPLC column to a nebuliser with the aid of a flow 
splitter. 
 
The chromatograms in Figure 2:34 show the Au signals during elution of unbound SFNG 
(SFNG standard containing 21.12 ng ml-1 Au) and SFNG-DNA (24 mer biotinylated 
oligonucleotide) tagging mixture. The unbound SFNG eluted at 1.72 minutes as signified 
by the single Au peak in Figure 2:34a. Two Au peaks were observed in Figure 2:34b, the 
first peak at 1.06 minutes corresponding to the SFNG-DNA conjugate and the second peak 
at 1.80 minutes relating to the unbound SFNG, which had a retention time consistent with 
the unbound SFNG shown in Figure 2:34a. 
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Figure 2:34: a)
 197
Au chromatogram of unbound SFNG containing 21.12 ng ml
-1
 Au. b) 
197
Au 
chromatogram of SFNG-DNA reaction mixture containing 14.8 ng ml
-1
 Au. Both samples were eluted 
from a Waters µBondapak C18 column (300 mm x 3.9 mm, 10 µm) with 5% methanol isocratic mobile 
phase. 10 µl injection volume.  
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The retention times of the unbound SFNG and SFNG-DNA conjugate shown in Figure 2:34 
were quite different to those observed in Table 2:13 in which the eluting species were 
fraction collected and then analysed by ICP-MS. The reason for this was attributed to the 
change in stationary phase; the fraction collected samples were separated on a Hypersil C18 
column, but the on-line separation was achieved with a Waters C18 column. Although both 
columns contained a C18 phase, they originated from different manufacturers’ and had 
different dimensions, which may have effected the retention times. In addition, ionic 
strength was thought to have influenced the retention time; this aspect will be discussed 
later in this section.  
 
The SFNG-DNA conjugate was the first species to elute because of its large size and 
therefore, it was likely to be largely excluded from the C18 phase. More importantly, the 
bound SFNG carried a highly charged oligonucleotide, resulting in less hydrophobic 
interaction with the surface of the non-polar stationary phase. The void volume of the 
Waters µBondapak column was determined with a 100 µM solution of uracil, which eluted 
after 3.87 minutes. Therefore, both SFNG species eluted within the void volume, 
suggesting that they were totally excluded from the pore space in the column and were 
retained due to surface interactions. 
 
The SFNG-DNA reaction mixture shown in Figure 2:34 contained 0.5 nmoles biotinylated 
24 mer olignucleotide and 0.27 nmoles of streptavidin or 1.07 nmoles of biotin binding 
sites (four binding sites per streptavidin). Therefore, the above reaction mixture contained a 
2.14 molar excess of biotin binding sites compared to biotinylated DNA. The reaction can 
therefore be written in two different ways by considering either the number of moles of 
streptavidin or biotin binding sites in relation to the DNA. 
 
Reaction: DNA +     Streptavidin   →   DNA-Streptavidin   +   Streptavidin 
No. nmoles: 0.5 +     0.27   
Or 
Reaction: DNA +     Binding sites   →   DNA-Binding sites   +   Binding sites 
No. nmoles: 0.5 +     1.07 
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Due to steric restraints only ~two biotin binding sites per streptavidin will be accessible to 
biotin, resulting in 0.54 nmoles of available biotin binding sites, or effectively an equal 
number of moles of biotin and binding sites. If all the biotinylated DNA molecules are 
labelled it would result in two DNA molecules per streptavidin protein. More importantly, 
this scenario would result in all the SFNG being bound, thus only one Au peak 
corresponding to SFNG-DNA conjugate would be observed in Figure 2:34. Since this is not 
the case, the peaks in Figure 2:34 were integrated giving areas of; 50 130 and 57 399 for 
the 1.06 and 1.80 minute peak respectively. Thus 46.6% of SFNG in the sample was bound, 
or considering 0.27 nmoles of streptavidin was present, 0.124 nmoles of streptavidin was 
bound to DNA. Considering this information, a maximum of 50% DNA labelling (0.25 
nmoles DNA labelled) can be achieved and only if two DNA molecules bind per SFNG. 
The DNA labelling efficiency decreases to 25% (0.124 nmoles DNA labelled) if only one 
DNA binds per SFNG. These scenarios are summarised below. 
 
1:1 Reaction: DNA +     Streptavidin   →  1DNA-Streptavidin   +   Streptavidin 
No. nmoles: 0.5 +     0.27       →  0.124-0.124           +   0.146   
Or, if two DNA molecules bind to SFNG:   
2: 1 Reaction: DNA +     Streptavidin   →   2 DNA-Streptavidin   +   Streptavidin 
No. nmoles: 0.5 +     0.27       →       0.25-0.124             +   0.146 
 
Although the amount of bound SFNG can be established, the above calculation does not 
identify the number of occupied biotin binding sites per streptavidin molecule because the 
experiment tracks gold not DNA, or effectively the labelling stoichiometry. The preferred 
labelling ratio is 1 DNA:1 SFNG since it results in each DNA molecule being labelled with 
~ 80 Au atoms. If two DNA molecules bound to one SFNG in a 2:1 ratio, then the number 
of Au atoms per DNA decreases to 40. As explained in the above case, the ratio of unbound 
SFNG/SFNG-DNA peak areas would be the same irrespective of one or two DNA 
molecules binding per streptavidin. This aspect of SFNG labelling will be discussed again 
in subsequent sections. 
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In addition to labelling efficiency, the enhancement in signal due to SFNG labelling has to 
be calculated, which was achieved by preparing an Au and P calibration curve and 
comparing the gradients. The Au calibration standards were prepared in the concentration 
range 0.20 – 1.5 ng ml-1 and the P calibration standards ranged from 10-200 ng ml-1. The 
Element 2 XR ICP-MS was used in the low and medium resolution mode for Au and P 
respectively. Gradients of 265 765 and 1082 were obtained for Au and P calibrations 
respectively, thus, a 246 times greater response was obtained for Au compared to P. Of 
course the gradient for P is reduced by working at medium resolution, but that is a 
necessary setting for the measurement. The biotinylated oligonucleotides used in the above 
example were 24 nucleobases in length, thus each oligonucleotide possessed 24 P atoms. 
Considering each oligonucleotide was labelled with 80 Au atoms, there were 3.3 times as 
many Au atoms compared to P. Thus, the 246 Au enhancement factor can be multiplied by 
3.3 to give a total signal enhancement of 812 for Au labelled oligonucleotides, assuming 
there were 80 Au atoms per nano-particle. SFNG was assayed in a subsequent experiment 
(Section 2.6.1.4, Quantification) and the actual number of Au atoms per nano-particle 
determined.  
 
It should be noted at this point that the 246 fold enhancement in signal obtained by Au, 
which resulted in a 812 total signal enhancement for SFNG labelled oligonucleotides was 
much greater than the signal enhancement calculated for MMN labelled oligonucleotides 
on page 122 (section 2.4.2.2). In the case of MMN, Au gave a 123 times greater response 
than P, resulting in a 406 fold signal enhancement (working on assumption of 80 Au atoms) 
when the MMN were attached to the oligonucleotide. The same type of Au nano-particle is 
incorporated on both SFNG and MMN, consisting of approximately 80 Au atoms. 
However, the MMN experiments were carried out on the PQ ExCell quadrupole 
instrument, whilst the Element 2XR was used for the SFNG experiments described above. 
It can only be assumed that the sensitive detection of heavier elements in low resolution 
operation of the double focussing instrument was responsible for the greater Au response, 
which in turn resulted in greater Au enhancement factors for the SFNG labelling 
experiments.  
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The SFNG-DNA reaction mixture which was shown in Figure 2:34 was injected again, but 
at a concentration 10 times greater than that of Figure 2:34. The retention time of the 
unbound SFNG was 2.41 minutes, which was considerably later then that previously 
observed (Figure 2:34). However, the SFNG-DNA conjugate still had a retention time of 
1.06 minutes. SFNG was supplied in a solution containing 20 mM phosphate buffer and 
0.150 M sodium chloride. The more concentrated SFNG solution therefore contained more 
salt and hence had a higher ionic strength. Therefore, a plausible explanation is that the 
ionic strength had an effect on the streptavidin configuration in solution, which in turn may 
have effected the retention time of the unbound SFNG. However, the exact effect of ionic 
strength on the protein structural configuration was unknown. The retention time of the 
SFNG-DNA conjugate did not change, presumably due to the highly charged 
oligonucleotide molecules having very little affinity for the non-polar phase, thus the 
conjugate eluted at the same retention time as seen previously. Since the unbound SFNG 
retention time was dependent upon concentration, it was deemed necessary to inject 
retention time markers in every experiment to confirm the retention time of the unbound 
SFNG species and ensure the correct Au species was being employed for quantification. 
 
A control sample was also prepared, which involved adding non-biotinylated 
oligonucleotide (unmodified 25 mer) to a 3.6 fold molar excess of biotin binding sites. The 
reaction conditions were similar to those described above and the chromatogram is shown 
in Figure 2:35. A single Au peak was observed in Figure 2:35, with the retention time 
consistent with unbound SFNG. The absence of a SFNG-DNA peak (expected at ~1.0 
minutes), implies that the reaction was dependent on the biotin functionality on the 
oligonucleotide and was therefore site specific. 
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Figure 2:35:
 197
Au chromatogram of SFNG control reaction containing 3.6 fold molar excess of binding 
sites and unmodified 25 mer. Eluted from a Waters µBondapak C18 column (300 mm x 3.9 mm, 10 µm) 
with 5% methanol isocratic mobile phase. 10 µl injection volume.  
 
It has been shown that the SFNG labelling route is viable, but in order to validate the 
method used above, several factors need to be investigated:  
1. Instrument configuration: Need to ensure the coupling of the HPLC to the ICP-MS 
is suitable in terms of stability and sensitivity. 
2. Quantification: The response of nanogold needs to be compared against atomic 
spectrometry Au standard, since the nanogold clusters may behave different in the 
plasma to aqueous ionic Au. 
3. Mass balance: Is the amount of Au injected equal to the amount recovered post 
separation? A discrepancy in injected and recovered Au could indicate that the 
nanogold is adsorbing onto the stationary phase walls, or that the mobile phase is 
not strong enough to elute the nanogold.  
4. Labelling efficiency and labelling ratio: The percentage of SFNG labelled DNA 
needs to be calculated. In addition, the number of DNA molecules bound to each 
SFNG needs to be established in each reaction. 
Each of the above aspects will be considered in turn. 
1.80 min 
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1. Instrument Configuration 
Several SFNG-biotinylated DNA reactions were prepared, each contained different molar 
excesses of biotin binding sites in relation to biotinylated DNA. Reactions containing an 
equal number of moles of biotinylated DNA and binding sites, two fold excess, four fold 
excess and ten fold excess of biotin binding sites compared to DNA were prepared and 
were denoted 1:1, 1:2, 1:4 and 1:10 respectively. Each sample was incubated at 4 oC for 
approximately 24 hours before being diluted and injected onto a C18 HPLC column; the 
resulting Au signal was then detected by ICP-MS. The HPLC-ICP-MS parameters were 
similar to those used previously. Again, the eluent flow to the plasma was restricted to 
~200 µl min-1, by employing a flow splitter. The samples were diluted in deionised water 
prior to analysis, hence a blank sample consisting of deionised water was injected at regular 
intervals to assess the Au baseline and carry over. Figure 2:36 shows the chromatogram 
corresponding to the first blank injection, which was carried out before the samples were 
injected. 
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Figure 2:36: 
197
Au signal intensity during injection of a deionised water blank. Eluted from a Waters 
µBondapak C18 column (300 mm x 3.9 mm) with 5% methanol isocratic elution at 1 ml min
-1
, 10 µl 
injection volume. 
 
1.56 min 
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A peak at 1.56 minutes was clearly evident in Figure 2:36. This retention time was quite 
similar to the retention time of the unbound SFNG, thus the peak in the blank 
chromatogram was thought to be carry over of Au, presumably due to contamination in the 
injector system. As discussed previously Au has the disadvantage of being ‘sticky’ in 
nature, resulting in carry over. Further blank injections did not remove the peak, therefore, 
it was decided to integrate the peak in the blank and subtract the area from the samples 
during any quantification calculations. The chromatogram in Figure 2:36 also exhibits a 
couple of spikes, which were quite erratic and not reproducible and therefore thought to be 
artefacts. The chromatograms corresponding to the 1:1 and 1:2 DNA:binding site reaction 
mixtures are shown in Figure 2:37. These chromatograms demonstrate that the SFNG 
labelling reaction and separation were reproducible, with the bound and unbound SFNG 
species clearly resolved and detected. 
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Figure 2:37: a)
 197
Au signal intensity during injection of 1:1 DNA:biotin binding site reaction. b) 
197
Au 
signal intensity during injection of the 1:2 DNA:biotin binding site reaction. Both samples eluted from a 
Waters Bondapak C18 column (300 mm x 3.9 mm) with 5% methanol isocratic elution at 1 ml min
-1
, 10 
µl injection volume. 
 
a 
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1.03 min 
1.79 min 
1.05 min 
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The 1:4 and 1:10 DNA:biotin binding site reactions did not exhibit the SFNG-DNA 
conjugate peak which was expected around 1 minute. Hence the chromatograms 
corresponding to these two failed reactions are not shown. Figure 2:38 shows an Au 
chromatogram of a deionised water blank injection which was injected after the above 
labelling mixtures.   
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Figure 2:38:
 197
Au signal intensity during injection of deionised water blank. Eluted from a Waters 
Bondapak C18 column (300 mm x 3.9 mm) with 5% methanol isocratic elution at 1 ml min
-1
, 10 µl 
injection volume. 
 
Figure 2:38 shows that the peak at 1.67 minutes is larger than that seen in the first blank 
injection in Figure 2:36. The increase in Au signal in the blank injections was thought to be 
due to the HPLC configuration. In normal operation of the HP 1090 LC system, the eluent 
flows through the column and then back into the instrument through the injector system. 
This has an effect of flushing the injector system. However, to minimise band broadening 
and to maintain resolution, the tubing connecting the column outlet and nebuliser was kept 
at a minimum length. As a result, the HPLC mobile phase was split post column, so ~20% 
of the flow went to the nebuliser and ~80% went directly to waste. The injector system 
flush was therefore by-passed, which may have resulted in the accumulation of SFNG in 
1.67 min 
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the injection system, thus causing carry over and producing small peaks in the blank 
injections. As a result, the coupling of the HPLC to the ICP-MS was modified. Briefly, the 
diode array UV detector that was integrated into the HP1090 was bypassed completely. The 
SFNG-DNA labelling reactions were diluted between 600-3500 fold with deionised water 
(depending on the Au concentration in the reaction mixtures) prior to ICP-MS analysis. 
These extremely low concentrations of SFNG and DNA were below the UV detector’s 
limit of detection. Hence, it was not deemed necessary to include the detector in the 
coupling. The flow splitter was employed again to achieve a 20:80 split in mobile phase 
post column, 20% was directed to the nebuliser as described previously, but the remaining 
80% was directed back into the HPLC, to flush the injector system. Although this did not 
completely eliminate carry over, it was reduced considerably. Complete removal of Au 
carry over between injections would require optimisation of the separation method. Aqua 
regia and hydrochloric acid have already been mentioned with regard to improving Au 
wash out time. However, these strong acids can not be used in conjunction with a silica 
stationary phase due the pH limitations of such phases (limited to pH 4-9). The addition of 
cysteine or another S containing species may be required in the mobile phase to complex 
Au and prevent adsorption onto the injector system, chromatographic phase and connection 
tubing between the column and nebuliser. However, S containing mobile phase additives 
was not investigated here. 
 
2. Quantification 
The SFNG was assayed to determine the number of Au atoms per nanogold particle. Two 
Au calibration curves were prepared, one for SFNG and one for an elemental Au standard. 
The slopes of the calibration curves were 4 510 624 (x axis expressed as nM streptavidin) 
and 265 217 (x axis expressed as ng ml-1) for SFNG and elemental Au respectively. From 
the data it was calculated that there were 86 Au atoms per nanogold particle. This figure is 
slightly higher than that given by the manufacturer, who state ~80 Au atoms per nanogold 
particle.95 However, the manufacturer states that there is an average of one nanogold 
particle to each streptavidin molecule,95 more than one nanogold particle per protein would 
increase the average number of Au atoms per particle and there may also be a small fraction 
of nanogold not bound to streptavidin. If either of these species were present they should be 
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resolved from the SFNG-DNA conjugate during HPLC separation. No evidence of 
additional peaks was observed in any of the chromatograms. The figure of 86 Au atoms per 
nanogold particle was used for further calculations, although this assay was only applied to 
one batch of SFNG, it is unknown whether the figure varies between batches. 
 
The enhancement in signal due to SFNG labelling assumes that the nanogold particles are 
completely ionised in the plasma and thus behave as Au atoms. Once the average number 
of Au atoms per nanogold particle was established, Au calibration curves for SFNG and 
elemental Au standards were compared for consistency. The gradients for the two sets of 
calibration data were 266 226 and 265 217 (x axis expressed as µg l-1 in both cases) for 
SFNG and elemental Au respectively. The two gradients were virtually identical, 
confirming that SFNG gave a similar response to the atomic Au solutions and is therefore 
ionised efficiently in the plasma. However, it should be noted that ICP-MS was employed 
to assay the SFNG to obtain the figure of 86 Au atoms per nano-particle. This figure was 
then used to prepare SFNG standard solutions and the slopes of SFNG and elemental Au 
calibration curves were compared, to check the assay data was correct. It does not however 
provide definitive proof that the nano-particles were completely processed within the 
plasma. This would require the figure of 86 Au atoms per nano-particle to come from an 
independent method. Recent work has suggested that for the plasma to process particles in 
a truly composition independent fashion requires them to be less than 90 nm in size (based 
upon the analysis of glass).102 Considering the nanogold particles were only 1.4 nm in 
diameter, it can be concluded that the particles were completely ionised. The presence of 
the fluorophore and streptavidin protein are not likely to have adversely effected the 
ionisation of the nanogold particle, since these are organic molecules, which as already 
discussed, may have beneficial effects due to their carbon content.  
 
The above analysis revealed that 86 Au atoms were present per nano-particle, considering 
these nano-particles are fully ionised in the plasma, a more accurate enhancement 
calculation can be conducted. In previous experiments biotinylated 24 mer oligonucleotides 
have been labelled with 86 Au atoms (as calculated above), resulting in 3.58 times more Au 
atoms compared to P atoms. Multiplying this figure by the Au enhancement factor of 246, 
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results in an 882 fold increase in signal for 24 mers labelled with SFNG, providing one 
DNA molecule binds to one SFNG.  
 
Although Au quantification can be achieved with SFNG solutions containing known 
concentrations of Au, an alternative method of quantifying Au signals was employed by 
Baranov et al.,10, 16 in which Ir was used as an internal standard. In addition, an acidic 
solution containing a known concentration of Tl was introduced post column via a T-piece 
just before the ICP sample introduction system. The ratio of Ir/Tl signals was employed to 
establish the stability of the system, whilst the Au signal was quantified using the Ir signal, 
which was expected to have a similar response to Au due to the similar first ionisation 
potentials and masses of Au and Ir.10, 16  
 
3. Mass Balance 
The 1:1 DNA:biotin binding site reaction that was observed above in Figure 2:37 was 
injected using the modified instrument configuration discussed above. A solution of 
unbound SFNG containing 9.34 ng ml-1 Au was also injected; this solution was used for 
quantifying Au in the separated peaks of the reaction mixture. The chromatogram of the 
standard and the re-injected 1:1 DNA:biotin binding site reaction can be seen in Figure 
2:39.  
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Figure 2:39:
 
a)
 197
Au signal intensity during injection of a SFNG standard containing 9.34 ng ml
-1
 Au. b) 
197
Au signal intensity during injection the equal molar biotin binding site reaction. Both samples eluted 
from a Waters µBondapak C18 column (300 mm x 3.9 mm) with 5% methanol isocratic elution at 1 ml 
min
-1
, 10 µl injection volume. 
a 
b 
1.78 min 
1.45 min 
0.76 min 
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The Au concentration in each of the peaks shown in Figure 2:39b was quantified using the 
SFNG standard peak area (Figure 2:39a). Briefly, the total peak area of the SFNG standard 
was divided by the Au concentration in the SFNG standard to give the unit area per ng ml-1 
of Au. From Figure 2:39b it was calculated that peak 1 at 0.76 minutes contained           
0.75 ng ml-1 Au, and peak 2 at 1.45 minutes contained 0.34 ng ml-1 Au, hence, the total Au 
recovered equated to 1.09 ng ml-1. However, the Au concentration of the injected reaction 
mixture was 11.3 ng ml-1, suggesting that only ~10% of the injected Au was recovered 
(note the injection volumes were the same so that concentration is mass equivalent). The 
same calculation was carried out on the 1:2 DNA:biotin binding site reaction (Figure 2:37) 
and a recovery of 10.6% was achieved. The discrepancy in the mass balance calculations 
was initially thought to be one of two factors: 
• SFNG and DNA were absorbing onto the walls of the polypropylene reaction 
vessels. 
• SFNG was being trapped on the column instead of being completely eluted. 
 
The Waters C18 column was cleaned in an attempt to remove residual Au and hence 
improve the baseline. The column was connected to the HPLC in the reversed flow 
direction (but not connected to the detector) and flushed with 5% methanol. It was hoped 
that any nanogold that had adsorbed at the head of the column would be removed by the 
continuous reversed flushing. The wash eluents were collected for subsequent ICP-MS 
analysis. Gold counts of ~1.4 x 106 cps were observed for the first column backflush, 
equating to ~2 ng ml-1 Au, which had collected at the head of the column. The Au signal 
intensity gradually decreased for subsequent reverse flush eluents, suggesting that SFNG 
had accumulated at the head of the column as expected.  
 
After thorough cleaning of the column, two fresh SFNG tagging samples were prepared. 
The first reaction contained 0.107 nmoles of biotin binding sites and 0.115 nmoles of 5’ 
biotinylated 24 mer oligonucleotide (2.24 µM), resulting in a 0.93 fold excess of binding 
sites (i.e. DNA slightly exceeded probe in terms of moles). This sample will be referred to 
as the 1:1 DNA:biotin binding site reaction. The second sample, which will be referred to 
as the 1:7.5 DNA: biotin binding site reaction, contained 0.44 nmoles biotin binding sites 
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and 58.7 pmoles of biotinylated DNA (2.24 µM), resulting in a 7.5 fold excess of binding 
sites. The two reactions mixtures were diluted so they contained an Au concentration of 
5.66 ng ml-1 and 5.55 ng ml-1 for the 1:1 and 1:7.5 DNA:biotin binding sites respectively. A 
SFNG standard containing 3.66 ng ml-1 Au was also prepared and used to quantify the Au 
contained in each of the peaks. After each injection, the column was disconnected from the 
nebuliser and reconnected to the HPLC system in the reverse flow direction. The column 
was then flushed in the reverse direction for approximately 2 minutes. During this time, the 
column eluent was collected and analysed. The aim was to establish whether any nanogold 
was accumulating at the head of the column during injection. It was hoped that this would 
help establish an accurate mass balance. The chromatograms corresponding to the 1:1 and 
1:7.5 DNA:biotin binding site reactions are shown in Figure 2:40. 
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Figure 2:40: a) 
197
Au signal intensity during injection of the 1:1 DNA:biotin binding site reaction 
mixture. b)
 197
Au signal intensity during injection of the 1:7.5 DNA:biotin binding site reaction mixture. 
Both samples eluted from a Waters µBondapak C18 column (300 mm x 3.9 mm) with 5% methanol 
isocratic elution at 1 ml min
-1
, 10 µl injection volume. 
b 
1.06 min 
1.60 min 
a 
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Duplicate injections of the SFNG standard gave an average peak area of 181 887 (RSD = 
0.75%), which was divided by the Au concentration of 3.66 ng ml-1 to give 49 695.90 unit 
area/ng ml-1 Au. The chromatogram corresponding to the 1:1 DNA:biotin binding site 
reaction (Figure 2:40a) revealed that 2.70 ng ml-1 and 3.07 ng ml-1 Au was present in the 
SFNG-DNA peak (0.98 minutes) and unbound SFNG peak (1.58 minutes) respectively, 
thus a total of 5.77 ng ml-1 Au was recovered. Considering 5.66 ng ml-1 Au was injected on 
the column, the resulting recovery was calculated to be 102%. The same calculation was 
performed on the 1:7.5 DNA:biotin binding site chromatogram in which 2.98 ng ml-1 and 
3.11 ng ml-1 Au was calculated for the 1.06 and 1.60 minute peak respectively. Therefore, a 
total of 6.09 ng ml-1 Au was recovered, resulting in a 109% recovery (5.55 ng ml-1 Au was 
injected on the column).  
 
The chromatograms in Figure 2:40 had an Au baseline of ~12 000 cps, which equated to 
approximately 70 pg ml-1 Au. This baseline level did not decrease, but remained constant. 
This continuous flux of Au was thought to be hydrophobically bound SNFG from previous 
injections slowly eluting from the column. Repeated injections of nanogold produced an 
accumulation of Au at the head of the column that could be reduced, but not totally 
removed by back flushing. The observed background Au signal may also have been 
enhanced due to the presence of 5% methanol in the mobile phase which was shown to 
increase Au signals by ~19%. The column eluents resulting from the reversed column flush 
post injection also revealed that ~70 pg ml-1 Au was present for both samples. This value of 
70 pg ml-1 was constant for all column backflushes, suggesting that no nanogold was 
depositing on the column head during the above experiment, and that all the Au was being 
eluted and thus detected.  
 
This data suggested that 100% recovery of the Au was possible if the column was cleaned 
before each injection of SFNG. These calculations ensure that all the Au is being detected, 
thus providing accurate quantification. The slightly elevated recoveries (>100%) were 
thought to be due to errors in background correction. It is hoped that this can be remedied 
by further improving the separation method. 
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The above chromatograms exhibited a dip in the baseline at approximately 1.4 minutes. 
This reduction in signal was consistent and observed in all chromatograms, suggesting it 
was an injection related event. The mobile phase consisted of 5% methanol, but the 
samples were diluted in deionised water. From the order of elution in Figure 2:40, it can be 
established that the SFNG-DNA conjugate eluted first, followed by the sample solvent, 
which contained a higher proportion of water compared to the mobile phase, and finally the 
unbound SFNG eluted. If the background Au was hydrophobically bound then the elution 
of the water sample solvent (weaker eluent than methanol) would transiently reduce the Au 
flux from the column. Further, reduced carbon load and higher surface tension of the water 
would reduce the Au signal, causing a temporary reduction in the baseline signal. In 
addition, a spike was observed in the 1:1 DNA:biotin binding site reaction at 1.35 minutes. 
This peak was found to be inconsistent and not reproducible, suggesting it was an artefact 
and not a true Au species. 
 
4. Labelling Efficiency and Labelling Ratio 
From the chromatogram in Figure 2:40b (1:7.5 DNA:binding site reaction), it can be 
concluded that 53.5% of the nanogold (compared to the amount injected) and hence 
streptavidin was bound to DNA. Considering 0.11 nmoles of streptavidin (0.44 nmoles 
binding sites) was present in the reaction, the number of moles of bound streptavidin was 
58.9 pmoles. If one biotinylated DNA molecule bound to one streptavidin protein, then 
58.9 pmoles of DNA also bound. Considering 58.7 pmoles of DNA was in the reaction 
mixture, 100.3% of the DNA was labelled with SFNG. This data suggests that with a 7.5 
molar excess of potential binding sites, or a 7.5/4 ~2 fold molar excess of nanogold probe, 
only one binding site per protein molecule was occupied.  
 
The labelling efficiency of the 1:1 DNA:biotin binding site reaction was also calculated as 
described above, but the labelling stoichiometry was not as straight forward to calculate. A 
total of 47.7% or 12.85 pmoles of SFNG was bound to DNA, if one DNA molecule bound 
to one streptavidin protein, then 12.85 pmoles of DNA would also be labelled. But 
considering 115 pmoles of biotinylated DNA was used in the reaction, this only equates to 
an 11.2% labelling efficiency. Conversely, two DNA molecules bound to one streptavidin 
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protein would result in 25.7 pmoles of labelled DNA and thus a 22.3% labelling efficiency. 
In this particular case there is more than one outcome; either one or two DNA molecules 
bound to one streptavidin.  
 
In an attempt to resolve this uncertainty, the retention time of the bound and unbound 
SFNG species were considered; if two DNA molecules bind to SFNG (2:1), the retention 
time of the species should be less than that of the 1:1 species which is known to elute at 
~1.06 minutes (Figure 2:40b), since the 2:1 species would be much larger and the 
separation has a significant size exclusion character. The retention time of the SFNG-DNA 
species for the equal molar reaction was 0.98 minutes (Figure 2:40a), which was shorter 
than the retention time of the 1:7.5 DNA:SFNG species (Figure 2:40b). However, the         
8 second difference in retention time between the two SFNG-DNA species was not 
considered significant enough to suggest that the SFNG species in Figure 2:40 were bound 
to different numbers of DNA molecules. A more accurate method of determining labelling 
stoichiometry has to be developed.    
   
It is accepted in ligand chemistry that as more ligands bind to a substrate such as a metal 
ion, the stepwise formation constants (Kn) generally decreases in the order K1>K2>K3, 
where the subscript numbers represent the increasing ligand number.138 Thus, the addition 
of subsequent ligands onto a substrate becomes more difficult. There are several reasons for 
this effect, namely: steric restraints and reduction in binding sites and ligand molecules 
upon successive binding and reduction in charge on the metal ion. It was expected that this 
would be the case for biotin binding to streptavidin, especially considering the 
oligonucleotide may contribute greater steric effects, and thus the preferred binding ratio 
was expected to be 1 DNA:1 SFNG. However a report by Williams et. al.,139 suggested 
otherwise. The binding of biotin to streptavidin is said to be positively cooperative, that is 
the binding of the first biotin moiety stabilises the streptavidin structure and actually 
promotes further biotin binding. Thus successive biotin binding occurs with increasing 
affinities.139 Although only 1-2 biotin binding sites are accessible on SFNG, it may be that 
two biotinylated oligonucleotides per streptavidin are actually favoured. However, it is 
unknown what effect the Alexa Fluor-488 molecules and Au nano-particle have on the 
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protein structure and if positively cooperative binding is still valid in these circumstances. 
The presence of these additional molecules may create larger steric effects, thus the 1:1 
DNA:SFNG binding ratio may actually be favoured. 
 
The SFNG-DNA reaction mixtures appeared to degrade over a period of a few weeks. 
When the samples were injected within two weeks of preparation, only one Au peak at 
~1.60 minutes was observed. This was attributed to the DNA degrading over time. It is 
possible that the DNA degraded in solution over time or even absorbed onto the walls of 
the sample vials. Such degradation would have ultimately resulted in the bound and 
unbound SFNG having similar molecular weights and charges and ultimately the same 
retention time. However, reproducible results were generally obtained when the SFNG-
DNA reactions were separated and detected within a few days of preparation. 
 
2.6.2 Summary 
The relative success of the SFNG labelling route was thought to be due to two factors. 
Firstly, both the SFNG and biotinylated DNA were stable in solution and at room 
temperature, resulting in easier sample handling. Specialised reaction conditions and 
extensive sample preparation procedures were not necessary. In addition, the labelling 
reaction was very easy and straight forward, which was attributed to the strong interaction 
between biotin and streptavidin. 
 
Several modes of separation were investigated in order to separate the bound and unbound 
SFNG. Numerous problems were encountered; gel filtration did not give adequate 
resolution and irreversible adsorption of the SFNG probe was observed on the anion 
exchange resin. IMAC did show some promise, although reversed phase HPLC was proven 
to be the most successful separation method. It was demonstrated that RP-HPLC gave good 
recoveries of SFNG. Also, the mobile phase was compatible with ICP-MS and the Au 
signal was enhanced in the methanol matrix, which was a further advantage. More 
importantly, the RP-HPLC method gave excellent resolution, with the bound and unbound 
SFNG being resolved within 3 minutes. There is however room for improvement with 
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respect to the reverse phase separation method, especially concerning carry-over. The 
addition of cysteine or another S containing molecule to the mobile phase may be necessary 
to prevent carry over between injections. The use of a non-porous resin or monolith column 
may also be beneficial, since these phases are more suited to macromolecule separations. In 
addition, polymeric monolithic phases such polystyrene divinylbenzene (PS-DVB) are 
more tolerant to extreme pH, thus acid solutions could be employed to remove residual Au. 
 
The improved SFNG-DNA binding efficiency compared to that of the MMN-thiol labelling 
route (~10% and 100% DNA labelling efficiencies achieved for the MMN and SFNG 
methods respectively) provided a much greater enhancement and detection power. The 
DNA signal could be enhanced by 882 fold when one DNA molecule bound to one SFNG 
in a 1:1 binding stoichiometry. When a 7.5 fold excess of SFNG was employed, a 1:1 
SFNG:DNA stoichiometry was observed, as demonstrated by the recovered DNA and Au. 
However, the stoichiometry was uncertain when a much smaller excess of SFNG was 
employed in the reaction. As a result, accurate methods of determining SFNG-DNA 
labelling stoichiometry need to be investigated further and this is currently one limitation of 
the method.  
 
Ultimately, two routes of nucleic acid labelling were identified using either MMN or 
SFNG. Both methods are capable of enhancing biomolecule signal and thus detection limits 
by ICP-MS, although there are numerous advantages and disadvantages associated with 
both methods. The preliminary results associated with the SFNG-biotinylated DNA 
labelling route have been published,17 although there is still room for improvement in this 
area of biomolecule signal enhancement.  
 
The vast majority of the time and effort put into developing the MMN and SFNG labelling 
procedures has concerned researching appropriate separation techniques to resolve the 
bound and unbound nanogold. The actual ICP-MS analysis has been the least time 
consuming and complicated. The following characterises the factors that are important in 
the separation and indicates how each of the methods investigated performed: 
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1. Good resolution of  the bound and unbound nanogold species 
• Low and inadequate resolution obtained by gel filtration 
• Good resolution achieved with anion exchange and RP-HPLC 
2. Reasonably short separation times 
• Long separation times observed with gel filtration (~20-60 minutes) 
• RP-HPLC baseline resolution within 3 minutes 
3. Mobile phase compatibility with ICP-MS 
• High salt levels in anion exchange HPLC are problematic 
• Methanol used in RP-HPLC was not troublesome with flow splitting 
4. On-line coupling capability with ICP-MS (also dependent upon point 3) 
• RP-HPLC coupling was fairly straight forward due to mobile phase and flow 
rate compatibility 
• IMAC coupling may be more technically demanding since eluent and sample 
introduction system may need modifying 
5. Good recoveries of nanogold species. 
• Poor SFNG recovery observed with anion exchange due to irreversible 
adsorption of SFNG onto phase. 
• Excellent recoveries (~100%) for RP-HPLC, since charged bio-molecules 
have very little interaction with C18 phase 
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3 Platinum Metallodrugs 
3.1 Introduction 
The treatment and diagnostic-imaging of disease is confined not only to organic 
compounds, but also employs inorganic metal complexes. Such inorganic compounds 
containing a metallic element to treat or diagnose disease are known as metallodrugs. There 
are a wide range of metals that are known to have therapeutic or diagnostic properties. 
These include some Pt complexes, which are known to have anti-tumour properties, 
likewise, Au36, 140, Tc36 and V140 amongst others have a niche in medicine. Table 3:1 
summarises some metallodrugs and their function in medicine and Figure 3:1 shows the 
structures of some common drug complexes.  
Table 3:1: Therapeutic functions of some metal complexes. 
Metal Function 
Platinum Anti-tumour agent141  
Ruthenium Anti-tumour agent141 
Rhodium Anti-tumour agent141 
Gold Treatment of arthritis and potential anti-tumour agent140 
Vanadium Anti-diabetic agent140 
Bismuth Anti-ulcer agent140 
Technicium Tissue imaging36  
 
It is important to understand a drug’s mechanism of action and potential side effects in 
order to develop future generations of drug with superior properties. More so, it is essential 
to ensure that the patient is receiving safe levels of the drug that are not posing a health risk 
greater than that of the disease itself. The metabolites of the metallodrug and its hydrolysis 
products also need to be assessed for their toxicity or potential biological activity.66 In 
addition, the transportation efficiency of the drug to reach the target site is important and 
may be dependent upon metallodrug-protein binding and releasing efficiency.142 
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Figure 3:1:   Examples of common therapeutic metallodrugs. 
 
The interactions of the drug with non-target species such as proteins may also of 
importance. For example, cisplatin (cis-diammindichloroplatinum(II)) is a cytotoxic 
compound, but when complexed to proteins, the drug exhibits no anti-tumour  
properties.141, 142 Conversely, ruthenium based anti-tumour drugs have been reported to 
maintain their activity upon binding to certain proteins.142 It has been known for some time 
that DNA is the target for Pt based metallodrugs. Extensive research has been carried out to 
establish how Pt based drugs interact with DNA and other non-target species.141-146  
 
3.1.1 Cisplatin 
Patients suffering with cancers of the head, neck, ovaries, testes or colon are treated with Pt 
based metallodrugs.36, 141, 144, 145, 147, 148 The most prominent Pt based metallodrug is 
cisplatin, which has demonstrated a huge success in treating certain tumours, but it has 
harsh side effects that include severe kidney complications145 and neurotoxicity.149 As a 
result, second and third generations of Pt drugs have been synthesised and investigated.  
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The Pt-based anti-cancer drugs such as cisplatin and oxaliplatin are known to interact with 
DNA in-vivo (and in-vitro) to form Pt-DNA adducts. DNA replication and transcription 
processes are thought to be inhibited by adduct formation.147-149 The hydrophobic cisplatin 
complex is capable of passing through cell membranes, but once in the low chloride 
medium of the cell cytoplasm, the Pt complex loses its chloride ligands and undergoes 
ligand exchange reactions with water molecules. This results in a reactive (hydrated) 
species that interacts with DNA nucleobases.147, 150 Numerous studies have shown that both 
cisplatin and oxaliplatin preferentially form adducts with guanine (G) nucleobases, 
followed by adenine (A) bases on DNA (see also Chapter 4).141, 148, 151 The vast majority 
(~60-65%) of adducts formed are intra-stranded cross-links between two neighbouring 
guanine bases (GG).144, 148, 149 Intra-stranded cross-links between neighbouring AG adducts 
are the next dominant species formed, accounting for approximately 25-30% of   
adducts.144, 149 Other minor adducts include: intra-stranded GNG (cross-links between non-
adjacent guanines), inter-stranded and monofunctional cross-links, which make up the 
remaining percentage of species produced.152 Figure 3:2 summarises the ligand exchange 
reactions and DNA binding observed with cisplatin.    
 
 
 
Figure 3:2: Cisplatin ligand exchange and DNA adduct formation. 
 
Pt 
Cl 
Cl NH3 
NH3 
Plasma ~0.10 M Cl
-
 
Cell 
membrane 
[Pt(NH3)2Cl(H2O)]
+ [Pt(NH3)2(H2O)2]
2+ 
Pt 
NH3 H3N 
Ligand exchange 
DNA 
Adduct 
formation Intra-cellular fluid 
<< 0.10 M Cl
-
 
185 
Although Pt-AG adducts account for approximately 25-30% of adducts formed, Pt-GA 
adducts do not form with DNA. The reasons for this were explained by Mantri et. al.,153 
who reported that the intermediate formed prior to Pt-AG di-adduct formation was 
stabilised by a phosphate group on the DNA backbone. However, the same was not true for 
the formation of the Pt-GA di-adduct. Thus the formation of Pt-AG was kinetically more 
favourable compared to Pt-GA.153, 154 The types of Pt adducts formed with DNA are 
illustrated in Figure 3:3. 
 
3.1.2 Oxaliplatin 
Oxaliplatin is a third generation anti-tumour agent that is used for treating colorectal 
cancer.149, 155, 156 Although oxaliplatin has many side effects, these are less severe compared 
to cisplatin. In addition, oxaliplatin has been successful in treating cisplatin resistant cell 
lines and tumours.144, 155, 156 
 
Oxaliplatin undergoes ligand exchange in physiological conditions, where the oxalate 
ligand is replaced by two chloride ligands to form [Pt(dach)(Cl)2].
157 Once within the cell, 
the complex becomes hydrated,155 and forms adducts with DNA nucleobases, preferentially 
binding to guanine as in the case of cisplatin (Figure 3:3).149, 156 Oxaliplatin reacts with 
plasma proteins and like cisplatin becomes un-reactive when bound to proteins such as 
glutathione.155 Despite the similarities between cisplatin and oxaliplatin, numerous 
differences in their mechanisms have been reported. Firstly, oxaliplatin forms fewer cross-
links with DNA compared to cisplatin, yet it exhibits comparable cytotoxic           
activity.149, 155-158 Arnould et. al., reported that five times fewer oxaliplatin adducts were 
formed on colon cancer cell lines compared to cisplatin, for the same cytotoxic effect.155 
The DNA adducts formed by oxaliplatin are more hydrophobic than their cisplatin 
counterparts, due to the presence of the diaminocyclohexane (dach) ligand, and are thought 
to interact with hydrophobic regions of proteins.149 Also, the presence of the dach non-
leaving group results in oxaliplatin forming bulky adducts, which may disrupt DNA 
structure more than cisplatin.149, 155 Disruption to the conformation of DNA may have 
dramatic consequences on replication and transcription. 
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Figure 3:3: Intra-stranded and inter-stranded Pt-adducts formed with DNA. Note, ligand R refers to 
the non-leaving group, which is diaminocyclohexane in the case of oxaliplatin and ammonia in the case 
of cisplatin. 
 
3.1.3 Metallodrug Detection 
There are numerous biological assays designed for detecting Pt-DNA adducts, namely, the 
comet assay156, 159, 160 and post labelling assay (PLA).42, 161, 162 Both of these assays provide 
a way of detecting DNA damage by Pt drugs. The comet assay is a qualitative method of 
detecting DNA damage. Cells treated with Pt drugs are embedded in agarose and then 
irradiated with x-ray radiation, which induces DNA strand breaks and thus causes the DNA 
to relax. The DNA then electrophoretically migrates through the gel to form a comet like 
tail from the cell body. The presence of Pt cross-links retards DNA migration, therefore 
reducing tail movement which indicates the presence of cross-links.156, 159 The protocols, 
advantages and potential applications of this assay were discussed by Tice et. al.160 
 
The PLA provides a way of quantifying Pt-DNA adducts by employing a 32P label as 
illustrated in Figure 3:4. The assay involves treating the platinated DNA to an enzymatic 
digest prior to 32P labelling. Within the enzymatic mixture there are several enzymes, 
namely: DNase 1, snake venom phosphodiesterase (SVPD), nuclease P1 (NP1), shrimp 
alkaline phosphatase (SAP) and T4 polynucleotide kinase (T4PNK).42, 161 Following 
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incubation with cisplatin and the subsequent enzymatic digestion, the adducted sites are 
labelled with 32P. The reaction mixture is then separated by polyacrylamide gel 
electrophoresis (PAGE), and the separated radio-labelled di-nucleotides that represent 
adduct sites can then be detected.161 It has been reported that one adduct in 109-1010 
nucleotides can be detected with the PLA.151, 162, 163 It should be noted that the PLA is 
capable of detecting intra-stranded AG and GG cross-links, but not inter-stranded or mono-
functional cross-links. However, as already stated the inter-stranded GG and AG cross-
links account for ~90-95% of all adducts formed. 
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Figure 3:4: The post labelling assay. 
 
DNase 1 cuts the gemonic DNA into smaller 
fragments.  
 
 
SVPD then cleaves phosphodiester bonds 
along the DNA strand, working from 3’→5’. 
Nuclease P1 has a similar role, but works from 
the opposite direction i.e. 5’→3’. These 
enzymes create mono-nucleotides. 
 
However, when the enzymes reach a platinated 
site, where a Pt atom bridges two neighbouring 
nucleotides, the phosphodiester bond between 
these bridged nucleotides can not be cleaved 
due to the presence of the Pt. As a result, di-
nucleotides are formed where Pt lesions are 
present. Therefore, amongst the mixture of 
mono-nucleotides, Pt-di-nucleotides will also 
be present. 
 
The terminal 5’ phosphate is then cleaved from 
the mono-nucleotides and di-nucleotides in the 
digested mixture by SAP. 
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At this point, the Pt atom is cleaved from the 
di-nucleotides by NH3 hydrolysis. This is 
carried out so the next enzyme, T4PNK can 
phosphorylate the di-nucleotides. It is crucial 
to note here that only the di-nucleotides are re-
phosphorylated, since T4PNK is a kinase 
enzyme that only uses polynucleotides as a 
substrate and not the mono-nucleotides. 
Therefore, only the di-nucleotides that 
represent previously platinated sites are 
phosphorylated with 32P. 
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The interactions of metallodrugs with biological molecules other than DNA are also of 
interest.141 For example, albumin accounts for ~52% of plasma proteins and contains many 
disulfide bonds, from cysteine and tryptophan residues, making it susceptible to cisplatin 
adduct formation.141 Methods such as; NMR, circular dichroism (CD) and fluorescence 
spectroscopy have been employed to study metallodrug-protein interactions.141 
Chromatographic techniques coupled with molecular mass spectrometry have also been 
employed for the structural characterisation of Pt species.151, 164-167 Molecular mass 
spectrometry can be employed to establish the targets of metallodrug binding. It will be 
described later how ESI-MS was employed to study the interaction of oxaliplatin with 
DNA nucleobases. 
 
ICP-MS is also suited to the study of metallodrug interactions, mainly due to the presence 
of the metal ion allowing for quantitative determination at very low levels in complex 
matrices.66, 168 The main disadvantage of ICP-MS is that the technique cannot distinguish 
between various adduct types (refer to Figure 3:3) since all structural information is lost in 
the plasma ionisation source, thus only total Pt is measured.169 This problem can be 
overcome by coupling chromatographic separation techniques to ICP-MS, which allows for 
the separation of different metallodrug species prior to ICP-MS analysis. This is important 
since biological systems are complex and many species of metallodrug adducts may form 
both in-vitro and in-vivo. HPLC with ICP-MS detection appears to be the method of choice 
for metallodrug studies.66, 142, 147, 151, 170-173 Szpunar amounst others have detailed the 
hyphenation of liquid chromatography with ICP-MS and has highlighted the advantages 
and limitations.66, 174 There have been several reports on the use of capillary electrophoresis 
coupled to ICP-MS for metallodrug research.175, 176 
 
Meczes et al., detailed the immunoreactivity of an antibody specific to cisplatin and 
carboplatin DNA adducts.152 It was established that the antibody recognises 1, 2 intra-
stranded GG and AG cisplatin adducts (Pt-GG and Pt-AG) with high sensitivity. However, 
factors such as the surrounding DNA sequence also appeared to effect antibody 
recognition.152 An earlier publication by Tilby et al.,177 also employed monoclonal 
antibodies to detect and quantify cisplatin and carboplatin adducts.177 The antibody 
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detection of cisplatin adducts was taken a step further by Liedert et al.,169 who employed 
two monoclonal antibodies specific to Pt-GG and Pt-AG adducts to quantify adducts in 
cells at clinically relevant levels.169  
 
Such reports demonstrate the array of instrumental and biological methods available for 
metallodrug research. This chapter will concentrate on developing an assay based on ICP-
MS for detecting and quantifying Pt-DNA adducts at the clinically important level, whilst 
the challenges associated with analysing biological samples by ICP-MS will be highlighted. 
 
3.2 Quantifying Pt adduct Formation by ICP-MS   
3.2.1 Introduction 
The aim of this research was to develop an ICP-MS method for determining Pt-DNA 
adducts in DNA samples after treatment with either cisplatin or oxaliplatin. Ultimately, the 
aim was to develop a clinical test suitable for determining Pt-DNA adducts in the DNA 
obtained from patients undergoing chemotherapy. An assay capable of determining Pt-
DNA adducts formed in-vivo should help identify patients who are responding effectively 
to the selected cancer drug. More importantly, it will potentially identify those patients who 
are not responding to the treatment, thus the treatment could be stopped and the unpleasant 
side effects minimised or avoided. This work was carried out in collaboration with Dr 
Rachel LePla, Dr Chris Harrington and Dr Don Jones from the Cancer Prevention and 
Biomarkers Research Group at Leicester University. The treatment of DNA with cisplatin 
and oxaliplatin, along with the PLA to confirm Pt binding, was carried out at Leicester 
University by Dr Rachel LePla. 
 
Although biological assays such as the PLA, comet assay and antibody detection methods 
are well established for detecting adduct formation at very low levels (refer to section 
3.1.3), they have their drawbacks. Firstly, the comet assay only provides qualitative 
information. The PLA is time consuming and expensive due to the range of enzymes 
employed to digest the DNA. In addition, the PLA utilises a radioisotope for adduct 
detection and quantification, which introduces additional hazards. Antibody methods of 
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detecting cisplatin-DNA adducts again may involve extensive sample preparation and there 
can be complications in adduct recognition, as detailed by Meczes.152 In comparison, an 
assay based on ICP-MS, which is capable of detecting trace levels of Pt, should allow 
adduct quantification with ease. Further, the method should be much less time consuming 
due to reduced sample preparation and rapid data acquisition.   
 
The challenge with this assay is that the Pt levels in DNA are likely to be very low. It has 
been reported by Welters et  al.,178 that 93 Pt-GG adducts and 30 Pt-AG adducts formed per 
107 nucleobases in a tumour biopsy.178 A review by Jamieson and Lippard145 also reported 
that as little as 9 Pt atoms are present per DNA molecule.145 However, the number of Pt 
adducts formed with genomic DNA varies between cell types due to numerous 
pharmacokinetic factors which were briefly discussed elsewhere.169 A quantitative method 
applicable to clinical samples (DNA obtained from chemotherapy patients) must be capable 
of detecting very low dose rates and thus ultra trace Pt levels. The amount of blood and 
hence DNA obtainable from a patient is limited, typically 10 ml blood can be taken from a 
patient. However, the number of white blood cells within the blood sample will vary 
depending on the health of the patient, thus the quantity of extractable DNA may vary 
significantly between patients. As a result of these factors, the ICP-MS method must be 
capable of not only detecting trace levels of Pt, but also trace levels of the adducts in very 
small quantities of DNA. 
 
Dr. Peter Winship was the first researcher within the Atomic Spectroscopy Group at 
Loughborough University to work on this area of research.179 Initial studies were conducted 
with the PQ ExCell quadrupole ICP-MS instrument, details of the initial experiments and 
results are reported elsewhere.179 Cisplatin and oxaliplatin adducts were successfully 
detected in calf thymus DNA (ctDNA) samples that were treated with drug doses ranging 
from 1 Pt per 100 nucleotides (1:100) to 1 Pt per 100 000 nucleotides (1:100K). However, 
the analysis was carried out on approximately 1 mg ctDNA.179 The work carried out by 
Winship was advanced in this chapter with the aid of a high resolution ICP-MS instrument 
and a different approach to sample preparation. The double focussing instrument enabled 
both trace levels of Pt and high levels of P associated with DNA backbone to be determined 
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simultaneously. In addition, due to the high sensitivity and low background levels 
associated with high resolution instruments, lower drug doses and thus lower levels of 
adducts could be detected, which were of more relevance to clinical studies.  
 
The research presented in this chapter was conducted on cisplatin and oxaliplatin treated 
ctDNA. These initial experiments employed ctDNA to establish the viability of the method 
before it was carried out on human cell lines or patient samples. Using ctDNA meant that 
larger quantities of DNA and thus Pt drug could be used to ensure the methods were viable, 
before progressing to the measurement of trace levels of adducts formed in-vivo in humans.  
 
3.2.2 Instrument Parameters 
An Element 2XR high resolution ICP-MS instrument (Thermo Finnigan, Bremen, 
Germany) was employed for all Pt and P determinations. The instrument was operated in 
standard solution mode with the basic parameters shown in Table 3:2. Any deviations or 
additional instrument parameters will be stated where appropriate. 
Table 3:2: Element 2XR instrument parameters. 
Cones Ni sampler and skimmer 
Nebuliser 200 µl min-1 Micromist (Glass Expansions, Victoria, Australia), or 
 100 µl min-1 PFA-ST (Elemental Scientific, Omaha, USA) 
Spray chamber Double pass or cyclonic (Glass Expansions, Victoria, Australia) 
Analytes 31P and 195Pt 
Magnet mass 30.968 (P) and 194.899 (Pt) 
Resolution Low (Pt) and medium (P) 
Mass range 30.968-30.978 (P) and 194.899-195.029 (Pt) 
Scan type E-scan 
Detection mode Triple 
Gas flows Cool = 15.5 l min-1 
Auxiliary = 0.82 l min-1 
Nebuliser = 1-1.13 l min-1 
Forward power 1240-1300  W 
 
The analogue secondary electron multiplier (SEM) and Faraday cup allowed the high P 
signal to be measured. Nickel cones were used in all analysis since the platinum cones 
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resulted in very high Pt background signals, which made the trace cisplatin and oxaliplatin 
determinations impossible. Normally platinum cones are preferred for samples containing 
high levels of carbon, and enable the use of oxygen addition to prevent carbon build up. 
This is not possible for Pt determinations and this in part led to the use of a digestion 
procedure to remove carbon as described later. 
 
3.2.2.1 Analysis of Whole ctDNA 
The treatment of the ctDNA was carried out at Leicester University by Dr. Rachel LePla of 
the Biomarkers and Cancer Prevention Research Group. Briefly, 1 mg of ctDNA was 
treated with cisplatin or oxaliplatin solution. The concentration and volume of Pt drug 
added to each ctDNA solution was dependent upon the required dose. For both drugs, doses 
of between 1 Pt per 100 nucleotides (1:100) to 1 Pt per 1 500 000 (1:1 500K) nucleotides 
were provided. After 24 hour incubation period at 37 oC with cisplatin or oxaliplatin, the 
ctDNA was precipitated with isopropanol and 3 M sodium acetate. The precipitate was then 
removed and washed three times with 70% ethanol solution to remove any unbound drug. 
All traces of organic solvent were then removed by vacuum centrifugation and the resulting 
ctDNA pellet was re-suspended in deionised water and supplied for analysis. The 
concentration of recovered DNA was calculated by Dr. LePla with UV/Vis spectroscopy. 
Both the cisplatin and oxaliplatin treated ctDNA samples described above were initially 
analysed by ICP-MS without any further sample preparation to establish total Pt content. 
Platinum binding was confirmed by performing the PLA, this was also carried out by Dr. 
LePla and is summarised in Figure 3:4.  
 
Solutions containing high concentrations of whole undigested ctDNA were delivered to a 
Micromist nebuliser with the aid of a peristaltic pump at a flow rate of ~200 µl min-1. A 
peristaltic pump was required for sample delivery due to the poor uptake and nebulisation 
of the viscous DNA solutions.  
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3.2.2.2 Analysis of Digested DNA 
In addition to the wide range of drug doses described above, a further set of cisplatin and 
oxaliplatin treated ctDNA was provided by Dr. LePla. These samples again contained 
ctDNA at a concentration of approximately 1.3 mg ml-1, but the ctDNA was treated with 
much lower doses of drug, namely: 1:100K, 1:300K, 1:500K, 1:1000K and 1:1500K of 
cisplatin or oxaliplatin. The sample preparation procedure was similar to that described 
above in section 3.2.2.1. These samples were subjected to a chemical digest to remove the 
organic matrix and improve the Pt signal of the lower dose samples. 
 
The obvious way to remove the ctDNA matrix was to perform an acid digest on the Pt 
treated DNA. The Biomarkers and Cancer Research Group at Leicester University use an 
ammonia hydrolysis method to cleave the Pt drug from the DNA. The method was detailed 
by Winship.179 Briefly, 0.5 ml cisplatin or oxaliplatin treated ctDNA solution was added to 
0.5 ml of 25% ammonia solution and incubated at 70 oC for 48 hours to cleave the drug 
from the DNA. The cleaved drug was then separated from the ctDNA by molecular weight 
centrifuge filters. These filters have a molecular weight cut-off of 10 000 Da, hence, the 
low molecular weight species such as unbound drug is filtered and collects towards the 
bottom of the centrifuge tube. Conversely, the high molecular weight ctDNA should not 
pass through, but becomes trapped on the filters resulting in separation of the cleaved drug 
and DNA for ICP-MS analysis. This method was used and investigated by Winship.179 
However, it was established that significant amounts of the drug was retained on the filter 
and thus not recovered at the base of the centrifuge tube. This was attributed to the 
ammonia hydrolysis method not efficiently cleaving the Pt drug; therefore, some Pt was 
still associated with the high molecular weight ctDNA and retained on the filter. In 
addition, a lot of P was detected at the base of the centrifuge tube, suggesting that some 
DNA was not being retained, but passing through the filter. This may have been due to the 
ammonia hydrolysis method partially digesting the DNA and the smaller fragments passing 
through the filter along with the Pt.179 Further, the efficiency of the filters may not have 
been 100% resulting in some Pt drug being retained and likewise some DNA passing 
through the filter.179 Since the ammonia hydrolysis and molecular weight filter method 
showed limitations, other methods of ctDNA removal were investigated.  
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A method detailed by Yamada et  al.,180 digested Pt treated ctDNA in the presence of nitric 
acid and hydrogen peroxide at 65 
oC. The resulting digest solution could then be analysed 
directly by ICP-MS and was used to establish the involvement of certain proteins in adduct 
removal.180 A similar digest method employing nitric acid was also reported by Ghezzi et 
al.,168 The method reported by Yamada was successfully used to detect adducts in DNA 
quantities of ~10 µg.180 This method was employed in this study but modified slightly. 
Thus, 80 µl of nitric acid (~68%) was added to 100 µl treated ctDNA in a polypropylene 
tube. The acidified mixture was incubated at 65 oC for one hour. After the initial one hour 
period, 80 µl of hydrogen peroxide (30%) was added to the digest mixture and allowed to 
stand at 65 oC for a further four hours.180 The caps of the vials containing the digested 
mixture were then removed and a stream of argon gas was allowed to flow over the vials to 
aid evaporation. The samples were evaporated to dryness and then re-suspended in 2% 
hydrochloric acid prior to ICP-MS analysis. The additional step of evaporating the digest 
mixtures to dryness (thereby removing nitric acid and hydrogen peroxide), followed by re-
suspension with hydrochloric acid, was beneficial because it allows a pre-concentration 
step if required. In addition, hydrochloric acid is the preferred medium for Pt. The resulting 
digested ctDNA samples were delivered to the PFA-ST nebuliser by self aspiration.  
 
3.2.3 Results 
3.2.3.1 Analysis of Whole ctDNA 
Since ctDNA contains ~10% P, solutions containing known concentrations of ctDNA were 
used to prepare a calibration curve to enable P quantification. Initially, solutions containing 
between 1-3 mg ml-1 ctDNA were prepared for calibration. However, above 2 mg ml-1 the 
solutions gave non-linear responses, presumably due to poor sample transport and reduced 
nebulisation efficiency due to the viscosity of the solutions. As a result, the ctDNA 
solutions were diluted to concentrations ranging from 0.1-1 mg ml-1, the resulting 
calibration curve can be seen in Figure 3:5. 
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Figure 3:5: 
31
P signal intensity against ctDNA concentration.  
 
Figure 3:5 clearly shows that there is a deviation from linearity above 0.5 mg ml-1 ctDNA. 
This deviation was again likely to be due the viscosity of the solution at higher DNA 
concentrations, or possibly due to a matrix effect from carbon. Carbon has been recognised 
as being able to enhance the signal for some high ionisation potential elements such as 
Se,136 but here curvature towards the concentration axis occurred so it was assumed that 
viscosity was the major influence. Alternatively carbon deposition on the cones may have 
been occurring, but as indicated above (section 3.2.2), oxygen addition was not 
recommended because of the need to use Ni cones.181 The linearity of the above calibration 
curve improved upon omitting the 1 mg ml-1 ctDNA standard, as shown in Figure 3:6. 
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Figure 3:6: 
31
P signal intensity against ctDNA concentration (0.1-0.5 mg ml
-1
 ctDNA). 
 
Figure 3:5 and Figure 3:6 suggest that for efficient transport and nebulisation, the platinated 
ctDNA samples containing whole ctDNA should be diluted. Hence, oxaliplatin treated 
ctDNA samples were diluted two fold so they contained 0.5 mg ml-1 ctDNA. This was 
achieved by taking a ~250 µl aliquot of the stock ctDNA sample (1 mg ml-1) and diluting it 
with the same volume of deionised water to yield ctDNA samples containing ~0.50 mg ml-1 
ctDNA, which equated to each sample containing ~0.25 mg ctDNA. Those samples 
containing higher Pt doses were diluted further with a 0.5 mg ml-1 ctDNA sample solvent to 
ensure the matrix was constant for all samples.  
 
A ctDNA calibration curve was prepared by measuring the 31P signal of ctDNA solutions 
containing 0.1-0.75 mg ml-1 ctDNA. Platinum standard solutions (0.022-1.85 ng ml-1) were 
prepared to allow for quantification and were spiked with 0.5 mg ml-1 ctDNA to ensure 
approximate matrix matching. This was particularly important since at this stage it was 
unknown whether the ctDNA matrix would cause matrix effects, resulting in Pt signal 
suppression or enhancement. Unfortunately, acid wash solutions could not be used between 
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samples to minimise carry over and memory effects, due to the DNA precipitating in the 
presence of nitric and hydrochloric acid. In an effort to minimise carry over, deionised 
water was aspirated between each sample and a blank was also placed between samples to 
assess carry over. 
 
Even at 0.75 mg ml-1 ctDNA, a small degree of non-linear behaviour was displayed in the 
ctDNA calibration; however, the ctDNA calibration data was employed to establish the 
ctDNA concentration in each sample. From the determined ctDNA concentrations, the P 
concentration in each sample could be calculated since P makes up 10.069% of the mass of 
DNA (the average molecular weight of a nucleotide is 307.61 Da and the accurate mass of 
P is 30.9738). The Pt calibration was linear and Pt data were successfully obtained for 
oxaliplatin treated ctDNA. In addition to calculating the total Pt concentration associated 
with each sample, additional information could also obtained. Since the concentration of 
ctDNA was known, the number of nucleotides per litre could be calculated along with 
number of Pt atoms exposed per litre. Such information was used to calculate the number 
of Pt-DNA adducts formed. These calculations were originally employed and detailed by 
Winship,179 but are briefly described below in Equation 1.1-3. Table 3:3 summarises the 
data collected for oxaliplatin treated ctDNA. 
 
Equation 1.1: Number of nucleotides per litre 
No. Nucleotides per Litre
[ ]( )
×




 ×
=
61307
0010
.
.DNA
Avagadro’s Constant 
Where [DNA] is the concentration of DNA in mg l-1. 
 
Equation 1.2: Number of Pt atoms exposed per litre 
No. of Pt atoms exposed/litre = No. Nucleotides/litre x No. drug molecules/nucleotide 
 
Equation 1.3: The number of Pt-DNA adducts formed 
No. Pt-nucleotide adducts per litre [ ]( ) ×


 ×
=
078195
0010
.
.Pt Avagadro’s Constant 
Where [Pt] is the concentration of Pt in mg l-1. 
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Note: 
307.61 = the average molecular weight of a polymerised (DNA incorporated) nucleotide. 
The average molecular weight of a free nucleotide is 325.61, but since polymerised 
nucleotides form through reaction with the 5’ phosphate of a free nucleotide and 3’ 
hydroxyl of the growing DNA chain, water is lost, hence a mass of 18 was subtracted from 
the average free nucleotide molecular weight of 325.61 to obtain 307.61. 
 
195.078 = the accurate relative atomic mass of Pt. 
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Table 3:3: Oxaliplatin data from treated ctDNA (0.5 mg ml
-1
 ctDNA matrix).  
Sample 
Dilution 
factor 
195Pt 
counts 
(cps) 
Pt conc 
(ng ml-1) 
Final Pt 
conc  
(ng ml-1) 
Final Pt 
conc  
(mg l-1) 
No. OxPt 
per 
nucleotide 
DNA 
conc  
(mg ml-1) 
UV data 
No. 
Nucleotides 
Per litre 
No. Pt 
atoms 
exposed 
per litre 
No. 
adducts 
per litre 
31P Counts 
(cps) 
DNA Conc 
(mg ml-1) 
ICP data 
31P Conc 
(mg l-1) 
Pt/P Ratio 
Control 1.93 316.70 -0.01 -0.02 0.0000 0.000000 1.17 2.29E+21 0.00E+00 0.00E+00 10210778.4 0.60 60.66 -3.84E-07 
1:500K 1.98 5604.40 0.27 0.54 0.0005 0.000002 1.01 1.98E+21 3.96E+15 1.65E+15 8839840.6 0.51 51.27 1.04E-05 
1:250K 2.00 9381.40 0.47 0.95 0.0009 0.000004 1.09 2.13E+21 8.50E+15 2.92E+15 8157923.7 0.46 46.60 2.03E-05 
1:100K 5.53 9524.20 0.48 2.66 0.0027 0.000010 1.03 2.01E+21 2.01E+16 8.20E+15 6953792.4 0.38 38.36 6.92E-05 
1:10K 18.99 22222.00 1.16 22.01 0.0220 0.000100 1.03 2.01E+21 2.01E+17 6.80E+16 6382520.1 0.34 34.45 6.39E-04 
1:5K 51.48 23149.70 1.21 62.22 0.0622 0.000200 1.12 2.19E+21 4.38E+17 1.92E+17 6664844.1 0.36 36.38 1.71E-03 
1:1000 279.37 24871.20 1.30 363.34 0.3633 0.001000 1.09 2.13E+21 2.13E+18 1.12E+18 6713488.9 0.36 36.72 9.90E-03 
1:500 760.48 9978.80 0.50 383.63 0.3836 0.002000 1.03 2.02E+21 4.05E+18 1.18E+18 6089746.8 0.32 32.45 1.18E-02 
1:300 717.56 26519.30 1.39 996.47 0.9965 0.003333 1.03 2.02E+21 6.72E+18 3.08E+18 6377861.4 0.34 34.42 2.90E-02 
1:200 1473.53 18143.40 0.94 1386.48 1.3865 0.005000 1.04 2.04E+21 1.02E+19 4.28E+18 6470596.6 0.35 35.05 3.96E-02 
1:150 1953.21 17222.80 0.89 1741.69 1.7417 0.006667 1.10 2.15E+21 1.43E+19 5.38E+18 6597623.3 0.36 35.92 4.85E-02 
1:100 3867.81 8872.10 0.45 1722.29 1.7223 0.010000 1.03 2.01E+21 2.01E+19 5.32E+18 7035644.9 0.39 38.92 4.42E-02 
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The ctDNA concentration associated with each sample was calculated by Dr. Rachel LePla 
to be ~1 mg ml-1 (determined with UV/vis spectroscopy), refer to column 8 of Table 3:3. 
However, each sample was diluted two fold prior to ICP-MS analysis to reduce the sample 
viscosity, resulting in each sample containing ~0.5 mg ml-1 ctDNA. In addition, any further 
sample dilutions were carried out with a 0.5 mg ml-1 ctDNA solution, so ultimately each 
sample should have contained ~0.5 mg ml-1 ctDNA. The ICP-MS determined ctDNA 
concentrations are shown in column 13 of Table 3:3, and should be half the value of the 
UV determined concentrations, i.e. ~0.5 mg ml-1. The ctDNA concentration in the control 
sample, which was the first ctDNA sample to be analysed, was calculated to be              
0.60 mg ml-1 by ICP-MS. If this value is multiplied by 1.93 to incorporate the dilution 
factor, a concentration of 1.16 mg ml-1 ctDNA is obtained, which is consistent with the UV 
data provided by Dr. LePla. However, the ICP-MS determined ctDNA concentrations 
gradually decreased as successive samples were aspirated, as signified by the decreasing P 
signal intensity. The P signal intensity and therefore ctDNA concentration for remaining 
samples was significantly lower than expected, indicating that unknown factors were 
effecting the analysis. Sample viscosity and high carbon content were initially though to be 
responsible for the variation in ctDNA concentration. Considering these observations, the 
UV determined ctDNA concentrations were used for subsequent calculations, whilst the 
ICP-MS determined ctDNA concentrations were deemed unreliable.  
 
The data shown in Table 3:3 indicates that between ~40-50% of the drug formed adducts. 
This can be seen by comparing the values in the two columns labelled; number of Pt atoms 
exposed per litre and number of adducts per litre. Taking the 1:1000 sample as an example, 
2.13 x 1018 Pt atoms were exposed per litre and 1.12 x 1018 adducts per litre formed, thus 
51% of the drug formed adducts with ctDNA. These values were much larger than 
expected, but it should be noted that these samples were prepared in-vitro with ctDNA, 
hence the DNA was acting as a bare ligand with no protection from the cell membrane or 
proteins as in the case of in-vivo preparations. Although the percentage of drug binding did 
vary slightly (~40-50%) between samples, the lowest percentage was observed for the 
1:100 sample where only 26% of the drug formed adducts. Presumably, this was due to the 
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larger dose of drug saturating the A and G bases, thus some of the drug was unable to form 
adducts.  
 
Considering that approximately 50% of Pt atoms formed adducts, the actual detection limit 
was not the lowest dose of 1:500 000, but in fact half of this value. Briefly, the lowest drug 
application or dose was 1 Pt per 500 000 nucleotides, which equates to 2 x 10-6 Pt atoms per 
nucleotide. If 50% of Pt atoms formed adducts, the adduct limit of detection in the above 
analysis was actually 1 x 10-6 Pt atoms per nucleotide (or 1 Pt per 1 x 106 nucleotides) in 
250 µg DNA. 
 
From the data in Table 3:3, it was also possible to establish a relationship between the 
number of adducts formed per litre and the number of oxaliplatin molecules per nucleotide. 
Figure 3:7 illustrates this relationship, whilst Figure 3:8 shows the linear relationship 
between the Pt/P concentration ratio (concentration in units of mg l-1 for both elements) and 
number of nucleotides per drug molecule. Note that the x axis in Figure 3:7 and Figure 3:8 
was derived from the data provided by Dr. LePla. 
y = 8E+20x + 2E+16
R
2
 = 0.9882
0.00E+00
1.00E+18
2.00E+18
3.00E+18
4.00E+18
5.00E+18
6.00E+18
0.000 0.001 0.002 0.003 0.004 0.005 0.006 0.007
No. Pt per nucleotide
N
o
. 
a
d
d
u
c
ts
 p
e
r
 l
it
r
e
 
Figure 3:7: Number of oxaliplatin adducts per litre against number of oxaliplatin per nucleotide (0.25 
mg ctDNA).  
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Figure 3:8: Pt/P concentration ratio against number of nucleotides per oxaliplatin molecule (0.25 mg 
ctDNA).  
 
A linear relationship can be observed in Figure 3:7, demonstrating that the number of Pt-
DNA adducts formed per litre was directly proportional to the number of drug molecules 
per nucleotide. Therefore, as the number of drug molecules increased (increased dose rate), 
the number of adducts formed also increased in a linear relationship. In addition, the ratio 
of Pt/P concentration was also proportional to the number of drug molecules per nucleotide. 
Significant carbon deposition was observed around the orifice of the sampler cone upon 
completing the experiment. As a result, it was decided that the analysis should be repeated 
but the platinated ctDNA samples should be diluted further to reduce the carbon loading.  
 
In the repeated analysis, cisplatin and oxaliplatin treated ctDNA samples were diluted to 
0.25 mg ml-1 ctDNA. i.e. a four fold dilution on the original samples. This was achieved by 
taking ~250 µl aliquot of the stock ctDNA sample (containing ~1 mg ml-1 ctDNA) and 
adding ~750 µl deionised water to yield ctDNA samples containing 0.25 mg ml-1 ctDNA, 
which equated to ~ 0.25 mg ctDNA being analysed. Any further dilutions were carried out 
with a 0.25 mg ml-1 ctDNA sample solvent to keep the ctDNA concentration and matrix 
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constant. This resulted in the viscosity and carbon content being reduced even further. Pt 
standards ranging from 0.052-16.1 ng ml-1 in 0.25 mg ml-1 ctDNA were prepared. The 
results for oxaliplatin and cisplatin treated ctDNA can be observed in Table 3:4 and Table 
3:5 respectively. Equation 1.1-3 were used for the calculations.  
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Table 3:4:  Oxaliplatin data from treated ctDNA (0.25 mg ml
-1 
ctDNA matrix). 
Sample 
Dilution 
factor 
195Pt counts 
(cps) 
Pt conc 
(ng ml-1) 
Pt conc 
(mg l-1) 
No. oxPt 
per 
nucleotide 
DNA conc 
(mg ml-1) 
UV data 
No. 
nucleotides 
per litre 
No. Pt atoms 
exposed per 
litre 
No. 
adducts 
per litre 
31P Counts 
(cps) 
DNA conc 
(mg  ml-1) 
ICP data 
31P conc 
(mg l-1) 
Pt/P ratio 
Control 4.01 571.5 -0.2 -0.0002 0 1.17 2.29E+21 0.00E+00 0.00E+00 37021629.5 0.28 28.05 -0.000006 
1:500K 3.97 12899.1 0.3 0.0003 0.000002 1.01 1.98E+21 3.96E+15 8.16E+14 26562478.9 0.20 19.88 0.000013 
1:250K 6.60 16446.2 0.6 0.0006 0.000004 1.09 2.13E+21 8.50E+15 1.97E+15 16198761.5 0.12 11.78 0.000054 
1:100K 3.89 66544.1 2.0 0.0020 0.00001 1.03 2.01E+21 2.01E+16 6.30E+15 22938755.2 0.17 17.05 0.000120 
1:10K 3.81 565868.5 18.2 0.0182 0.0001 1.03 2.01E+21 2.01E+17 5.63E+16 25101105.1 0.19 18.74 0.000974 
1:5K 8.47 513739.2 36.8 0.0368 0.0002 1.12 2.19E+21 4.38E+17 1.14E+17 25505974.8 0.19 19.05 0.001931 
1:1000 32.79 650859.7 180.8 0.1808 0.001 1.09 2.13E+21 2.13E+18 5.58E+17 19145013.9 0.14 14.08 0.012840 
1:500 40.68 806645.9 278.4 0.2784 0.002 1.03 2.02E+21 4.05E+18 8.60E+17 13746893.5 0.10 9.86 0.028227 
1:300 100.82 514098.4 438.2 0.4382 0.003 1.03 2.02E+21 6.72E+18 1.35E+18 14497623.3 0.10 10.45 0.041930 
1:200 117.87 509984.8 508.1 0.5081 0.005 1.04 2.04E+21 1.02E+19 1.57E+18 13062797.4 0.09 9.33 0.054469 
1:150 166.20 549061.3 772.0 0.7720 0.007 1.10 2.15E+21 1.43E+19 2.38E+18 12658600.6 0.09 9.01 0.085646 
1:100 233.46 516125.6 1018.7 1.0187 0.01 1.03 2.01E+21 2.01E+19 3.15E+18 9619933.2 0.07 6.64 0.153444 
Table 3:5: Cisplatin data from treated ctDNA (0.25 mg ml
-1 
ctDNA matrix). 
Sample 
Dilution 
factor 
195Pt counts 
(cps) 
Pt conc 
(ng ml-1) 
Pt conc 
(mg l-1) 
No. cisPt 
per 
nucleotide 
DNA conc 
(mg ml-1) 
UV data 
No. 
nucleotides 
per litre 
No. Pt atoms 
exposed litre 
No. 
adducts 
per litre 
31P 
Counts 
(cps) 
DNA conc 
(mg ml-1) 
31P conc 
(mg l-1) 
Pt/P ratio 
Control 4.16 358.4 -0.2 -0.0002 0 1.03 2.01E+21 0.00E+00 0.00E+00 10825518.8 0.08 7.58 -0.000022 
1:500K 3.96 21885.9 0.6 0.0006 0.000002 1.12 2.20E+21 4.40E+15 1.75E+15 13122696.1 0.09 9.38 0.000061 
1:250K 4.00 36541.6 1.1 0.0011 0.000004 1.08 2.12E+21 8.47E+15 3.32E+15 9455398.3 0.06 6.51 0.000165 
1:100K 4.00 102866.9 3.3 0.0033 0.00001 1.15 2.25E+21 2.25E+16 1.03E+16 9980338.4 0.07 6.92 0.000482 
1:10K 20.53 118841.7 19.9 0.0199 0.0001 1.06 2.07E+21 2.07E+17 6.16E+16 6729739.1 0.04 4.38 0.004551 
1:5K 13.33 398607.7 44.8 0.0448 0.0002 1.15 2.26E+21 4.52E+17 1.38E+17 6148964.7 0.04 3.93 0.011406 
1:1000 8.42 2751573.3 197.5 0.1975 0.001 1.02 2.00E+21 2.00E+18 6.10E+17 5712337.7 0.04 3.59 0.055071 
1:500 194.97 310924 509.1 0.5091 0.002 1.13 2.22E+21 4.43E+18 1.57E+18 5205336.9 0.03 3.19 0.159630 
1:300 278.78 245536.7 572.3 0.5723 0.003 1.12 2.20E+21 7.32E+18 1.77E+18 5007022.8 0.03 3.03 0.188610 
1:200 474.53 249184.4 989.0 0.9890 0.005 1.17 2.28E+21 1.14E+19 3.05E+18 4861418.6 0.03 2.92 0.338613 
1:150 566.79 249283.2 1181.8 1.1818 0.007 1.08 2.12E+21 1.41E+19 3.65E+18 4857053.0 0.03 2.92 0.405084 
1:100 651.65 389693.1 2140.0 2.1400 0.01 1.10 2.15E+21 2.15E+19 6.61E+18 5101874.6 0.03 3.11 0.688403 
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The P signal intensities and therefore calculated ctDNA concentrations (columns 11 and 12 
respectively) in Table 3:4 and Table 3:5 were highly variable, even though all the samples 
contained 0.25 mg ml-1 ctDNA. In the above case, the oxaliplatin samples were analysed 
first followed by cisplatin. The ICP-MS determined ctDNA concentration of the oxaliplatin 
control sample was 0.28 mg ml-1, if the dilution factor of 4.01 is considered, a ctDNA 
concentration of 1.12 mg ml-1 is obtained, which is consistent with the UV determined 
concentration of 1.17 mg ml-1. The P signal intensities and therefore ICP determined 
ctDNA concentrations decreased steadily throughout the analysis, with ~7 fold decrease in 
signal observed during analysis of the oxaliplatin and cisplatin samples. The correlation 
between ICP-MS and UV determined ctDNA concentrations were expected to be closer in 
the more dilute ctDNA samples, due to the reduced matrix. However, this was not the case, 
the ICP-MS determined ctDNA concentrations in Table 3:3, which contained ~ 0.5 mg ml-1 
ctDNA were closer to the concentrations calculated by UV, whilst the more dilute ctDNA 
solutions (Table 3:4 and Table 3:5) gave the largest deviations. The sample introduction 
system was inspected post analysis for signs of blockages, but the nebuliser, torch and 
sample cones appeared to be free from such obstructions. Again, these spurious P counts 
were attributed to matrix effects, namely high carbon content and sample viscosity. 
Considering these observations, the ICP-MS determined ctDNA concentrations were 
considered to be unreliable, thus the UV determined ctDNA concentrations were used for 
further data analysis (e.g. to calculate the number of nucleotides per litre and the number of 
Pt atoms per nucleotide etc.). 
 
The total Pt concentrations for oxaliplatin (Table 3:4) were lower than those seen 
previously in Table 3:3. For example, the 1:100 oxaliplatin sample gave a total Pt 
concentration of 1.72 mg l-1 in the first experiment (Table 3:3) and 1.02 mg l-1 in the second 
experiment (Table 3:4), again pointing to the fact that matrix effects may be responsible. 
The long term continual aspiration of viscous, high carbon material may have caused the 
unstable and decreasing signals. This would also explain why the P signal intensities 
gradually decreased with the lowest P signals observed in the cisplatin samples. 
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The data in Table 3:4 and Table 3:5 shows that between 15-30% of oxaliplatin and 25-40% 
of cisplatin formed adducts. For both drugs, the highest percentage of Pt adduct formation 
is generally found at the lower drug doses (e.g. between 1:500K-1:1000). At doses greater 
than 1:1000 the percentage of Pt forming adducts generally decreased, with the lowest 
percentages generally found at the very highest dose rates of between 1:300-1:100. This 
suggests that a saturation point is reached and all available adduct sites on the DNA are 
occupied at the very high Pt doses. The percentage of oxaliplatin adducts was lower in the 
above experiment compared to the first analysis seen previously in Table 3:3. The reason 
for this can only be attributed to matrix effects, since both sets of data were obtained from 
the same set of samples. Figure 3:9 shows the relationship between the numbers of adducts 
per litre and number of drug molecules per nucleotide for oxaliplatin and cisplatin. Note 
that the values on the x axis (number of Pt atoms per litre) were calculated from the data 
given by Dr LePla. 
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Figure 3:9: Number of cisplatin and oxaliplatin adducts per litre formed against number Pt molecules 
per nucleotide (0.25 mg ctDNA). 
 
Cisplatin 
Oxaliplatin 
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A linear relationship was again observed between the number of adducts formed and the 
number of drug molecules per nucleobase. This relationship was displayed by both drugs. 
However, from Figure 3:9 the gradient for the cisplatin data was twice as high as that for 
oxaliplatin (6x1020 and 3x1020 for cisplatin and oxaliplatin respectively), indicating that 
cisplatin formed more Pt-DNA adducts per litre compared to oxaliplatin. This observation 
is consistent with the reported literature, which states that cisplatin forms more adducts 
than oxaliplatin (see 3.1.2 above). Figure 3:10 shows the relationship between Pt/P ratio 
and the number of nucleotides per Pt for both cisplatin and oxaliplatin.  
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Figure 3:10: Pt/P ratio against the number of drug molecules per nucleotide (0.25 mg 
 
ctDNA). 
 
From Figure 3:10 it can be established that as the number of Pt molecules increased 
(increased dose rate), the ratio of Pt concentration/P concentration also increased in a linear 
fashion. The above data therefore supports the data shown in Figure 3:9, as dose rate 
increases, the number of adducts formed increases and thus the concentration of total bound 
Pt increases as expected.  
 
Oxaliplatin 
Cisplatin 
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It has been shown in the data presented so far in this chapter that the presence of the ctDNA 
matrix was problematic in terms of viscosity and carbon content. Carbon deposition on the 
sampler cone was significant and sample uptake was only possible with the aid of a 
peristaltic pump. The Element 2XR instrument gave a signal intensity of ~1.6x106 cps for  
1 ng ml-1 115In upon tuning prior to the above analysis (1x106 cps/ppb 115In is the quoted 
sensitivity by Thermo-Finnigan).65 Considering 195Pt is only 33% abundant and the first 
ionisation potential of Pt is approximately double that of In, a signal intensity of           
~256 000 cps was expected for 1 ng ml-1 195Pt, which equates to approximately 4x106 cps 
for a solution containing 16 ng ml-1 Pt. However, the highest Pt calibration standard of     
16 ng ml-1 only gave a signal intensity of ~1.9x106 cps, which was a 53% reduction of the 
expected Pt signal. These observations suggested that matrix effects were causing a large 
reduction in sensitivity. If the high carbon matrix is removed prior to analysis, better 
sensitivity should be obtained. To confirm that the ctDNA matrix was suppressing the Pt 
signal, two calibration curves were prepared; one set of calibration standards contained Pt 
in a 2% hydrochloric acid matrix, whilst the second set of standards contained Pt in a     
0.25 mg ml-1 ctDNA matrix. Both sets of standards ranged from 0.50-2 ng ml-1 Pt and the 
calibration curves can be seen in Figure 3:11. 
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Figure 3:11: Pt calibration curves in a 2% hydrochloric acid and 0.25 mg ml
-1
 ctDNA matrix. 
 
The data presented in Figure 3:11 shows that the gradients for the two calibrations were 
252 305 and 27 550 counts per ng ml-1 for the hydrochloric acid and ctDNA matrix 
respectively. Thus, by comparing the gradients of the two calibration curves, it was 
established that the 0.25 mg ml-1 ctDNA matrix suppressed Pt signal by 89%. In addition, 
the Pt limit of detection (LOD) was determined for both sets of calibration data using the 
formula shown in Equation 2. 
Equation 2: Limit of detection. 
Limit of detection
( )
m
SD blank×
=
3
 
Where: 
SDblank = standard deviation of the blank. 
m = the gradient of the calibration slope. 
 
ctDNA matrix 
HCl matrix 
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The LOD formula shown above is dependent upon the instrument blank and sensitivity, the 
LOD for Pt was calculated to be 0.99 pg ml-1 and 6.38 pg ml-1 in the hydrochloric acid 
matrix and ctDNA matrix respectively. 
 
These results confirm that the ctDNA matrix was problematic and needed to be removed 
prior to ICP-MS analysis. By removing the high carbon matrix, the Pt response should be 
higher (~90% improvement in signal) and lower drug doses should be detected and 
quantified. Table 3:4 and Table 3:5 show that even when the lowest drug dose of 1:500 000 
was diluted four fold to contain 0.25 mg ml-1 ctDNA, the Pt counts were 12 514 cps and   
21 537 cps for oxaliplatin and cisplatin respectively. These signal intensities equated to 0.3 
and 0.6 ng ml-1 Pt. Hence, if the ctDNA matrix is removed the expected signal intensity for 
these low dose samples should be much higher than those observed in the above data 
tables.  
 
3.2.3.2 Analysis of Digested DNA 
Trial experiments were performed before the nitric acid/hydrogen peroxide digest 
procedure was carried out on the cisplatin and oxaliplatin treated ctDNA supplied by Dr. 
LePla. The trial experiments consisted of spiking a 1 mg ml-1 ctDNA solution with a Pt 
standard of known concentration (21 ng ml-1). A 100 mg aliquot of the Pt spiked ctDNA 
solution was then digested (in duplicate) as described in section 3.2.2.2. Upon completing 
the digest, the sample was evaporated to dryness and re-suspended in 1.5 ml hydrochloric 
acid (2% w/w). The resulting digest solutions contained 1.39 (digest A) and 1.45 ng ml-1 
(digest B) Pt in 2% hydrochloric acid. A Pt standard solution containing 1.37 ng ml-1 Pt in 
2% hydrochloric acid was prepared along with 1.4 ng ml-1 Pt standard solution in           
0.25 mg ml-1 ctDNA matrix. The signal intensities of all the Pt solutions were compared to 
establish whether the nitric acid/hydrogen peroxide digest was effective at digesting the 
ctDNA and therefore removing the non-spectroscopic interferences. The data is 
summarised in Figure 3:12. A control sample consisting of digested ctDNA in the absence 
of Pt standard was also prepared.  
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Figure 3:12: Pt signal intensity for digested DNA samples and Pt standards in hydrochloric acid and 
DNA matrix. 
 
The re-suspended digest samples gave very similar counts to the 1.37 ng ml-1 Pt standard in 
hydrochloric acid, whilst the solution containing Pt at a concentration of 1.4 ng ml-1 in   
0.25 mg ml-1 ctDNA resulted in very low counts as expected. An approximate eight fold 
difference in Pt signal intensity was observed between the ctDNA and aqueous acid matrix. 
From Figure 3:12 it can be concluded that the nitric acid/hydrogen peroxide digest was 
effective at digesting the organic matter, which resulted in reducing non-spectroscopic 
interferences. No matrix effects were observed in the digested DNA samples, this was 
confirmed by the equivalent Pt signal intensities in the digest samples and the 1.37 ng ml-1 
Pt standard in hydrochloric acid. In addition, the viscosity of the DNA solutions decreased 
after digestion, so self aspirating nebulisers could be employed, which had the advantage of 
improved signal stability and reduced sample consumption compared to pumped nebulisers.  
 
Once it was confirmed that the nitric acid/hydrogen peroxide procedure was successful in 
digesting the DNA and removing the matrix interferences, it was applied to ctDNA samples 
that had been treated with cisplatin or oxaliplatin. These samples were again prepared by 
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Dr. LePla at Leicester University. The following dose rates were supplied for both drugs: 
1:100K, 1:300K, 1:500K, 1:1000K and 1:1500K. Each sample stock solution contained 
approximately 1.3 mg ml-1 ctDNA and a 100 mg aliquot of each sample was initially taken 
and digested as described above, hence the actual mass of DNA digested was 
approximately 130 µg. After digestion, the samples were reduced to dryness and re-
suspended in 2% hydrochloric acid (0.5 ml), which was accurately weighed to establish the 
dilution factor for each sample. The results for the cisplatin and oxaliplatin samples are 
summarised in Table 3:6 and Table 3:7 respectively, where the mass of ctDNA digested is 
clearly shown. The Pt concentrations look reasonable, with the Pt concentration gradually 
increasing with increasing dose rate as expected for both drugs. The lowest cisplatin dose 
rate of 1:1500K gave a higher Pt signal than expected, as did the oxaliplatin 1:1000K 
sample. The reason for this could only be explained by potential contamination during the 
sample preparation procedure.  
Table 3:6: Pt signal intensity and concentration in digested cisplatin treated samples. 
Cisplatin 
sample 
Pt per 
nucleotide 
195
Pt counts 
(cps) 
Dilution 
factor 
Pt conc 
(ng ml
-1
) 
Mass of DNA 
digested (µg) 
Control 0.0000000 1201.1 4.17 0.13 115.18 
1:100K 0.0000100 241356.1 5.10 4.53 125.13 
1:300K 0.0000033 78917.3 5.18 1.60 138.42 
1:500K 0.0000020 58375.9 4.65 1.09 127.63 
1:1000K 0.0000010 35809.1 4.75 0.73 131.34 
1:1500K 0.0000007 76633.9 5.15 1.55 134.88 
 
Table 3:7: Pt signal intensity and concentration in digested oxaliplatin treated samples. 
OxPt 
sample  
Pt per 
nucleotide 
195
Pt counts 
(cps) 
Dilution 
factor 
Pt conc  
(ng ml
-1
) 
Mass of DNA 
digested (µg) 
Control 0.0000000 1425.0 2.05 0.003 130.00 
1:100K 0.0000100 78945.3 2.53 1.02 131.92 
1:300K 0.0000033 25969.6 2.51 0.32 132.73 
1:500K 0.0000020 21549.3 1.99 0.21 136.76 
1:1000K 0.0000010 24557.8 2.00 0.24 136.35 
1:1500K 0.0000007 11165.5 2.03 0.11 135.85 
 
Figure 3:13 shows the above data graphically, where the number of adducts formed was 
calculated as described previously and then plotted against the number of Pt atoms per 
nucleotide. It should be noted that the x axis (number of Pt atoms per nucleotide) was 
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calculated from the information given by Dr. Rachel Le Pla. A linear relationship between 
Pt signal and drug dose rate was observed as expected. The cisplatin 1:1500K and 
oxaliplatin 1:1000K results, which gave slightly higher Pt signals than expected, were 
included in Figure 3:13. Before these two data points were included in the graphs, 
regression analysis was carried out on the respective data sets where the standard error 
(95% confidence level) of the data was established, along with the predicted y values (No. 
Pt-DNA adducts formed per litre). It was shown in the suspect cisplatin and oxaliplatin 
samples that the number of Pt-DNA adducts formed per litre (determined by ICP-MS) was 
outside of the predicted y value ± 1 standard error (SE), but within ± 2 SE. Since 2 SE give 
the greatest confidence, it was decided not to omit the suspect data points but to include 
them in the graphs shown below.  
 
y = 3E+20x + 1E+14
R
2
 = 0.9774
y = 1E+21x + 1E+15
R
2
 = 0.9263
0.00E+00
2.00E+15
4.00E+15
6.00E+15
8.00E+15
1.00E+16
1.20E+16
1.40E+16
1.60E+16
0.0E+00 2.0E-06 4.0E-06 6.0E-06 8.0E-06 1.0E-05
No. Pt per nucleotide
N
o
. 
P
t-
D
N
A
 a
d
d
u
c
ts
 p
e
r
 l
it
r
e
 
Figure 3:13: Relationship between Pt signal and the number of Pt atoms per nucleotide for both 
cisplatin and oxaliplatin following digestion with nitric acid and hydrogen peroxide. 
 
The above sets of data illustrate that the nitric acid/hydrogen peroxide was effective at 
digesting the organic matrix and removing matrix effects. More importantly, the digest was 
applied to relatively small quantities of DNA (~130 µg) and still allowed for the very low 
Cisplatin 
Oxaliplatin 
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doses of Pt drug to be determined and quantified. The linearity of the data in Figure 3:13 
was poor compared to that seen in Figure 3:9, where whole ctDNA was analysed. This can 
be attributed to the lower quantities of DNA under analysis and the much lower drug 
application rates. 
 
Figure 3:12 illustrates that the Pt standard containing ctDNA matrix gave signal intensity 
eight times lower than the digested ctDNA containing Pt. Thus, the Pt signal intensities in 
Table 3:7 (acid digested ctDNA) were expected to be eight times greater than those in 
Table 3:4, which showed data for samples containing whole ctDNA at 0.25 mg ml-1. When 
the Pt counts were compared for equivalent amounts of ctDNA, ~1.5 times greater Pt signal 
intensity was obtained in the digested ctDNA samples (Table 3:7) compared to the whole 
ctDNA (Table 3:4).  Although a much larger increase in Pt signal intensity was expected, it 
should be noted that the two sets of data originated from different sets of samples, which 
could explain why the two sets of data do not completely correspond.  
 
The nitric acid/hydrogen peroxide digest was repeated on the Pt treated ctDNA samples, 
but a much lower quantity of sample and therefore DNA was digested. As stated 
previously, if the method is to be applied to patient samples, only small quantities of DNA 
may be obtained, so the method has to be suitable for use on approximately 10 µg of DNA. 
This quantity of DNA could realistically be obtained from patients, but 100 µg DNA or 
greater may not be feasible. The cisplatin treated ctDNA stock samples which were 
digested previously (see above experiments) were used in this analysis. Briefly, an aliquot 
of the cisplatin stock solution (~12 mg) was added to a polypropylene microcentrifuge vial, 
accurately weighed and then digested as described previously. Figure 3:14 shows the 
relationship between the number of Pt-DNA adducts formed against the number of Pt 
atoms per nucleotide for cisplatin treated ctDNA. The mass of ctDNA digested in this 
experiment ranged from 13-18 µg. Although, the data shows a general increase in Pt 
concentration with increasing dose rate, the 1:1000K sample from this batch exhibited very 
high Pt counts (~31527 cps). Again, regression analysis was carried out on the data, which 
showed that the 1:1000K data point was within the predicted y value ± 2 SE (95% 
confidence level) and included in Figure 3:14.  
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Figure 3:14: Relationship between the number of adducts formed and the number of drug molecules 
per nucleotide for cisplatin treated ctDNA digested with nitric acid and hydrogen peroxide. 
 
The next step involved digesting the oxaliplatin treated ctDNA samples along with a 
repeated attempt at digesting the cisplatin treated ctDNA. For both sets of samples 
approximately 12 µg ctDNA was digested. Both the 195Pt and 31P signals were measured for 
these two sets of samples, Figure 3:15 and Figure 3:16 show the data for these two digests. 
The cisplatin data was slightly better than that obtained for oxaliplatin. The oxaliplatin 
control and 1:300K samples gave very high Pt signals that were not consistent with the 
remaining samples. Regression analysis showed that the control was within ±2 SE of the 
predicted values, but the 1:300K sample was outside the predicted values. For this reason, 
the 1:300K sample was omitted from Figure 3:15 and Figure 3:16. Figure 3:15 illustrates 
the linear relationship between the number of Pt-DNA adducts formed and the number of 
drug molecules per nucleotide. It should be noted that the cisplatin samples again displayed 
greater Pt concentrations and therefore greater numbers of adducts than oxaliplatin as 
expected. Figure 3:16 shows the linear relationship between Pt/P ratios and the number of 
drug molecules per nucleotide, as expected the ratio increased with increased dose of drug. 
However, the linearity of these two sets of data was inferior to those seen in Figure 3:9. 
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This was again attributed to error associated with the low Pt signal intensities resulting 
from the small quantities of DNA analysed and the low dose rates. 
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Figure 3:15: The relationship between number of Pt-DNA adducts formed and the number of drug 
molecules per nucleotide, for both cisplatin and oxaliplatin treated ctDNA digested with nitric 
acid/hydrogen peroxide. Approximately 12 µg of ctDNA digested. 
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Figure 3:16: Pt/P ratio against the number of drug molecules per nucleotide for both cisplatin and 
oxaliplatin treated ctDNA digested with nitric acid/hydrogen peroxide. Approximately 12 µg of ctDNA 
digested. 
Oxaliplatin 
Cisplatin 
Cisplatin 
Oxaliplatin 
219 
3.2.4 Summary 
The application of ICP-MS to the detection and quantification of Pt-DNA adducts, formed 
after incubation with either cisplatin or oxaliplatin anti-cancer drugs has been 
demonstrated. It has been established that HR-ICP-MS can be employed for detecting the 
high levels of P associated with the DNA backbone and trace levels of Pt associated with 
Pt-DNA adducts. The DNA solutions could be analysed whole without additional sample 
preparation, and the Pt measured with doses as low as 1:500 000 nucleobases being 
detected. However, severe matrix effects were observed which resulted in a suppression of 
the Pt signal. These matrix effects were a consequence of the high carbon matrix which is 
associated with biological materials such as DNA. Carbon deposition on or around the 
orifice of the sampler cone was problematic and resulted in signal drift. In addition, the 
viscosity of the whole DNA solutions compromised sample uptake and nebulisation 
efficiency. These problems were overcome and lower drug dose rates were successfully 
detected by digesting the DNA in a mixture of nitric acid and hydrogen peroxide. Drug 
doses as low as 1:1 500 000 nucleobases could then be detected. 
 
In addition to drug doses of 1:1 500 000 being detected, such levels were successfully 
quantified in samples containing ~12 µg ctDNA when digested with nitric acid and 
hydrogen peroxide. This is particularly important if the method is to be applied to clinical 
samples, where DNA has to be extracted from blood samples obtained from chemotherapy 
patients and the quantity of DNA is restricted. However, ~12 µg DNA would be possible to 
obtain from patient blood samples.  
 
The research detailed in this chapter has illustrated the potential of ICP-MS in detecting 
and quantifying low doses of Pt in microgram quantities of DNA. The digest and analysis 
method detailed here was successfully employed during an MSc. Project carried out by 
Albano Fialho at Loughborough University.182 In this project, two lung cancer cell lines 
(A549 and H23) were treated with cisplatin or oxaliplatin. The digest method was then 
applied to 40 µg of extracted DNA, with the associated Pt successfully detected and 
quantified.182 The next step would be to extract blood from patients undergoing treatment 
with these drugs, extract and then analyse the DNA. If the extent of Pt-DNA adduct 
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formation can be detected in clinical samples, it could help identify those patients who are 
responding to treatment and those who are not responding as well. More importantly, if 
those patients who are not responding, are identified early in the treatment phase, the 
treatment could be stopped and the severe side effects associated with these drugs could be 
minimised. Levels of adduct formation will be much lower in-vivo, since the cell is exposed 
to the drug and not the DNA directly. However, clinical adduct levels may be higher than 
1:1500K measured here.  
 
A recent publication detailed very similar work to that discussed in this chapter.183 The 
authors described a method based on capillary LC-ICP-MS, which was used to separate and 
detect Pt-GG adducts, which were produced in-vivo upon treating D. Melanogaster with 
cisplatin.183 The authors studied the correlation between cisplatin adduct levels (determined 
by LC-ICP-MS) and genotoxicity (determined by the comet assay), however, the author did 
not study oxaliplatin.183 The reported detection limit for the capillary LC-ICP-MS method 
was 1 adduct per 106 nucleotides,183 which is similar to the doses detected in this chapter, 
although the author did not specify the total mass of DNA required to detect 1 Pt adduct per 
106 nucleotides. 
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4 Investigation of Oxaliplatin Interactions with DNA 
Nucleobases by means of Organic Mass 
Spectrometry 
 
4.1 Introduction 
There have been numerous investigations into the interactions of oxaliplatin with 
proteins141, 173 and the effect of DNA binding in the presence of specific proteins, 
particularly those rich in sulfur containing amino acids.141, 184, 185 Extensive studies 
investigating the interaction of oxaliplatin with DNA nucleobases have also been 
conducted. However, the techniques used to study oxaliplatin-DNA interactions have been 
predominantly x-ray crystallography, 186 NMR 144, 187 and biological assays such as the 
Comet assay.156 These techniques have their disadvantages, namely; crystals of a suitable 
quality are required for crystallography and relatively large quantities of high purity sample 
are required for NMR.188, 189 Mass spectrometry has been used to study and characterise 
cisplatin-DNA adducts, 151, 164, 190 but to our knowledge, the same has not been true for the 
study of oxaliplatin-DNA adducts. ESI-MS has been employed to investigate the structure 
of oxaliplatin adducts with methionine and guanine monophosphate (GMP).184 A LC-ESI-
MS/MS method has been developed previously to measure GG and AG intra-stranded 
cross-links in oxaliplatin treated DNA, where limits of detection for the two cross-links 
were determined.167 These authors reported proposed structures for the two major 
oxaliplatin adducts and their corresponding fragments, however, the source was operated in 
negative ion mode, not positive as used here, and detailed fragmentation pathways for the 
remaining oxaliplatin-DNA adducts were not investigated. Here the focus is on the 
interactions of oxaliplatin with the nucleobases adenine, guanine, cytosine and thymine, 
where the drug was combined with free nucleobases as opposed to oligonucleotides or 
intact DNA. This fundamental investigation provides the initial step towards a more 
complete understanding of the drug's interaction and binding mode with intact DNA where 
other factors such as steric strain and binding site geometry might impact upon binding 
location and stability of the drug complex.  
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A linear ion trap mass spectrometer employing ESI was employed here to study the binding 
of oxaliplatin to DNA nucleobases. Oxaliplatin was combined with each DNA nucleobase 
and the identities of all the resulting complexes were investigated using ESI-MS. The 
preferential binding of oxaliplatin to guanine and adenine in the presence of all four 
nucleobases will be discussed. It will also be demonstrated that ESI-MSn is an ideal 
technique for the study of oxaliplatin-nucleobase interactions since structural information 
can be obtained in relatively short periods of time and the disadvantages of NMR and x-ray 
crystallography are avoided.190  
 
In addition to demonstrating the potential of linear ion trap mass spectrometry in 
metallodrug studies, this chapter will also highlight the complementary nature of organic 
and inorganic mass spectrometry; namely, inorganic mass spectrometry was employed in 
the previous chapter to detect and quantify trace amounts of Pt drug bound to DNA. 
Conversely the following chapter details structural information and fragmentation pathways 
of oxaliplatin-nucleobase adducts.   
 
The work detailed in this chapter was conducted in the Atomic Spectrometry Research 
Group, under the supervision of Dr Barry Sharp and in collaboration with Dr Tamer 
Shoeib, who was a visiting academic from the British University in Egypt.  
 
4.2 Instrumentation and Reagents 
A Thermo Finnigan LTQ linear ion trap mass spectrometer (Thermo Finnigan, San Jose, 
California) was used for all mass spectrometric determinations. Version 2.0 of the Xcalibur 
software (Thermo Finnigan, San Jose, California) was employed for all data processing. 
The instrument was calibrated with a mixture of ultra mark and caffeine in accordance with 
the manufacturer’s recommendations. Resolution was calculated according to R=m/∆m. 
Resolving powers achieved were in the order of 1200 for higher mass di-adducts, although 
lower mass species exhibited resolving powers of approximately 800-1000. The LTQ Ion 
Max auto-tune routine was used to obtain settings for lens, quadrupole and octapole 
voltages for maximum transmission of the ions of interest. Helium gas admitted into the ion 
trap at a maintained pressure of approximately 10-3 Torr was used as the buffer gas to 
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improve the trapping efficiency and as the collision gas for collision induced dissociation 
(CID) experiments. Experiments designed to elucidate ion structures or fragmentation 
pathways were performed as follows: the ion of interest was selected with an isolation 
width set to 1 m/z units (unless stated otherwise), collisional activation was introduced by 
setting the activation amplitude (which defined the amplitude of the radio frequency (RF) 
voltage applied) at 25–35% of the maximum voltage available (determined empirically), 
and the activation Q setting (used to adjust the frequency of the RF-excitation voltage) was 
set at 0.25 unit. Sample solutions were continuously infused at a flow rate of 5 µl min-1 into 
the pneumatically assisted electrospray probe using dry nitrogen as the nebulising gas. The 
basic instrument operating conditions are summarised in Table 4:1. The instrument ion 
optics and gas flows were tuned daily with the analyte of interest to obtain maximum signal 
intensity and stability.  
Table 4:1: ESI-MS operating conditions. 
Scan type Positive ion 
Nebulising gas N2 
Flow rate 5 µl min-1 
Spray voltage 5-5.5 kV 
Sheath gas flow (arbitrary units) tuned daily (typically ~0-10) 
Auxiliary gas flow (arbitrary units) tuned daily (typically ~0-10) 
 
The nucleobases, adenine (A), guanine (G), cytosine (C) and thymine (T) were obtained 
from Fisher Scientific (Loughborough, UK), as was HPLC grade methanol. Oxaliplatin was 
kindly supplied by Dr. LePla, but the drug originated from Sanofi-Synthelab (Surrey, UK). 
The drug was in powder form and was dissolved in deionised water to a concentration of 
2.6 mg ml-1 (6.6 mM oxaliplatin) to form the stock solution, which was used to prepare 
further drug-nucleobase solutions. All solutions were prepared in 50% methanol in 
deionised water. 
 
Initial experiments concentrated on identifying the oxaliplatin parent ion and fragmentation 
products in the absence of nucleobase. Since oxaliplatin would be present in all solutions, it 
was considered important to become familiar with its fragmentation pathway before 
progressing to more complex mixtures containing nucleobases. As a result, a solution 
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containing oxaliplatin at a concentration of 3.3 mM in 50% methanol was prepared and 
infused into the mass spectrometer before the drug-nucleobase interactions were 
investigated. 
 
Initially four solutions containing oxaliplatin were prepared; each oxaliplatin solution 
contained a different base, so the drug was present in a mono-base solution. Two solutions 
containing the drug with all four nucleobases were prepared, one of these solutions 
contained oxaliplatin at an equi-molar concentration to each of the bases. The second mixed 
solution contained an excess of oxaliplatin in the presence of the four bases. A final 
solution containing oxaliplatin with adenine and guanine at near equal molar concentrations 
was also prepared. The concentration of drug and base in each solution is shown in Table 
4:2.  
Table 4:2: Concentration of oxaliplatin and nucleobase in individual and mixed base solutions. 
Solution Reagent Concentration 
1 3.3 mM oxaliplatin + 9.4 mM adenine 
2 1.6 mM oxaliplatin + 5.8 mM cytosine 
3 1.6 mM oxaliplatin + 1.6 mM guanine 
4 1.6 mM oxaliplatin + 8.3 mM thymine 
5 1.7 mM oxaliplatin + 1.6 mM A, C, G and T 
6 3.0 mM oxaliplatin + 0.46 mM A, C, G and T 
7 2.2 mM oxaliplatin +  1.5 mM adenine + 1.7 mM guanine 
 
The drug to nucleobase molar concentrations were adjusted to obtain clear spectra, 
consequently these ratios corresponded to the order of formation constants as indicated by 
the analysis of the mass spectra, which will be discussed in subsequent sections. Each 
solution was allowed to sit at room temperature overnight before being analysed. Solutions 
1-4 each contained oxaliplatin and a single nucleobase and were employed to confirm the 
formation of oxaliplatin adducts in each case. Solutions 5 and 6 were used to study the 
formation of oxaliplatin adducts in the presence of all four nucleobases. Further, solution 7 
was employed to study the preferential binding of oxaliplatin to adenine and guanine. 
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4.3 Results 
4.3.1 Oxaliplatin Analysis 
A 3.3 mM oxaliplatin solution absent of nucleobase was infused into the mass spectrometer 
and analysed using the instrument conditions summarised in Table 4:1. Prior to nucleobase 
binding oxaliplatin loses the oxalate ligand, which acts as a leaving group enabling adduct 
formation, whilst the diaminocylohexane (dach) ligand remains attached to the Pt centre. 
The full scan mass spectrum of the oxaliplatin sample exhibited a cluster of ions around m/z 
398 and 307, corresponding to the whole oxaliplatin complex and the oxaliplatin without 
the oxalate leaving group (Pt-dach) respectively. A full scan spectrum of the drug is shown 
in Figure 4:1.  
 
Figure 4:1: Full scan mass spectrum of 3.3 mM oxaliplatin. 
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Figure 4:1 shows that the dominant Pt containing species present in the mass spectrum 
were at m/z 307, 398 and 420. The Pt isotopic pattern corresponding to 194Pt (32.8%), 195Pt 
(33.8%), 196Pt (25.3%) and 198Pt (7.2%) was clearly observed for each of these dominant 
species, with the heights of the Pt peaks clearly represented the isotopic abundances which 
are shown in brackets above. The peak at m/z 365 was present in the majority of mass 
spectra, but could not be assigned and did not exhibit the characteristic Pt isotopic pattern, 
indicating that it did not correspond to a Pt containing species. Since the peak was present 
in mass spectra containing oxaliplatin only, it was attributed to an impurity or ingredient 
present in the drug. The Pt species at m/z 420 was thought to be a Na adduct of the 
oxaliplatin drug, whilst the remaining two species were initially thought to be the parent 
oxaliplatin ion (195Pt m/z 398) and the diaminocyclohexane platinum complex (195Pt m/z 
308). To confirm the two latter assumptions, the identity of the peaks at m/z 398 and       
m/z 308 were confirmed using MS/MS. The principles of tandem and multiple mass 
spectrometry were detailed in Chapter 1. Briefly, the ions of interest were selected and thus 
‘trapped’ within the quadrupole, whilst all other ions were ejected from the ion trap. 
Fragmentation was then induced by bombarding the selected parent ions with He collision 
gas. The resulting product ions were then scanned out of the quadrupole ion trap and 
detected to produce a MS/MS spectrum, which helped reveal the identity of the adducts. A 
further mass spectrometry experiment was sometimes possible (MS3) providing the ion 
signal was of sufficient intensity, which helped further confirm the identity of the species.  
 
The MS/MS spectrum of the parent ion (m/z 398) is shown in Figure 4:2. Note that the 
spectrum in Figure 4:2 was obtained using a peak isolation width of 10 Da; hence all the 
peaks ± 5 mass units from m/z 398 were selected and fragmented to give numerous product 
ions. As a result, the Pt isotopic pattern was observed for all product ions. 
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Figure 4:2: MS/MS spectrum of product ions obtained by CID of the oxaliplatin parent ion at m/z 398, 
collision energy = 20 eV, isolation width =10 Da.  
 
Figure 4:2 shows three main fragmentation product ions at m/z 308, 336 and 354. 
Unfortunately, since the ion signal was quite weak, further MS experiments could not 
carried out on these product ions. However, an attempt was made at identifying the 
molecular structure of the dominant product ions, as seen in Figure 4:2. It was thought that 
the isotopic peaks around m/z 354 corresponded to the parent ion minus a mass of 44, 
which equated to a loss of CO2 from the oxalate ligand. A mass loss of 62 was also 
observed to give product ions at m/z 336, which were attributed to the loss of CO2 + H2O, 
again from the oxalate ligand. The final product ions around m/z 308 corresponded to the 
diaminocyclohexane platinum (Pt-dach) complex, which is effectively oxaliplatin minus 
the oxalate leaving group. The structures shown in Figure 4:2 are thought to be the most 
rational, but were not definitively proven.  
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The three main isotopes of the oxaliplatin parent ion at m/z 397, 398 and 399 were then 
fragmented with a peak isolation width of 1 Da (peaks within ± 0.5 mass units of the ion of 
interest were selected and fragmented), the ion tree in Figure 4:3 summarises the product 
ions formed upon fragmenting each of the isotopic parent ions. The mass spectra from these 
experiments can be seen in Figure 9:1-Figure 9:3 in Appendix 2.1 (Section 9.1). 
 
Figure 4:3: Oxaliplatin fragmentation ion tree. 
 
As stated previously, oxaliplatin loses the oxalate ligand prior to nucleobase binding to 
form the Pt-dach species at m/z 308 (195Pt). Therefore, it was expected that the peaks 
corresponding to the Pt-dach species (m/z 308) and oxaliplatin parent ion (m/z 398) would 
be observed in all further mass spectra containing the drug.  
 
4.3.2 Evidence of Adduct Formation 
Upon infusing the oxaliplatin solutions containing individual nucleobase (oxaliplatin 
solutions 1-4, refer to Table 4:2), it was established that the drug formed both mono-
adducts (oxaliplatin bound to one nucleobase) and di-adducts (oxaliplatin bound to two 
nucleobases) with all four nucleobases, when present individually in solution. In all four 
mono-base solutions the complexes were formed at the expected mass-to-charge ratios and 
the identity of each species was further confirmed by performing multiple MS experiments 
on the ions of interest.  
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The mass spectra of each sample exhibited a cluster of ions around m/z 398 and 308; as 
discussed above, these isotopic peaks corresponded to the whole oxaliplatin complex and 
the Pt-dach species respectively. Table 4:3 summarises the mass-to-charge ratios of the 
194Pt containing ions observed in each of the oxaliplatin solutions. Although the masses in 
Table 4:3 refer to the 194Pt isotopic species, the Pt isotopic pattern was clearly observed for 
all adducts, further confirming the binding of the drug to the individual bases. For 
clarification the fragmentation of the 194Pt adducts will be discussed, although the same 
principles apply to the 195 and 196 Pt complexes.   
Table 4:3: Oxaliplatin adducts formed with individual DNA nucleobases. 
Ion m/z 
Adenine-oxaliplatin solution   
[adenine-H]+ 136 
194Pt(adenine)+ 442 
194Pt(adenine)2
+ 577 
Cytosine-oxaliplatin solution  
[cytosine-H]+ 112 
194Pt(cytosine)+ 418 
194Pt(cytosine)2
+ 529 
Guanine-oxaliplatin solution  
[guanine-H]+ 152 
194Pt(guanine)+ 458 
194Pt(guanine)2
+ 609 
Thymine-oxaliplatin solution  
[thymine-H]+ 127 
194Pt(thymine)+ 433 
194Pt(thymine)2
+ 559 
 
Each oxaliplatin-nucleobase di-adduct lost a neutral nucleobase upon CID, resulting in the 
formation of mono-adducts at the expected m/z. Fragmentation of the mono-adducts 
resulted in the loss of H2 and ammonia. The de-protonated ions were signified by product 
ions with m/z two and four mass units lower than the parent ion, suggesting successive 
loses of H2 from the complex. Such loses of neutral H2 molecules during CID has been 
reported elsewhere,191, 192 although the reported fragmentation occurred on Ag complexes 
as opposed to Pt complexes. The de-protonated mono-adducts further fragmented to lose a 
neutral base, thus numerous species around m/z 307 were observed. In addition, product 
ions having a mass difference of 17 were observed, which is consistent with ammonia 
removal. The fragmented H2 and ammonia could have originated from either the dach 
ligand or the nucleobases. The exact origin of these fragmented species cannot be 
definitively established. Finally, the neutral base was also removed from the mono-adducts 
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during CID to produce the free Pt-dach complex at m/z 307, as shown in Figure 4:4. The 
mass spectra, suggested structures and fragmentation pathways for each oxaliplatin-
nucleobase adduct are shown in Figure 4:4-Figure 4:11, where the species derived from 
194Pt are shown. The fragmentation pathways and structures shown are thought to be the 
most rational, but are not definitive.  
 
4.3.2.1 Oxaliplatin-Adenine Adduct Fragmentation 
Figure 4:4 shows the MS/MS spectra of both the mono and di- adducts of adenine, where 
the main peaks have been labelled with the proposed species. Figure 4:4 was derived from 
the 194Pt parent species only, thus the Pt isotopic pattern was not observed for the parent 
ion. In addition, because only one isotope was selected for CID, only one product ion 
isotope was observed and not the whole suite of Pt isotopes.  
 
Adenine base was lost from the di-adduct at m/z 577 upon CID to yield the mono-adduct at 
m/z 442 (see Figure 4:4a). The 194Pt-A adduct at m/z 442 fragmented further to give a 
dominant product ion at m/z 440, indicating the loss of H2 (see Figure 4:4b). The ions at m/z 
423 and 305 (Figure 4:4b) were thought to coincide with the loss of ammonia and adenine 
from the dominant product ion at m/z 440 respectively. The fragmentation pathway of 
oxaliplatin-adenine adducts is summarised in Figure 4:5; very similar schemes were 
observed for the remaining three oxaliplatin-nucleobase adducts. The structures in Figure 
4:5 show the Pt atom interacting with the N7 position of the adenine base (refer to Chapter 
1 for purine and pyrimidine ring numbering system), which is the most likely position due 
to its high nucleophilicity.151, 164, 183 However, the exact position of oxaliplatin-adenine 
interaction was not confirmed here and the structures shown are thought to be the most 
rational. The full scan mass spectrum of the oxaliplatin-adenine mono-base solution is 
shown in Figure 9:4 (Appendix 2.2). The mass spectra showing the fragmentation of the 
195 and 196 Pt-AA and Pt-A species are shown in Figure 9:5-Figure 9:8 in Appendix 2.2. 
In addition, the MS3 spectrum of the 195Pt-AA adduct is illustrated in Figure 9:9. These 
spectra were used to establish the fragmentation pathways illustrated in Figure 4:5. 
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Figure 4:4: MS/MS spectrum of product ions obtained by CID of: a) 
194
Pt-AA adduct at m/z 577, 
collision energy = 20 eV, isolation width = 1 Da. b) 
194
Pt-A adduct at m/z 442, collision energy = 20 eV, 
isolation width = 1 Da. 
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Figure 4:5: Proposed fragmentation pathway for 
194
Pt-adenine adducts. 
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4.3.2.2 Oxaliplatin-Guanine Adduct Fragmentation 
The 194Pt-GG ion at m/z 609 was selected and fragmented to give the 194Pt-G product ion at 
m/z 458, indicating the loss of guanine. Further fragmentation of the m/z 458 ion resulted in 
product ions, which are shown in the MS3 spectrum in Figure 4:6. It should again be noted 
that the guanine mono-adduct fragmented to produce many product ions, but the most 
dominant was that at m/z 456, resulting from the mono-adduct losing H2. The summarised 
fragmentation pathway and suggested product ion structures are shown in Figure 4:7. 
Figure 9:11-Figure 9:17 in Appendix 2.2 show the spectra corresponding to the full scan 
mass spectrum of the guanine mono-base solution, the MS/MS and MS3 spectra 
corresponding to the 195 and 196 Pt-GG and Pt-G adducts.  
 
As in the case of adenine, Figure 4:7 shows oxaliplatin forming adducts with the N7 
position of guanine, which is thought to be the most likely site of drug interaction.151, 164 In 
addition, the guanine oxygen atom is also shown to be interacting with the Pt centre via a 
dative bond. It has been reported that cis-[Pt(NH3)2]
2+ complexes such as cisplatin interact 
with both the N7 and oxygen atom on guanine, which subsequently disrupts GC base 
pairing in double stranded DNA.193 Considering both cisplatin and oxaliplatin behave 
similarly with DNA and proteins, it is not unrealistic to suspect that oxaliplatin also forms a 
dative bond with the oxygen atom on guanine as shown in Figure 4:7. 
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Figure 4:6: MS
3 
spectrum of product ions obtained by CID of the 
194
Pt-G adduct at m/z 458, which was 
obtained through CID of the 
194
Pt-GG ion at m/z 609.
 
Collision energy = 15 eV, isolation width = 1 Da. 
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Figure 4:7: Fragmentation pathway of oxaliplatin-guanine adducts. 
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4.3.2.3 Oxaliplatin-Thymine Adduct Fragmentation 
Fragmentation data was obtained only for the thymine mono-adduct, since the di-adduct 
(m/z 560) was present at very low levels and the signal for this ion was not sufficient to 
perform MSn experiments. It has already been suggested that oxaliplatin preferentially 
interacts with purine bases and this data suggests that the drug has a particularly low 
affinity for thymine, resulting in the very low abundance of the di-adduct. Figure 4:8 shows 
that the 194Pt-T ion at m/z 433 fragmented to give a dominant product ion at m/z 429, which 
is consistent with the removal of 2H2 from the mono-adduct. This is in contrast to the other 
three nucleobase adducts, which fragmented to form a dominant product ion with two less 
protons.  
 
Figure 4:9 shows the proposed structures and fragmentation pathway, whilst the spectra 
corresponding to full scan mass spectrum of the oxaliplatin-thymine solution and CID of 
the 195 and 196Pt-T adducts are in Appendix 2.2, Figure 9:18-Figure 9:20. There was very 
little reported in the literature regarding the co-ordination site of Pt drugs with thymine, 
presumably because these drugs do not readily interact with the pyrimidine bases. The Pt 
co-ordination site shown in Figure 4:9 is donated the N1 position. If the thymine was in the 
form of a nucleotide (i.e. bound to deoxyribose sugar), it would bind to the sugar through 
the N1 nitrogen atom (see Chapter 1 for nucleotide structures). However, since thymine is 
present without the sugar, the N1 position is the most nucleophilic, hence the most likely 
place for Pt co-ordination. Conversely, the other nitrogen atom in the thymine ring (N3) is 
adjacent to two carbonyl groups, which are highly electronegative and may result in the 
lone pair electrons on the N3 nitrogen atom being less available than those at the N1 
position. 
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Figure 4:8: MS/MS spectrum of product ions obtained from CID of the 
194
Pt-T adduct at m/z 433, 
collision energy = 20 eV, isolation width =1 Da. 
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Figure 4:9: Fragmentation pathway for oxaliplatin-thymine adducts. 
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4.3.2.4 Oxaliplatin-Cytosine Adduct Fragmentation 
Up until now discussions on adduct fragmentation have concentrated on the 194Pt species, 
however, the 195Pt species will be employed for the cytosine discussions to illustrate how 
all the Pt isotopic species behaved the same during CID. The MS/MS spectra for the mono 
and di-adduct are shown in Figure 4:10. Note, the spectrum in Figure 4:10a was obtained 
with an isolation width of 10 Da, thus all the parent ions ±5 mass units of m/z 530 would 
have been selected for MS/MS analysis, hence the presence of the ion at m/z 531. The 
cluster of ions around m/z 525 is most likely a result of proton removal from the various 
cytosine di-adducts during CID, with m/z 525 being the most abundant. The summarised 
fragmentation pathway and suggested structures are shown in Figure 4:11. The spectra 
corresponding to the full scan and tandem MS of the 196Pt-C and 195Pt-CC species are 
shown in Appendix 2.2, Figure 9:21-Figure 9:23. The structures shown in Figure 4:11 show 
the oxaliplatin co-ordinating to cytosine through the N3 position in addition to the oxygen 
atom. The N3 position is nucleophillic making it a likely co-ordination site for Pt. In 
addition, it has been reported that trans-Pt species can co-ordinate to cytosine through the 
N3 atom,194 as can cisplatin.183 
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Figure 4:10: MS/MS spectrum of product ions obtained by CID of: a) 
195
Pt-CC adduct at m/z 530, 
collision energy = 10 eV, isolation width = 10 Da.  b) 
195
Pt-C ion at m/z 419, collision energy = 20 eV, 
isolation width = 1 Da. 
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Figure 4:11: Fragmentation pathway of the oxaliplatin-cytosine adducts. 
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4.3.2.5 Branching Diagrams 
The successive loss of H2, ammonia and neutral nucleobases from the oxaliplatin adducts 
has been illustrated in Figure 4:4-Figure 4:11. Only small abundances of the protonated 
nucleobases were observed in the mass spectra upon CID, which was attributed to the 
nucleobases fragmenting to preferentially form neutral species. More importantly, this 
behaviour was consistent for all four nucleobase adducts. In addition to the product ions 
discussed above, numerous hydrated complexes of adenine and guanine were observed. It 
is known that Pt(II) complexes are more stable when co-ordinated to four ligands to 
produce square planar geometries. The reasons for this are well known and are discussed 
elsewhere.138 Thus, the formation of the mono-adducts gives the Pt atom a co-ordination of 
three, prompting the addition of a fourth ligand such as water to the Pt centre, creating a 
stable square planar complex. Since guanine preferentially binds to the drug, followed by 
adenine the complexes, [Pt(dach)G(H2O)]
+ and [Pt(dach)A(H2O)]
+ were evident in the 
spectra, whilst the hydrated complexes of cytosine and thymine were less evident due to the 
much lower affinities of these nucleobases to oxaliplatin.  
 
The branching diagrams in Figure 4:12 summarise the main adduct fragmentation, where 
the hydrated adenine and guanine fragments are included. The spectra showing the 
fragmentation of the three dominant Pt-G(H2O) species are shown in Appendix 2.2, Figure 
9:24-Figure 9:26. In each case the hydrated adduct was selected with isolation width of 1 
Da and fragmented to produce the corresponding Pt-G ion, which was selected and 
fragmented further in a MS3 experiment to produce many product ions characteristic of the 
Pt-G species that were discussed above for the guanine mono-base solution. Unfortunately, 
tandem MS was not conducted on the Pt-A(H2O) species at m/z 460, thus the identity of 
this species could not be definitively proven and no product ions are indicated. Note that 
the three dominant Pt isotopic species are included in Figure 4:12 to further show how all 
three isotopic complexes behaved similarly.  
 
It should be noted that Figure 4:12 shows a range of Pt-dach species, covering a mass range 
of approximately 4 Da that were formed upon fragmenting the mono-adducts. The range of 
Pt-dach masses were a consequence of proton loss from the mono-adducts. Each mono-
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adduct lost between two and six protons upon CID to form various deprotonated mono-base 
adducts. These deprotonated mono-adducts then fragmented further, losing the nucleobase 
to produce several deprotonated Pt-dach species. This effect was illustrated in the 
fragmentation pathways in Figure 4:5, Figure 4:7, Figure 4:9 and Figure 4:11 above.  
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Figure 4:12: Branching diagrams summarising the fragmentation of oxaliplatin nucleobase adducts.
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4.3.3 Isobaric Interferences 
Until now 194Pt species have been primarily used as examples when discussing 
fragmentation pathways, the reason being to simplify the discussions by concentrating 
on one isotope. In addition these species were mainly free from isobaric interferences, 
which are inevitable in these situations where complex spectra with multiple isotopes 
are being analysed. However, serious isobaric overlaps did occur between some species 
and are discussed here. Such interferences could have resulted in misinterpretation of 
mass spectra and therefore incorrect fragmentation pathways being constructed.  
 
The first such interference occurred between the 194Pt-A(H2O) and 
196Pt-G complexes, 
which both have the same nominal mass of 460. Evidence of the 194Pt-A(H2O) species 
interfering with the 196Pt-G complex during single stage mass spectrometry can be seen 
in Figure 4:13, which shows a mass spectrum of the solution containing all four bases in 
the presence of excess drug. Figure 4:13 clearly shows the isotopes of the Pt-G species 
around m/z 459. The dominant guanine mono-adduct contained 195Pt, suggesting that 
195Pt-G at m/z 459 should be most abundant of all the Pt-G ions. However, from Figure 
4:13 the dominant ion was m/z 460, which corresponds to 196Pt-G. This can be 
explained since the 194Pt-A(H2O) ion, which also occurs at m/z 460 was contributing to 
the 196Pt-G signal, causing this peak to be larger than expected. This isobaric 
interference was observed in Figure 4:13 since the sample contained all four bases. In 
the absence of adenine, three main peaks at m/z 458, 459 and 460 were observed, 
corresponding to 194Pt-G, 195Pt-G and 196Pt-G respectively. See Figure 4:14, which 
shows that the relative abundance of the 458 and 460 peaks were roughly equal, whilst 
the 459 peak was dominant as expected. Likewise, in the absence of guanine, the 
oxaliplatin-adenine solution displayed isotopic peaks around m/z 461, again with the 
most abundant peak at m/z 461 due to the presence of the dominant 195Pt isotope. Refer 
to Figure 9:4 in Appendix 2.2 for the full scan mass spectrum of the oxaliplatin-adenine 
mono-base solution. As already stated, tandem MS was not carried out on the              
Pt-A(H2O) complexes, thus the observed species in Figure 4:13 were not investigated 
further.   
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Figure 4:13: Mass spectrum of product ions from the oxaliplatin solution containing all four 
nucleobases and an excess of drug, with the Pt-G and Pt-A(H2O) isotopes labelled. 
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Figure 4:14: Mass spectrum (expanded scale) of product ions obtained from the oxaliplatin-guanine 
mono-base solution, showing the Pt-G and Pt-G(H2O) isotopes. 
 
Such interferences were also possible with the 196Pt-C and [194Pt(dach)(C2O4)]Na
+ drug 
adduct, both of which occur at the nominal mass of 420. The full scan mass spectrum of 
oxaliplatin in the absence of nucleobase is shown in Figure 4:1, where isotopic peaks 
around m/z 420 are clearly visible and where thought to correspond to the oxaliplatin-
Na+ adduct. However, these species were not investigated further by tandem mass 
spectrometry.  
 
Figure 9:22 in Appendix 2.2 shows the mass spectrum resulting from MS/MS of the 
196Pt-C adduct. The mass spectrum clearly shows the mono-adduct losing H2 (product 
ions at m/z 416 and 418) and cytosine base (product ions at m/z 305, 307 and 309). 
These observations are consistent with the fragmentation pathways shown in Figure 
4:11 and Figure 4:12, and suggest that although the 196Pt-C and [194Pt(dach)(C2O4)]Na
+ 
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species have the same nominal mass, the spectrum and fragmentation pathway of the 
196Pt-C adduct can still be studied without interference from the oxaliplatin-Na+ adduct. 
 
4.3.4 Oxaliplatin Binding in the Presence of all Four Nucleobases 
Once it was confirmed that each base formed adducts with the drug, the solutions 
containing oxaliplatin together with all four bases were analysed. The full positive ion 
scan of the solution containing adenine, cytosine, guanine, thymine and oxaliplatin all at 
near equal molar concentrations is shown in Figure 4:15. The adducts corresponding to 
mono-adenine oxaliplatin (194Pt-A m/z 442), mono-guanine oxaliplatin (194Pt-G m/z 
458) and the mono cytosine adduct (194Pt-C m/z 418) were all observed in the mass 
spectrum shown in Figure 4:15. Initially the mono-adduct of thymine was thought to be 
absent from the spectrum, so tandem MS was not carried out on this species. However, 
later expansion of the full scan mass spectrum showed that the mono thymine adduct 
(194Pt-T m/z 434) was present, but only at very low levels. It should therefore be noted 
that Appendix 2.3 does not include tandem MS data for the Pt-T species. The di-adducts 
of adenine (194Pt-AA) and guanine (194Pt-GG) were also observed at m/z 577 and 609 
respectively. In addition, the di-adduct containing both adenine and guanine (194Pt-AG 
m/z 593) was also present. The identity of each adduct was again confirmed using 
multiple stage MS, refer to Figure 9:27-Figure 9:41 in Appendix 2.3 for all spectra 
corresponding to the fragmentation of the species observed in Figure 4:15. Various 
other peaks corresponding to unbound adenine, cytosine, guanine and thymine at       
m/z 136, 112, 152, 127 respectively were also observed. Peaks corresponding to 194Pt-
dach (m/z 307), mono-solvated Pt-dach ([194Pt dach(H2O)]
+ m/z 324) and oxaliplatin 
(m/z 398) were also present in solution as expected. 
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Figure 4:15: Full scan mass spectrum of the oxaliplatin solution containing A, C, G and T. The 
oxaliplatin was present in a near equal molar concentration to each of the bases. 
 
Despite the abundance of adducts formed in the above solution, there were many 
adducts that were absent in the mixed nucleobase solution, but present in the individual 
nucleobase solutions. The absent adducts included the di-adducts of cytosine (Pt-CC 
m/z 529) and thymine (Pt-TT m/z 560). In addition, adducts corresponding to the mixed 
cytosine and thymine di-adducts were also absent. In summary, these results show when 
all four nucleobases were present in solution at near equi-molar concentration to the 
drug, oxaliplatin preferentially bound to guanine and adenine, as reported in the 
literature, cytosine formed adducts with oxaliplatin to a lesser extent, whilst the yield of 
thymine adducts was minimal.  
 
Cytosine and thymine oxaliplatin adducts were clearly observed from mixed base 
solutions, but only when the drug was present in a large molar excess in relation to the 
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nucleobases. Figure 4:16 shows the full scan mass spectrum of the drug solution which 
contained all four nucleobases in the presence of excess drug.  
 
Figure 4:16: Full scan mass spectrum of oxaliplatin solution containing excess drug with all four 
nucleobases. 
 
Numerous species were again present in the mass spectrum. Peaks at m/z 112 and 127 
corresponding to unbound cytosine and thymine respectively were again observed. 
Unbound adenine and guanine were also present at m/z 136 and 152 respectively, but 
the signals for these two species were very much weaker. The weaker adenine and 
guanine signals may be another indicator of the stronger binding of these bases to the 
drug. Alternatively, the degree of ionisation of adenine and guanine may have been 
lower than that of thymine and cytosine, resulting in a weaker signal for these two bases 
(although there was no evidence to support this in the other spectra).  
 
Mono-adducts corresponding to Pt-A (m/z 442), Pt-C (m/z 419), Pt-G (m/z 458) and    
Pt-T (m/z 433) were observed, as shown in Figure 4:16, but in contrast to equi-molar 
drug conditions, no di-adducts were evident. It has already been discussed that the 
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stepwise formation constants (Kn) generally decreases in the order K1>K2>K3>….Kn 
(where the subscript numbers represent the increasing ligand number) with successive 
ligand binding to a given metal.138 Thus, the addition of subsequent ligands onto a metal 
becomes less favourable; there are several reasons for this effect. Firstly, steric 
hindrance may make it difficult for more than one ligand to bind to the metal. Secondly, 
as more ligands bind to a metal centre, the charge density of the metal decreases, hence, 
subsequent ligands have reduced affinity. Finally, both the number of available 
coordination sites (balanced by metals exhibiting a preferred coordination number) and 
free ligand concentration are reduced with each successive binding.138 There are 
exceptions to these rules where structural changes to the co-ordination complex may 
increase subsequent formation constants.138 The data presented in Figure 4:16 
confirmed the general rules, when oxaliplatin was present in excess of the nucleobases, 
the drug preferentially bound to the minimum number of bases, which was one per drug 
molecule. The identity of the mono-adducts observed in Figure 4:16 was again 
confirmed with tandem mass spectrometry; the corresponding spectra are shown in 
Figure 9:42-Figure 9:47 in Appendix 2.4 and show how each of the mono-adduct 
species fragmented to produce the free drug along with numerous products consistent 
with the loss of protons and ammonia. The fragmentation pathways were similar to 
those outlined in Figure 4:12. 
 
4.3.5 Preferential Binding Studies 
The preferential binding of oxaliplatin with adenine and guanine was further 
investigated. The solution containing oxaliplatin with adenine and guanine only was 
infused into the mass spectrometer. The full scan MS of this sample is shown in Figure 
4:17. The di-adduct containing both adenine and guanine (Pt-AG) was selected and 
fragmented with increasing collision energies. The relative intensities of the parent ion 
(Pt-AG) and product ions (Pt-G and Pt-A) were recorded with every 1 eV increase in 
collision energy between 0-30 eV. The branching diagram of the oxaliplatin solution 
containing adenine and guanine is illustrated in Figure 4:18, where the 194Pt isotopic 
species was used to illustrate the fragmentation of the mixed di-adduct. The mass 
spectra showing the tandem MS of the mixed base di-adduct are shown in Figure 9:48-
Figure 9:52 in Appendix 2.4. Further, Figure 9:48-Figure 9:52 show how the mixed 
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base di-adduct fragmented to produce two distinct product ions, further MS3 
experiments on the product ions to confirm the presence of adenine and guanine.  
 
The 195Pt species was used during the experiment, since it was the most abundant and 
gave the largest signal intensity. Thus the 195Pt-AG (m/z 594), 195Pt-G (m/z 459) and 
195Pt-A (m/z 443) species were monitored when applying the increasing collision 
energies. The aim of this experiment was to establish the preferential binding and 
affinity of adenine and guanine to the drug.  
 
Figure 4:17: Full positive ion scan of the adenine, guanine and oxaliplatin solution. 
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Figure 4:18: Branching diagram summarising the fragmentation of the Pt-AG adduct. 
 
Upon increasing collision energy, the relative intensities of the product ions at m/z 459 
and 443 increased, whilst the parent ion (m/z 594) intensity decreased as expected. 
However, the relative intensities of the two product ions were not equal; the Pt-G 
product (m/z 459) was more abundant than the Pt-A (m/z 443) ion. Thus, guanine 
appeared to bind more strongly to the drug, whilst the adenine base was more likely to 
fragment. Figure 4:19 shows the relative intensities of all three ions during each 1 eV 
increase in collision energy. Note that the parent ion was the most abundant ion up until 
~20 eV, thus the x axis on Figure 4:19 only starts from 15 eV.  
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Figure 4:19: Relative signal intensities of the Pt-AG adduct (m/z 594) and the product ions, Pt-G 
(m/z 459) and Pt-A (m/z 443) during increasing collision energies. 
  
Figure 4:19 clearly illustrates that at lower collision energies (<20 eV), the Pt-AG 
adduct (m/z 594) was the dominant species, but above this collision energy, the di-
adduct parent ion fragmented to form two mono-adduct product ions (Pt-G and Pt-A). 
 
Following the fragmentation of the Pt-AG adduct to form the Pt-A and Pt-G adducts, 
MS3 experiments were conducted, where the 195Pt-G ion was selected and fragmented 
with increasing increments of collision energy (1 eV increments) and the formation of 
the free drug (Pt-dach) and guanine base were monitored. The same was carried out on 
the 195Pt-A product ion. From these two sets of data (not shown), adenine fragmented 
from the drug at ~13 eV and guanine at 15 eV, again confirming that guanine had 
greater affinity for oxaliplatin compared to adenine. Virtually no peaks corresponding to 
unbound adenine and guanine bases were observed during the above mass spectrometry 
analyses, again suggesting that the unbound bases fragmented as neutral species.   
 
The experiment discussed above was only applied to the Pt-AG adduct and its 
corresponding product ions. A further area of research would be to conduct similar 
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studies on the other oxaliplatin adducts and compare the various nucleobase binding 
energies. 
 
4.4 Summary 
Oxaliplatin-nucleobase interactions have been studied using ESI-MSn. It was shown that 
oxaliplatin formed adducts with all four nucleobases when present individually in 
solution. Multiple stage ESI-MS data revealed successive losses of H2, ammonia and 
nucleobase from each of the adducts. The MSn data enabled detailed fragmentation 
pathways to be established for each oxaliplatin-nucleobase species and proposed 
structures for each product ion were presented, demonstrating the ease and versatility of 
ESI-MS for the study of drug-DNA interactions. 
 
The preferential binding of oxaliplatin to adenine and guanine was also verified by the 
small proportion of cytosine and thymine adducts formed in the mixed base solution. 
However, mono-adducts of all four bases were clearly observed when the drug was 
present in excess of all four bases. This follows the expected pattern of mono-
substitution being favoured over di-substitution and a reduction in successive formation 
constants. Further evidence of preferential adenine and guanine binding was shown 
when fragmenting the Pt-AG adduct. Two product ions corresponding to Pt-A and Pt-G 
were produced, however, the product corresponding to Pt-G was always dominant 
compared to Pt-A, suggesting that guanine remains attached to the metal, whilst adenine 
preferentially fragments, thus demonstrating that guanine has a greater affinity for the 
drug.  
 
It has been illustrated that linear ion trap ESI-MS can be employed for investigating 
oxaliplatin-DNA interactions. However, it should be noted that this study was 
conducted on free nucleobases as oppose to oligonucleotides or intact genomic DNA. 
Factors such as steric restraints may well effect oxaliplatin interactions with 
nucleobases incorporated in the DNA molecule. The next step would be to conduct 
these experiments on oxaliplatin treated oligonucleotides or genomic DNA and 
establish whether drug-base affinity is the same as discussed above. Detailed structural 
information can be revealed in relatively short periods of time, although confirmation of 
256 
structure still requires use of other techniques such NMR, crystallography or 
computational methods. 
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5 Anion Exchange HPLC-ICP-MS of Single 
Nucleotide Polymorphisms (SNPs) 
 
5.1 Introduction 
Previous chapters have demonstrated how the ICP-MS signal of DNA can be enhanced 
by means of metal nano-particle labelling, or by Pt adducts in the case of cisplatin and 
oxaliplatin treated DNA. This chapter illustrates how ICP-MS can be used to detect 
DNA by measuring the P associated with the sugar-phosphate backbone. A HPLC 
separation method was developed for separating nucleic acids which differ only by one 
nucleobase. The HPLC was then coupled to an ICP-MS to allow for on-line separation 
and element specific detection. The HPLC separation method was used in conjunction 
with P ICP-MS detection methods, developed by Peter Winship in the Analytical 
Atomic Spectroscopy Research Group as part of his PhD thesis.179 This chapter 
demonstrates the ease of coupling chromatographic systems to ICP-MS instruments and 
also the limitations of P detection by quadrupole ICP-MS. 
 
Single nucleotide polymorphisms (SNPs) are defined as a single incorrect nucleobase 
insertion into a gene sequence. Such errors are usually harmless and can occur in coding 
and non-coding regions of the genome. SNPs are the most common genetic variation 
and are utilised in evolution studies and population genetics.195 However, certain 
polymorphisms can cause serious genetic diseases.196 In addition, the way individuals 
react towards pharmaceuticals is sometimes determined by a certain SNP. As a result, 
the study of SNPs is of great interest to medicine and pharmaceutical research.195-197 
The ability to identify SNPs and use them as a diagnostic tool for disease, tailoring 
drugs to suit people with a certain polymorphisms and to predict how people with 
certain SNP will react to a drug is a desirable goal.195-197   
 
Two different 25 base length oligonucleotides (25 mers) were employed in this study. 
The oligonucleotides differed in base sequence by a single base thus mimicking a SNP. 
A method of separating the oligonucleotides by anion exchange HPLC coupled to ICP-
MS is detailed, although numerous publications have reported on similar hyphenated 
techniques.1, 32, 60, 198, 199 The HPLC system used in this study was complete with UV 
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absorption detection, thus the eluting oligonucleotides were detected due to the 
chromophores associated with the bases. In addition the ICP-MS detected the eluting 
nucleic acids by P which is contained in the sugar phosphate back bone. Two methods 
of P measurement were investigated; collision cell technology (CCT) with oxygen 
reaction gas and a cool plasma method. Collision/reaction cell methods of P 
measurement have been extensively studied using either O2 
9, 10, 52, 59 or He 1, 61, 62 
reaction gases, these methods were discussed in detail in Chapter 1. To our knowledge 
this is the first time the cool plasma method has been employed for P determinations in 
conjunction with nucleic acids. Both UV absorption and elemental mass spectrometry 
data were obtained during the chromatographic separations. Both sets of data confirmed 
that the oligonucleotides could be resolved on an anion exchange column. 
 
5.2 Instrumentation and Reagents 
The oligonucleotide 25 mers used in this part of the investigation were obtained from 
Invitrogen (Paisley, UK), the sequences are shown in Table 5:1 and are denoted 
unmodified 25 mers 1 and 2. The oligonucleotides were not modified with any 
additional functional groups and were diluted in 20 mM Tris-HCl buffer at pH 9 to a 
concentration of 10 µM.  
Table 5:1: Oligonucleotide Base Sequences. 
Oligonucleotide Sequence (5’→3’) 
Backbone 
Molecular Weight 
Unmodified 25 mer 1 TGA AGA AAT TCA GTT CAT AGC TTG T 7696 
Unmodified 25 mer 2 TGA AGA AAT TCA GTT CAT AGC TTG G 7721 
 
The stationary phase was a TSKgel-DNA-NPR analytical column (7.5 cm x 4.6 mm) 
and was obtained from Tosoh Bioscience (Stuttgart, Germany). Tetramethylammonium 
hydroxide (TMAH) was from Apollo Scientific (Stockport, Cheshire). Citric acid (free 
acid) and tris base was obtained from Sigma Aldrich. Ammonium chloride was obtained 
from Fluka (Buchs, Switerland). Hydrochloric acid (super pure acid grade) was from 
Romil (Cambridge, UK). Oxygen gas (99.999% purity) was obtained from BOC 
(Sussex, UK). 
 
A PQ ExCell ICP-MS instrument (Thermo Electron Corporation, Winsford, Cheshire) 
complete with a quadrupole mass filter and collision cell technology (CCT) was used 
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for the chromatographic detection of SNPs. The torch position and ion optics were 
tuned daily with 115In to obtain maximum sensitivity and stability. Both methods of P 
detection resulted in the formation of 31P16O+ at m/z 47 as discussed in Chapter 1. 
 
An Agilent HP 1090 series 2 HPLC system (Agilent Technologies, Waldbronn, 
Germany) was employed for all separations. The instrument was equipped with a 
variable wavelength UV detector (Applied Biosystems) and HP3396A integrator 
(Hewlett Packard), which was employed for the acquisition of UV data. The same 
mobile phases and chromatographic conditions were used for both methods of P 
detection and are summarised in Table 5:2. 
Table 5:2: HPLC parameters for the separation of SNPs. 
Parameter Setting 
Stationary Phase TSKgel-DNA-NPR, 7.5 cm x 4.6 mm, 2.5µm particle size 
Mobile phase A= 20 mM Tris-HCl, pH 9 
B= 20 mM Tris + 0.3 M Citrate + 0.1 M NH4Cl, pH 9 
Flow rate 0.7 ml min-1 
Injection Volume 5 µl 
Wavelength 257 nm 
Gradient  Time (min)           % B 
      0                       40 
    15                      100 
    20                      100 
Stop time 20 minutes 
Post time 4 minutes 
 
The UV detector outlet was connected directly to the back of a 1 ml min-1 Conikal 
nebuliser (Glass Expansions, Australia), using PEEK tubing. The HPLC eluent was not 
split post column as detailed in Chapter 2, but the entire column eluent entered the 
nebuliser. An impact bead spray chamber was also employed; the schematic in Figure 
5:1 illustrates the instrumental set-up. Any amendments to the chromatographic 
conditions will be stated where appropriate. The ICP-MS was operated in transient time 
resolved analysis (TRA) mode. 
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Figure 5:1: Schematic showing the HPLC and ICP-MS coupling. 
 
5.2.1 Collision Cell 
The first method investigated was that employing the CCT with O2 as the reaction gas, 
the ICP-MS operating conditions are summarised in Table 5:3. Note that the forward 
power was maintained at 1350 W, but O2 was bled into the collision cell to facilitate 
31P16O+ formation. 
Table 5:3: ICP-MS operating parameters for the collision cell method. 
Parameter Setting 
Gas Flows Cool = 12.8 l min-1 
Auxiliary = 0.80 l min-1 
Nebuliser = 1.0-1.2 l min-1 
Quadrupole bias + 1V 
Hexapole Bias  ~+ 7.5-8 V  
Forward Power 1350 W 
CCT O2 Flow  0.4 ml min
-1 
Nebuliser 1 ml min-1 glass conikal 
Spray Chamber Impact bead 
 
The formation of 31P16O+ and the removal of polyatomic interferences were discussed 
extensively in Chapter 1. It was noted that 47Ti could potentially interfere with the 
31P16O+ signal; however, it is unlikely that 47Ti would be present in the biological 
samples and Ti readily reacts with oxygen to form an oxide at a higher m/z ratio.9  
  Detector 
HPLC 
Waste 
Torch box 
Nebuliser 
Impact bead 
spray 
chamber 
Torch 
 Integrator 
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The Ion kinetic energy effect (IKEE) was implemented by adjusting the hexapole bias 
to 7.5-8 V. By applying a positive potential to the collision cell, the kinetic energy of 
the incoming plasma ions would be retarded, thus facilitating the reaction between 31P+ 
and O2 collision cell gas. The main P interferences at m/z 31 are 
1H14N16O and 15N16O 
(refer to Table 1:5). It was discussed in section 1.3.2.2 that these polyatomic species do 
not react with O2 due to such reactions being thermodynamically and/or kinetically 
unfavourable, thus these polyatomic species would not interfere with 31P16O+.9 For these 
reasons, kinetic energy discrimination (KED) was not implemented and the quadrupole 
was maintained at a lower potential to the collision cell (1 V).  
 
5.2.2 Cool Plasma 
The second method employed a ‘cool plasma’ for measuring P, which used a forward 
power of 800 W compared with 1350 W used in standard and collision cell mode. At 
this lower forward power the formation of 31P16O+ occurs in the plasma which can then 
be directly measured. The operating parameters for the cool plasma method were 
identical to those above (Table 5:3); however, the collision cell and O2 reaction gas was 
not used, and the forward power was decreased to 800 W. Since the collision cell was 
not in operation, the hexapole bias was at the default setting (-1.93V). 
 
5.3 Results 
5.3.1 Collision Cell 
Retention time markers containing either 25 mer 1 or and 25 mer 2 were injected first 
using the chromatographic conditions outlined in Table 5:2. The UV chromatogram 
corresponding to 25 mer 1 is shown in Figure 5:2, in which a retention time of 15.24 
minutes was observed. 
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Figure 5:2: UV chromatogram of 25 mer 1 (10 µM) eluted from a TSKgel-DNA-NPR column (7.5 
cm x 4.6 mm), 40%B at 0 mins, 100%B at 15 mins and 100% B at 20 mins, 0.7 ml min
-1
, 5 µl 
injection volume, 260 nm detection wavelength. 
 
Figure 5:3 shows both the UV and mass spectrometry data during the elution of 25 mer 
2. It should be noted that both sets of data were obtained during a single injection of the 
oligonucleotide. A retention time of 16.01 minutes was obtained for 25 mer 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15.24 min 
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Figure 5:3: a) UV Chromatogram corresponding to 25 mer 2 (10 µM), 260 nm detection 
wavelength. b) ICP-MS 
47
PO signal intensity during elution of 25 mer 2. Oligonucleotide eluted 
from a TSKgel-DNA-NPR column (7.5 cm x 4.6 mm), 40%B at 0 mins, 100%B at 15 mins and 
100% B at 20 mins, 0.7 ml min
-1
, 5 µl injection volume. 
 
 
 
a 
b 
16.01 min 
16.00 min 
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Once it was confirmed that the two 25 mer oligonucleotides had different retention 
times, a mixture containing the two 25 mers at equal concentrations (10 µM) was 
injected and eluted using the same gradient. Refer to Figure 5:4 for the UV and mass 
spectrometry data for the 25 mer mixture, which shows how the two oligonucleotides 
were successfully resolved by the separation method. Again the two sets of data shown 
in Figure 5:4 were obtained simultaneously during a single injection of the 
oligonucleotide mixture. 
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Figure 5:4: a) UV Chromatogram corresponding the oligonucleotide mixture containing 25 mer 1 
and 2, each at a concentration of 10 µM, 260 nm detection wavelength. b) ICP-MS 
47
PO signal 
intensity during elution of the oligonucleotide mixture, eluted from a TSKgel-DNA-NPR column 
(7.5 cm x 4.6 mm), 40%B at 0 mins, 100%B at 15 mins and 100% B at 20 mins, 0.7 ml min
-1
, 5 µl 
injection volume. 
 
a 
b 
15.18 min 
15.95 min 
15.16 min 
15.94 min 
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Note that the retention times of the oligonucleotides in the 31P16O chromatograms 
shown in Figure 5:3b and Figure 5:4b are slightly earlier than the retention times 
observed in the UV chromatograms, even though the UV detector was positioned before 
the ICP-MS. Since there was no communication between the HPLC and ICP-MS, the 
ICP-MS data acquisition was started manually upon injection of the samples, thus the 
retention times observed with ICP-MS may not be as accurate as the UV retention 
times.  
 
The resolution between the two oligonucleotide peaks was calculated for both sets of 
data shown in Figure 5:4 and compared. Equation 3 was used for calculating resolution: 
Equation 3: Peak resolution Rs = 2(trb-tra)/(Wa + Wb) 
Where: 
tr = retention time of oligonucleotide 
W = peak width 
Subscript a and b refers to the first and second eluted oligonucleotide respectively. 
 
            Peak resolution using UV data: 
Rs = 2(15.95 - 15.18)/(0.4 + 0.4) 
= 1.93 
         Peak resolution using MS data: 
Rs = 2(15.94 - 15.16)/(0.44 + 0.44) 
= 1.77 
The resolution values obtained for both sets of data were above 1.50, which suggests 
that the oligonucleotides were baseline resolved. Although the resolution for the ICP-
MS data was slightly lower than that of the UV data, the loss in resolution was not 
significant and baseline resolution was still observed in the 31P16O chromatogram.  
 
The UV and ICP chromatograms exhibited a rising baseline. In the UV chromatograms 
this was attributed to the residual absorbance of citrate increasing as the citrate 
concentration increased during the gradient elution. Since ICP-MS is an elemental 
detector, the rising baseline in the 31P16O chromatograms was thought to be caused by 
interferences at m/z 47. The cause of interferences at this m/z was likely to be due to 
nitrogen and carbon based polyatomic species such as; 1H14N16O16O, 15N16O16O, 
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13C18O16O, 12C18O16O1H and 15N14N18O resulting from the mobile phase.134 Mobile 
phase B contained Tris base, ammonium chloride and citrate, so by increasing the 
proportion of mobile phase B during the gradient elution, the amount of nitrogen and 
carbon was also increasing. As a result, carbon and nitrogen based polyatomic 
interferences at m/z 47 would have increased resulting in the rising baseline. Since KED 
was not implemented, both the 31P16O+ analyte and the interfering polyatomic species 
from the plasma would have been transmitted through to the quadrupole and thus 
detected. In an attempt to reduce this rising baseline, the gradient was modified (Table 
5:4) to use a lower percentage of mobile phase B, but the run time was extended to 30 
minutes to compensate for the weaker gradient. 
Table 5:4: Shallow gradient used for the HPLC-ICP-MS of SNPs, in an attenpt to reduce the rising 
baseline. 
Time (min) % B 
0 50 
30 80 
 
Figure 5:5 shows the UV chromatogram and 31P16O+ signal intensity during elution of 
the oligonucleotide mixture using the above shallow gradient. Retention times of 22 and 
24.40 minutes were observed in the UV data for 25 mers 1 and 2 respectively. The 
peaks were broad, but well resolved with a 2.4 minute time gap between them; this is a 
consequence of the longer retention time. The ICP-MS data shows retention times of 
22.16 and 24.71 minutes which coincides with the UV chromatogram. However, the 
peaks were less well defined above the baseline. Although, a 2.4 minute peak separation 
is observed in the UV chromatogram, the peaks were broader and the calculated 
resolution (calculated using equation 3) was 1.78 and 1.96 for the UV and ICP data 
respectively, which was comparable to that obtained with the 20 minute gradient 
observed in Figure 5:4. In addition, although a lower background was achieved with the 
shallow gradient, more pronounced peaks were observed with the original 20 minute 
gradient (see Table 5:2). After considering the above factors it was decided that there 
was no analytical benefit of using the shallow gradient. 
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Figure 5:5: a) UV Chromatogram corresponding to 25 mer 1 and 2 each at a concentration of 10 
µM, 260 nm detection wavelength. b) ICP-MS 
47
PO signal intensity during elution of 25 mer 1 and 
2 mixture. Oligonucleotide eluted from a TSKgel-DNA-NPR column (7.5 cm x 4.6 mm), 50%B at 0 
min, 80%B at 30 min, 0.7 ml min
-1
, 5 µl injection volume. 
 
The choice of mobile phase was an important consideration when coupling HPLC to 
ICP-MS, since the ICP is not tolerant to organic solvents and high concentration 
buffers.62 This was a particularly important consideration when employing anion 
exchange chromatography, as this mode of separation employs an increasing gradient of 
salt to increase the ionic strength of the mobile phase and elute the analyte.36 Sodium 
chloride, typically up to 1 M is traditionally used for increasing the eluent ionic 
b 
a 
22.16 min 
24.71 min 
22.00 min 
24.47 min 
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strength. However, ICP-MS is not compatible with high concentrations of Na since it 
has a low first ionisation potential and is preferentially ionised over other elements 
including the analyte in the plasma. As a result, the plasma equilibrium is disrupted and 
analyte ionisation is suppressed, this is known as a non-spectral interference.27, 200 
Alternative salts therefore have to be considered. In this method, the gradient consisted 
of a mixture of citrate and ammonium chloride. At pH 9, citrate carries a triple negative 
charge, making it a very strong anion. However, for reasons not fully understood, citrate 
alone would not elute the 25 mer oligonucleotides, so ammonium chloride was also 
added to the eluent. Such a mixture of salts appeared to be ICP-MS compatible. 
 
Other mobile phases were investigated prior to the Tris, citrate and ammonium chloride 
gradient. One of the phases investigated was tetramethylammonium chloride (TMACl). 
This mobile phase appeared to be suitable for ICP-MS analysis but it resulted in severe 
suppression of the m/z 47 signal, thus the oligonucleotides were not being detected by 
ICP-MS, even though UV data clearly showed the oligonucleotides eluting. 
 
5.3.2 Cool Plasma 
The cool plasma method of 31P16O+ detection was also applied to the detection of SNPs. 
This involved reducing the plasma forward power to 800 W. The 25 mer mixture was 
injected and eluted using the 20 minute gradient outlined in Table 5:2, refer to Figure 
5:6 for the 31P16O+ chromatogram. The UV chromatogram is not shown, since it is 
identical to that seen in Figure 5:4a above. 
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Figure 5:6: ICP-MS 
31
P
16
O signal intensity during elution of 25 mer 1 and 2 mixture (10 µM). 
Oligonucleotide eluted from a TSKgel-DNA-NPR column (7.5 cm x 4.6 mm), 40%B at 0 mins, 
100%B at 15 mins and 100% B at 20 mins, 0.7 ml min
-1
, 5 µl injection volume.  
 
The oligonucleotides eluted around 15 minutes as shown in the UV chromatogram in 
Figure 5:4a, but Figure 5:6 only shows two very weak 31P16O+ peaks at 14.76 and 15.37 
minutes. The shallow gradient which was outlined in Table 5:4 was also applied to the 
cool plasma method and retention times of approximately 22 and 24 minutes were 
observed in the UV data, but no 31P16O+ peaks were observed when this gradient was 
used in conjunction with cool plasma method. The UV data confirmed that the 
oligonucleotides were eluting, but the ICP-MS data did not exhibit any 31P16O+ peaks at 
the corresponding retention times. One possible explanation is that at a low forward 
power, the plasma was unable to cope with the high matrix which consisted of high 
concentration salts from the mobile phase. The formation of 31P16O+ may have been 
suppressed in the plasma under such conditions, resulting in the absence of 31P16O+ 
peaks as the oligonucleotides eluted.  
 
 
 
14.76 min 
15.37 min 
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5.4 Summary for Anion Exchange HPLC-ICP-MS of SNP’s 
A method of separating and detecting DNA SNPs by HPLC-ICP-MS has been 
demonstrated. Anion exchange chromatography was successful in resolving 
oligonucleotides that differed in sequence by one base. In addition, ICP-MS with CCT 
was successful in detecting the P signal associated with DNA. Both UV and ICP-MS 
data was acquired simultaneously during the separation of the oligonucleotides, which 
enabled the retention times to be verified. Both sets of data corresponded well in terms 
of retention time. 
 
Two methods of P determination were discussed. The first method employed CCT and 
O2 reaction gas to convert P into 
31P16O+. This method was successful in detecting the 
eluted oligonucleotides, with both species baseline resolved. More importantly, 
resolution was not lost upon the coupling of the HPLC to the ICP-MS. The cool plasma 
method of P detection was not successful. Even though the UV data confirmed that the 
oligonucleotides were eluting, the P signal in the ICP-MS data was very weak. As 
discussed above, the likely explanation for this is that the reduced plasma power and 
high matrix levels suppressed PO formation.  
 
A rising baseline was observed in the ICP data throughout the separation step, which 
was attributed to nitrogen and carbon based polyatomic interferences at m/z 47. The 
increasing gradient of tris-HCl, citrate and ammonium chloride was thought to be the 
cause of these increasing interferences. By employing KED the polyatomic 
interferences may have been prevented from entering the quadrupole, thus minimising 
the rising baseline at m/z 47 during the gradient elution. The application of KED is an 
aspect that should be investigated in the future.  
 
It has been demonstrated that the HPLC-ICP-MS method using CCT is suitable for 
detecting P containing species such as DNA. The HPLC-ICP-MS method developed in 
this chapter can be employed qualitatively, but quantitative analysis will be limited due 
to the gradient elution employed. It was briefly discussed in Chapter 2 that isocratic 
elution is preferred when coupling HPLC systems to ICP-MS, since the mobile phase 
composition is constant throughout the separation. Conversely, gradient elution results 
in a changing mobile phase composition which ultimately results in the plasma 
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conditions constantly changing throughout the separation step. This was evident in the 
rising baseline which was attributed to increasing mobile phase B as the elution 
progressed. Thus, it would be difficult to quantify separated analytes, since the degree 
of analyte ionisation may vary at different stages of the separation.201 An internal 
standard could be added to the mobile phase to assess the degree of signal suppression 
during the elution and should be considered for quantitative analysis.  
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6 Conclusions  
The application of elemental mass spectrometry in genomics and related research has 
been demonstrated in this thesis. It has been shown that nucleic acids can be detected by 
ICP-MS due to the high P content in the nucleic acid sugar phosphate backbone. 
However, there are numerous problems associated with P detection, particularly 
concerning its poor detection limit. This problem can be alleviated if the nucleic acid 
analyte is labelled with Au nano-particles. Gold has a lower ionisation potential than P 
and does not suffer the same polyatomic interferences owing to its higher mass. As a 
result, enhancements in nucleic acid detection by ICP-MS were observed for Au 
labelled oligonucleotides. Of the two labelling methods investigated, that employing 
biotin derivatised olignucleotides and streptavidin functionalised Au particles (SFNG) 
was the most successful. The SFNG-DNA conjugates were successfully separated from 
un-reacted SFNG with HPLC-ICP-MS. Labelling efficiencies of 100% were observed, 
which resulted in an 882 fold enhancement in signal for 25 mer oligonucleotides. More 
importantly, all the Au was recovered from the HPLC column. Much lower labelling 
efficiencies and hence signal enhancements were observed when labelling sulfhydryl 
derivatised oligonucleotides with maleimide functionalised Au nano-particles (MMN). 
This was attributed to the lengthy and difficult sample preparation required to initiate 
labelling. Further, both the sulfhydryl derivatised oligonucleotides and MMN were 
reactive once in solution or when exposed to air, adding to the difficulties. 
 
The labelling methods developed here have advantages over those already published. 
Firstly, both the SFNG and MMN methods are site specific and stiochiometery can be 
established.17 Secondly, these methods are not dependent on nucleic acid base sequence 
or peptide sequences,48 hence they can be applied to any bio-molecule possessing a 
biotin or sulfhydryl functionality. Further, the signal enhancement obtained with SFNG 
and MMN is only dependent on the efficiency of one conjugation step. This is in 
contrast to the peptide labelling method reported by Patel et  al., which was dependent 
on the protein-cDPTA derivatisation efficiency followed by the efficiency of Eu binding 
to the chelating agent.49 
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ICP-MS can be applied to clinical samples; this concept was demonstrated in Chapter 3, 
where ctDNA was treated with either cisplatin or oxaliplatin anti-cancer drugs. 
Although the treated ctDNA could be analysed by ICP-MS without any additional 
sample preparation, severe matrix effects resulted in Pt signal suppression. 
Consequently, digestion of the ctDNA resulted in decreased matrix effects and allowed 
Pt dose rates of 1Pt atom per 1 500 000 nucleotides to be detected in approximately     
12 µg DNA. Such a sensitive mass spectrometric method may have important 
implications in clinical research, where trace levels of metallodrug need to be detected 
and quantified in a limited amount of patient sample. Consequently, this approach was 
proven by an MSc. student who successfully applied the procedure to two cancer cell 
lines which were treated with cisplatin or oxaliplatin. 
 
Finally, the complementary nature of elemental and molecular mass spectrometry was 
highlighted in Chapter 4. Here, ESI linear ion trap mass spectrometry was employed to 
study the binding and subsequent fragmentation pathways of oxaliplatin with DNA 
nucleobases. Detailed fragmentation pathways could be established and proposed 
structures were presented.  
 
6.1 Further Research 
6.1.1 Improving Existing Methodologies 
The first aspect to consider is improving the methodologies developed in this thesis. It 
was established in Chapter 2 that RP-HPLC-ICP-MS could be used to separate SFNG-
DNA conjugates with the mass balance reaching 100%, suggesting that all the Au was 
recovered from the column. However, to ensure this was the case, the column had to be 
disconnected from the nebuliser and reverse flushed after each injection to ensure Au 
was not accumulating at the head of the column. This may be avoided if an S containing 
compound such as cysteine is added to the mobile phase to aid Au removal from the 
chromatographic phase and ICP sample introduction system. Gold has high affinity for 
S, so its addition to the mobile phase may ensure that all the injected Au is detected by 
the ICP-MS.  
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Another approach in improving the HPLC separation is to use polymeric 
chromatography phases such as PS-DVB instead of silica phases. Polymeric phases are 
generally more tolerant to extremes in pH compared to their silica counterparts. As a 
result, low concentrations of aqua regia or HCl may be added to the mobile phase to aid 
Au removal from the column. As discussed previously, Au is relatively soluble and 
stable in HCl, which may also result in its efficient removal. Monolithic polymeric 
phases are also more suited to the separation of large molecules such as DNA and 
proteins, owing to rapid diffusion and lack of intra-particular voids which hamper 
macromolecule separations.    
 
Another potential area for improvement is in the chromatography described in Chapter 
5. The baseline of the 31P16O chromatograms in this Chapter appeared to increase during 
gradient elution. The rising baseline was attributed to the increased formation of carbon 
and nitrogen containing polyatomic interferences at m/z 47, caused by the increasing 
amounts of citrate and ammonia chloride mobile phase. Although IKEE was 
implemented by applying a positive potential to the collision cell, KED was not 
implemented and the quadrupole bias was maintained at 1V. However, by increasing 
the positive potential on the quadrupole, it may be possible to discriminate between the 
31P16O analyte and polyatomic interferences, thus minimising the rising baseline during 
gradient elution. Such experiments were not conducted here, but may improve the 
31P16O chromatograms. 
6.1.2 Combining Elemental Labelling with Pt-DNA Adduct Detection 
The concept of signal enhancement by means of metal or nano-particle labelling has 
been demonstrated, as has the application of ICP-MS in the analysis of clinical samples. 
The next step in this research would be to combine these two aspects, namely to label 
Pt-DNA adducts with Au nano-particles to further increase the detection of Pt-DNA 
adducts by ICP-MS. This final section looks at two methods which could be employed 
to further enhance the detection of Pt-DNA adducts. Both methods utilise established 
biological techniques in conjunction with metal nano-particle labelling and elemental 
mass spectrometry. Although neither of these methods has been investigated, it is hoped 
that they will pave the way for future developments in both cancer research studies and 
elemental mass spectrometry. 
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6.1.2.1 Elemental Labelling with the Post Labelling Assay 
The nanogold labelling procedures observed in Chapter 2 could potentially be used to 
label Pt-DNA adducts formed after treatment with Pt drugs. SFNG was assayed in 
Chapter 2 and a figure of 86 Au atoms per nano-particle was calculated. The 
incorporation of 86 Au atoms onto the platinated sites would result in a significant 
enhancement in signal by ICP-MS, resulting in the detection of ultra trace levels of Pt-
DNA adducts.  
 
Platinum and Au have similar masses (m/z 195 and 197 respectively) and similar first 
ionisation potentials (Pt = 9 eV and Au = 9.2 eV), thus the two elements would be 
expected to give similar signals by ICP-MS. However, unlike Au which is 
monoisotopic, Pt has six isotopes with the most abundant at m/z 195 (33.8% abundant). 
Therefore, the 195Pt signal intensity would be expected to be 33% lower than the signal 
given by 197Au at the same concentration. Given that each nano-particle contains 86 Au 
atoms and Au gives three times greater signal than the most abundant Pt isotope, a total 
enhancement factor of 258 should be possible for nanogold labelled di-nucleotides 
compared to measuring Pt alone.   
 
The site specific labelling of Pt-DNA adducts with nanogold could be achieved if used 
in conjunction with the post labelling assay. Figure 3:4 illustrates the assay and shows 
how the adduct sites are converted to di-nucleotides upon enzymatic digestion. The final 
step in the assay requires the di-nucleotides to be phosphorylated at the 5’ end by the 
enzyme T4PNK, which only phosphorylates the di-nucleotides and hence the previously 
platinated sites. In the conventional PLA, 32P is used for phosphorylation. The digest 
mixture containing the radio-labelled di-nucleotides and mono-nucleotides can then be 
separated by gel electrophoresis and the 32P detected. However, in the case of elemental 
labelling, cold phosphorus can be used for phosphorylating the di-nucleotides and then 
the 5’ phosphate can be derivatised to incorporate either biotin or a sulfhydryl group. 
The newly incorporated reactive group can then be labelled with SFNG or MMN 
depending on the reactive group employed. The modified PLA is summarised in Figure 
6:1 and illustrates how the di-nucleotides, which represent previously platinated sites 
are specifically labelled with ~86 Au atoms, whilst the mono-nucleotides that 
correspond to the non-adducted sites are not labelled and thus not detected by ICP-MS. 
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Figure 6:1: Site specific nanogold labelling of Pt adducts using the PLA. 
 
Considering the same type of nanogold particle is present in both SFNG and MMN,95 
both nanogold labelling routes incorporate approximately 86 gold atoms onto the di-
nucleotides. This method could potentially allow for the ultra trace detection of Pt-DNA 
adducts by ICP-MS.  
6.1.2.2 Elemental Labelling of Adduct Recognition Antibodies 
Antibodies specific to cisplatin intra-stranded GG and AG cross-links have been 
identified and used in the analysis of Pt-DNA adducts and provide yet another 
alternative method of ultra sensitive adduct detection.152, 169, 177 Such antibodies could be 
used in a sandwich type immunoassay, where cisplatin treated DNA is incubated with 
adduct recognition antibodies. In a second step, a secondary antibody can then be 
employed to bind to the adduct recognition antibody. If the secondary antibody carries 
an Au or rare earth nano-particle, the ICP-MS detection of Pt adducts can be 
dramatically improved. Figure 6:2 shows the schematic of the potential method.  
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Figure 6:2: Potential metal nano-particle immunological assay combined with ICP-MS for 
cisplatin-DNA adduct detection. 
 
The actual enhancement in signal due to nano-particle labelled antibodies will 
inevitably be dependent upon the metal employed and the number of metal atoms 
present on the secondary antibody. In addition, the affinity of the selected secondary 
antibody to the primary antibody will effect the overall signal enhancement. The nano-
particle based immunological method should be capable of detecting between ~90-95% 
of all Pt species formed, since the antibodies recognise GG and AG intra-stranded 
cross-links.152, 169 However, the above method is only viable if a secondary antibody 
specific to the adduct recognition antibodies can be identified. In addition, the 
secondary antibody will have to be labelled with metal nano-particles, unless such metal 
containing antibodies are commercially available.  
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8 Appendix 1: TSKgel-DNA-NPR Phase 
The anion exchange stationary phase chosen for the separation of nucleic acids and 
nucleic acid-Au conjugates was a non-porous resin functionalised with 
diethylaminoethane (DEAE) anion exchanger. The structure of DEAE is illustrated in 
Figure 8:1. The phase has a pKa of approximately 11.2, so the tertiary amine functional 
group carries a positive charge at or below pH 9. Therefore, compounds carrying a 
negative charge are retained on the phase and positive or neutral species repel the phase 
and are eluted. However, a mixture of negatively charged compounds may be separated 
from one another if the species have different charge densities and /or hydrophobicities, 
since they will have different degrees of interaction with the phase. 
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Figure 8:1:  Structure of the DEAE phase. 
 
The stationary phase is commercially known as; TSKgel-DEAE-NPR. A non-porous 
resin was chosen for the separation of large biomolecules, since the phase is free from 
intraparticular pores and voids. This has the advantage of preventing the large 
molecules becoming irreversibly trapped within the intraparticulate pores. Also, the 
mass transfer of the molecules is increased, which is advantageous due to the naturally 
low diffusivity observed with large biomolecules. Table 8:1 summarises the properties 
of the stationary phase. 
Table 8:1: properties of  the TSKgel-DEAE-NPR Stationary Phase. 
 Property TSKgel-DNA-NPR 
Dimensions 4.6 mm x 750 mm, 2.5 µm 
Pore size Non porous media 
pH stability 2-12 
Max salt conc ≤ 1 M 
Max organic solvent ≤ 20% 
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9 Appendix 2: LTQ Data from oxaliplatin-DNA 
adducts 
9.1 Appendix 2.1: Oxaliplatin Mass Spectrometry Data (in 
the absence of nucleobase) 
The following spectra were obtained from a 3.3 mM oxaliplatin solution in the absence 
of nucleobase.  
 
 
Figure 9:1: MS/MS spectrum of product ions obtained by CID of oxaliplatin parent ion at m/z 397, 
collision energy = 20 eV and isolation width = 1 Da.  
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Figure 9:2: MS/MS spectrum of product ions obtained by CID of oxaliplatin parent ion at m/z 398, 
collision energy = 20 eV and isolation width = 1 Da. 
 
Figure 9:3: MS/MS spectrum of product ions obtained by CID of oxaliplatin parent ion at m/z 399, 
collision energy = 20 eV and isolation width = 1 Da. 
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9.2 Appendix 2.2: Mass Spectrometry Data from Oxaliplatin 
Mono-Nucleobase Solutions 
Oxaliplatin-Adenine Mass Spectra 
 
Figure 9:4: Full scan mass spectrum of oxaliplatin-adenine mono-base solution. 
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Figure 9:5: MS/MS of product ions obtained by CID of the 
195
Pt-A adduct at m/z 443 to yield the 
free Pt drug at m/z 304-308 and free adenine base at m/z 136. Collision energy = 20 eV and isolation 
width =1 Da. 
 
Figure 9:6: MS/MS of product ions obtained by CID of the 
196
Pt-A adduct at m/z 444 to yield the 
free Pt drug at m/z 309 and free adenine base at m/z 136. Collision energy = 15 eV and isolation 
width =1 Da. 
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Figure 9:7: MS/MS spectrum of product ions obtained by CID of the 
195
Pt-AA adduct at m/z 578 to 
yield the 
195
Pt-A adduct at m/z 443. Collision energy = 20 eV and isolation width = 10 Da. 
 
Figure 9:8: MS/MS spectrum of product ions obtained by CID of the 
196
Pt-AA adduct at m/z 579 to 
yield the Pt-A adduct at m/z 444. Collision energy = 20 eV and isolation width = 1 Da. 
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Figure 9:9: MS
3 
spectrum of product ions obtained by CID of the 
195
Pt-A adduct at m/z 443 
(collision energy = 15 eV), which was obtained by CID of the 
195
Pt-AA adduct at m/z 578 using 
collision energy of 20 eV.  
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Oxaliplatin-Guanine Mass Spectra 
 
Figure 9:10: Full scan mass spectrum of the oxaliplatin-guanine mono-base solution. 
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Figure 9:11: MS/MS spectrum of product ions obtained by CID of the 
195
Pt-G adduct at m/z 459 to 
yield the free Pt drug at m/z 306 and free guanine base at m/z 152. Collision energy = 20 eV and 
isolation width = 1 Da. 
 
Figure 9:12: MS/MS spectrum of product ions obtained by CID of the 
196
Pt-G at m/z 460 to yield 
the free Pt drug at m/z 307 and free guanine base at m/z 152. Collision energy = 20 eV and isolation 
width = 1 Da. 
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Figure 9:13: MS/MS spectrum of product ions obtained by CID of the 
194
Pt-GG adduct at m/z 609 
to yield the Pt-G adduct at m/z 458. Collision energy = 20 eV and isolation width = 1 Da. 
 
Figure 9:14: MS/MS spectrum of product ions obtained by CID of the 
195
Pt-GG adduct at m/z 610 
to yield the 
195
Pt-G adduct at m/z 459. Collision energy =15 eV and isolation width = 10 Da. 
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Figure 9:15: MS/MS spectrum of product ions obtained by CID of the 
196
Pt-GG adduct at m/z 611 
to yield the 
196
Pt-G adduct at m/z 460. Collision energy =20 eV and isolation width = 1 Da. 
 
Figure 9:16: MS
3
 spectrum of product ions obtained by CID of the 
195
Pt-G adduct at m/z 459 
(collision energy = 15 eV), which was obtained by CID of the 
195
Pt-GG adduct at m/z 610 (collision 
energy = 20 eV). 
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Figure 9:17: MS
3
 spectrum of product ions obtained by CID of the 
196
Pt-G adduct at m/z 460 
(collision energy =15 eV), which was obtained by CID of the 
196
Pt-GG adduct at m/z 611 (collision 
energy = 20 eV). 
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Oxaliplatin-Thymine Mass Spectra 
 
Figure 9:18: Full scan mass spectrum of oxaliplatin-thymine mono-base solution. 
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Figure 9:19: MS/MS spectrum of product ions obtained by CID of the 
195
Pt-T adduct at m/z 434 to 
yield the free drug at m/z 306. Collision energy = 20 eV and isolation width = 1 Da. 
 
Figure 9:20: MS/MS spectrum of product ions obtained by CID of the 
196
Pt-T adduct at m/z 435 to 
yield the free drug at m/z 307. Collision energy = 20 eV and isolation width = 1 Da. 
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Oxaliplatin-Cytosine Mass Spectrometry Data 
 
Figure 9:21: Full scan mass spectrum of the oxaliplatin-cytosine mono-base solution. 
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Figure 9:22: MS/MS spectrum of product ions obtained by CID of the 
196
Pt-C adduct at m/z 420 to 
yield the free drug at m/z 307. Collision energy = 20 eV and isolation width = 1 Da. 
 
Figure 9:23: MS/MS spectrum of product ions obtained by CID of the 
195
Pt-CC adduct at m/z 530 to 
yield the mono-adduct, collision energy =20 eV and isolation width = 10 Da. 
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Hydrated Complexes of Guanine 
These spectra were obtained from the oxaliplatin-guanine mono-base solution and show 
how the hydrated guanine complex fragmented to form the Pt-G mono-adduct. Further 
CID was conducted on the Pt-G product ion to yield many product ions, which were 
characteristic to Pt-G fragmentation. 
 
Figure 9:24: MS
3 
spectrum of product ions obtained by CID of the 
194
Pt-G adduct at m/z 458, 
(collision energy = 20 eV) which was obtained by CID of the 
194
Pt-G(H2O) adduct at m/z 476. 
Collision energy of 15 eV 
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Figure 9:25: MS
3 
spectrum of product ions obtained by CID of the 
195
Pt-G adduct at m/z 459, 
(collision energy = 15 eV) which was obtained by CID of the 
195
Pt-G(H2O) adduct at m/z 477. 
Collision energy of 20 eV. 
 
Figure 9:26: MS
3 
spectrum of product ions obtained by CID of the 
196
Pt-G adduct at m/z 460, 
(collision energy = 20 eV) which was obtained by CID of the 
196
Pt-G(H2O) adduct at m/z 478, 
collision energy = 15 eV. 
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9.3 Appendix 2.3: Oxaliplatin mixture containing A, C, G 
and T in equal-molar proportions 
 
Figure 9:27: MS/MS spectrum of product ions obtained by CID of the 
196
Pt-C adduct at m/z 420 to 
yield the free drug at m/z 305. Collision energy = 15 eV and isolation width = 10 Da. 
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Figure 9:28: MS/MS spectrum of product ions obtained by CID of the 
196
Pt-C adduct at m/z 420 to 
yield the free drug at m/z 306. Collision energy = 20 eV and isolation width = 1 Da. 
 
Figure 9:29: MS/MS of spectrum of product ions obtained by CID of the Pt-A adduct at m/z 441 to 
yield the free drug at m/z 307. Collision energy = 15 eV and isolation width = 10 Da. 
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Figure 9:30: MS/MS spectrum of product ions obtained by CID of the 
195
Pt-A adduct at m/z 443 to 
yield the free Pt drug at m/z 308 and free adenine base at m/z 136. Collision energy = 20 eV and 
isolation width = 1 Da. 
 
Figure 9:31: MS/MS spectrum of product ions obtained by CID of the 
194
Pt-G adduct at m/z 458 to 
yield the free Pt drug at m/z 307. Collision energy = 15 eV and isolation width = 10 Da. 
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Figure 9:32: MS/MS spectrum of product ions obtained by CID of the 
195
Pt-G adduct at m/z 459 to 
yield the free Pt drug at m/z 306 and free guanine base at m/z 152. Collision energy = 20 eV and 
isolation width = 1 Da. 
 
Figure 9:33: MS/MS spectrum of product ions obtained by CID of the 
195
Pt-AA adduct at m/z 578 to 
yield the Pt-A adduct at m/z 443. Collision energy = 15 eV and isolation width = 10 Da. 
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Figure 9:34: MS/MS spectrum of product ions obtained by CID of the 
196
Pt-AA adduct at m/z 579 to 
yield the 
196
Pt-A adduct at m/z 444. Collision energy = 20 eV and isolation width = 1 Da. 
 
Figure 9:35: MS
3
 spectrum of product ions obtained by CID of the 
196
Pt-A adduct at m/z 444 
(collision energy = 20 eV and isolation width = 1 Da), which were obtained through CID of 
196
Pt-AA 
adduct at m/z 579 (collision energy = 20 eV and isolation width = 1).  
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Figure 9:36: MS/MS spectrum of product ions obtained by CID of the 
195
Pt-GG adduct at m/z 610 
to yield the Pt-G adduct at m/z 459. Collision energy = 15 eV and isolation width = 10 Da. 
 
Figure 9:37: MS/MS spectrum of product ions obtained by CID of the 
196
Pt-GG adduct at m/z 611 
to yield the 
196
Pt-G adduct at m/z 460. Collision energy = 20 eV and isolation width = 1 Da. 
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Figure 9:38: MS/MS spectrum of product ions obtained by CID of the Pt-AG adduct at m/z 592 to 
yield the Pt-G and Pt-A adduct at m/z 459 and 443 respectively. Collision energy = 20 eV and 
isolation width = 10 Da. 
 
Figure 9:39: MS/MS spectrum of product ions obtained by CID of the 
195
Pt-AG adduct at m/z 594 
to yield the 
195
Pt-A and 
195
Pt-G adducts at m/z 443 and 459 respectively. Collision energy = 20 eV 
and isolation width = 1 Da. 
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Figure 9:40: MS
3 
spectrum of product ions obtained by CID of the Pt-G adduct at m/z 459 (collision 
energy = 20 eV and isolation width = 10), which was obtained by CID of the Pt-AG adduct at m/z 
594 (collision energy = 15 eV and isolation width = 10 Da). 
 
Figure 9:41: MS
3 
spectrum of product ions obtained by CID of the Pt-A adduct at m/z 443 (collision 
energy = 15 eV), which was obtained by CID of the Pt-AG adduct at m/z 594 (collision energy = 20 
eV and isolation width = 10 Da). 
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9.4 Appendix 2.4: Oxaliplatin mixture containing A, C, G 
and T with an excess of oxaliplatin 
 
Figure 9:42: MS/MS spectrum of product ions obtained by CID of the 
196
Pt-C adduct at m/z 420 to 
yield the free Pt drug at m/z 307. Collision energy = 20 eV and isolation width =1 Da. 
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Figure 9:43: MS/MS spectrum of product ions obtained by CID of the 
195
Pt-T adduct at m/z 434 to 
yield the free Pt drug at m/z 306. Collision energy = 20 eV and isolation width =1 Da. 
 
Figure 9:44: MS/MS spectrum of product ions obtained by CID of the 
195
Pt-A adduct at m/z 443 to 
obtain the free Pt drug at m/z 308 and free adenine base at m/z 136. Collision energy =20 eV and 
isolation width =1 Da. 
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Figure 9:45: MS/MS spectrum of product ions obtained by CID of the 
194
Pt-G adduct at m/z 458 to 
yield the free Pt drug at m/z 305 and free guanine base at m/z 152. Collision energy = 20 eV and 
isolation width =1 Da. 
 
Figure 9:46: MS/MS spectrum of product ions obtained by CID of 
195
Pt-G(H2O) adduct at m/z 477 
to obtain the 
195
Pt-G adduct at m/z 459. Collision energy = 20 eV and isolation width = 1 Da. 
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Figure 9:47: MS
3 
spectrum of product ions formed by CID of the 
195
Pt-G adduct at m/z 459 
(collision energy = 20 eV), which was obtained by CID of the 
195
Pt-G(H2O) adduct at m/z 477 
(collision energy = 20 eV and isolation width = 1). 
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9.5 Appendix 2.5: Fragmentation of the Pt-AG adduct 
 
Figure 9:48: MS/MS spectrum of product ions obtained by CID of the Pt-AG adduct at m/z 594 to 
yield the Pt-G and Pt-A adducts at m/z 459 and 443 respectively. Collision energy = 20 eV and 
isolation width = 10 Da. 
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Figure 9:49: MS/MS spectrum of product ions obtained by CID of the 
194
Pt-AG adduct at m/z 593 
to yield the 
194
Pt-A adduct and 
194
Pt-G adduct at m/z 442 and 458 respectively. Collision energy = 20 
eV and isolation width = 1 Da. 
 
Figure 9:50: MS
3 
spectrum of product ions obtained by CID of the Pt-A adduct at m/z 443 (collision 
energy = 20 eV and isolation width = 10 Da), which were obtained by CID of Pt-AG adduct at m/z 
593 (collision energy = 20 eV and isolation width = 10 Da). 
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Figure 9:51: MS
3  
spectrum of product ions obtained by CID of the Pt-G adduct at m/z 458 (collision 
energy = 20 eV and isolation width = 10), which were obtained by CID of the Pt-AG adduct at m/z 
593 (collision energy = 20 eV and isolation width = 10 Da). 
 
Figure 9:52: MS
3 
spectrum of product ions obtained by CID of the 
194
Pt-G adduct at m/z 458 
(collision energy = 20 eV and isolation width = 1 Da), which was obtained by CID of the
 194
Pt-AG 
adduct at m/z 593 (collision energy = 20 eV and isolation width = 1 Da). 
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10 Appendix 3: Continued Professional Development 
Record 
Event Organisation/Department Date 
Attended 
Duration 
Statistics and Chemometrics Short 
Course 
Professor Miller, Chemistry 
October 
2004 
2 days 
PhD. Induction Professional Development 
October 
2004 
½ day 
Proteomics Seminar Waters Corporation 
November 
2004 
1 day 
Raman Spectroscopy Course 
Loughborough University, 
Physics Department 
11th -12th 
Nov 2004 
2 days 
Preparing to Teach Professional Development 19/11/04 ½ day 
Promoting Learning Professional Development 25/11/04 ½ day 
Supervising Practical Activities Professional Development 30/11/04 ½ day 
Laser Safety Training John Tyler, Physics  8th December ½ day 
Leicester University, Cancer 
Biomarkers and Prevention Group 
Dr. R. Le Pla, Leicester 
University 
13-14/09/05 2 days 
Waters Proteomics Seminar Waters Corporation 19/10/05 1 day 
Keeping your Research up-to Date Professional Development 17/11/05 ½ day 
Conference Presentation Skills (Parts 
A and B) 
Professional Development 24/01/06 & 
7/02/06 
1 day 
Presentation at Leicester University on 
the application of ICP-MS to Pt drug 
research. 
Leicester /Loughborough 
collaboration 
8/02/06 ½ day 
Biological Applications of Elemental 
and Molecular Mass Spectrometry 
RSC 16/03/06 1 day 
Reading for Research Professional Development 13/03/06 ½ day 
Personal Organisation and Time 
Management 
Professional Development 22/05/06 ½ day 
Career Management Professional Development 12/05/06 ½ day 
Getting the Most out of Supervision Professional Development 13/06/06 ½ day 
Managing Projects for PG and RA Professional Development 27/06/06 ½ day 
BNASS Conference, Glasgow 
Caledonian University. Presentation 
on the ICP-MS analysis of Au labelled 
nucleic acids. 
RSC 10-12th July 
2006 
3 days 
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Continued Professional Development continued: 
Event Organisation/Department Date 
Attended 
Duration 
Cricket Secretary Role:  
Taking and distributing minutes at 
monthly committee meetings. 
Issuing correspondence to club 
members. 
Organising end of season presentation 
evening 
 Nov 2005-
July 2007 
15 days 
Viva - What Happens? Professional Development 5/10/06 ½ day 
Visit to Loughborough High School 
(career management) 
 02/10/06 1 day 
Visit to Burleigh College (career 
management) 
 09/10/06 1 day 
Intellectual Property Professional Development 14/12/06 ½ day 
Successful Applications Professional Development 31/01/07 ½ day 
Toarmina Plasma Winter conference 
Oral presentation given on the 
analysis of Au labelled nuclic acids by 
HPLC-ICP-MS 
 Feb 2007 6 days 
Emerging Young Professionals 
Conference: 
Presentation given on the analysis of 
Au labelled nucleic acids by ICP-MS. 
Also attended team building exercises 
RSC – Analytical Science 
Network 
29-31/05/07 2 days 
Presentation given to MSc. students 
on the biological applications of ICP-
MS, followed by instrument 
demonstrations 
Chemistry  ½ day 
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11 Published Material 
Two journal articles were produced from this thesis; the first article detailed the 
enhancement of nucleic acid signal by nano-particle labelling, whilst the second 
publication discussed the study of oxaliplatin-nucleobase interactions by linear ion trap 
ESI-MS. These two research ares were outlined in Chapter 2 and 4 respectively. The 
full journal citations are shown below and the full published versions are shown on the 
following pages. 
 
S. L. Kerr and B. L. Sharp, Nano-particle labelling of nucleic acids for enhanced 
detection by inductively coupled plasma-mass spectrometry (ICP-MS), Chem. 
Commun., 2007, 4537-4539. 
 
S. L. Kerr, T. Shoeib and B. L. Sharp, A study of oxaliplatin-nucleobase interactions 
using ion trap, electrospray mass spectrometry, Anal. Bioanal. Chem., 2008, DOI 
10.1007/s00216-008-2128-3 
 
Publications in Preparation 
S. L. Kerr, P. D. Winship, R. Le Pla, C. Harrington, H. J. Reid, G. D. D. Jones and B. L. 
Sharp, Determination of cisplatin and oxaliplatin adducts by ICP-MS. 
 
P. D. Winship, S. L. Kerr and B. L. Sharp, Comparison of collision reaction cell and 
cold plasma methods of P detection by ICP-MS. 
 
 
 
 
 
 
 
 
 
 
